Modified leader editing guide RNA
By designing a pilot editing guide RNA (PEgRNA) containing specific sequence and structural characteristics, combining Cas protein and DNA polymerase, the problem of insufficient pilot editing efficiency and accuracy in the prior art is solved, and efficient gene mutation correction is achieved.
Patent Information
- Application Number
- CN202280089683.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-20
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-05
AI Technical Summary
Existing pilot editing techniques have shortcomings in efficiency and accuracy, especially in the process of guiding RNA (PEgRNA) design and target DNA editing, it is difficult to achieve efficient gene mutation correction.
Provides a lead editing guide RNA (PEgRNA) containing spacer, gRNA core, extension arm, primer binding site (PBS) and 3'nucleic acid motif, which is designed to contain specific sequence composition and structural features such as VEGF Gene promoter, potato leaf roll virus pseudo-knot, MS2 protein binding sequence and Moloney murine leukemia virus reverse transcriptase recruitment sequence enhance the binding ability to Cas protein and DNA cleavage accuracy.
The editing efficiency of PEgRNA on target DNA is improved. Compared with control RNA, the editing efficiency is at least 1.1 times higher, significantly improving the ability and accuracy of gene mutation correction.
Smart Images

Figure BDA0004955711930000561 
Figure BDA0004955711930000571 
Figure BDA0004955711930000581
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 283,076, filed on November 24, 2021, and U.S. Provisional Application No. 63 / 417,857, filed on October 20, 2022, the entire contents of each of which are hereby incorporated by reference. Background Art
[0003] Lead editing is a gene editing technology that allows researchers to make nucleotide substitutions, insertions, deletions, or combinations thereof in cellular DNA. Lead editing can be used to correct disease-associated gene mutations and can be used to treat diseases with a genetic component. Improved lead PEgRNAs with desirable properties, such as the ability to promote lead editing with improved efficiency, are needed. Summary of the invention
[0004] Provided herein are prime editing guide RNAs (PEgRNAs) that can be used for prime editing, as well as methods of using and making such PEgRNAs.
[0005] In some aspects, provided herein is a lead editing guide RNA (PEgRNA) comprising: (a) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; (b) a guide RNA (gRNA) core capable of binding to a Cas protein; (c) an extension arm comprising: (i) an editing template comprising an expected edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and (d) a 3' nucleic acid motif selected from the group consisting of SEQ REF NO 1-15.
[0006] In some aspects, the present invention also provides a lead editing guide RNA (PEgRNA), which comprises: (a) a spacer region comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; (b) a guide RNA (gRNA) core capable of binding to a Cas protein; (c) an extension arm comprising: (i) an editing template comprising an expected edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and (d) a 3' nucleic acid motif, wherein the 3' nucleic acid motif comprises a sequence selected from the group consisting of: (A) a G-quadruplex or a C-quadruplex derived from a VEGF gene promoter, (B) a pseudoknot derived from a potato leaf roll virus (PLRV), (C) an MS2 protein binding sequence, (D) a Moloney Murine leukemia virus (MMLV) reverse transcriptase recruitment sequence, or a Moloney Murine Leukemia Virus (MMLV) replication recognition sequence.
[0007] In some embodiments, the 3' nucleic acid motif is a G-quadruplex or C-quadruplex derived from a VEGF gene promoter (e.g., wherein the G-quadruplex comprises SEQ REF NO: 10 and / or the C-quadruplex comprises SEQ REF NO: 11). In some embodiments, the 3' nucleic acid motif is a pseudoknot derived from a potato leaf roll virus (PLRV) (e.g., wherein the pseudoknot comprises SEQ REF NO: 4). In some embodiments, the 3' nucleic acid motif comprises an MS2 protein binding sequence (e.g., wherein the MS2 protein binding sequence is SEQ REF NO: 9). In some embodiments, the 3' nucleic acid motif comprises an MMLV reverse transcriptase recruitment sequence (e.g., the MMLV reverse transcriptase recruitment sequence comprises SEQ REF NO: 8). In some embodiments, the 3' nucleic acid motif comprises an MMLV replication recognition sequence.
[0008] In some embodiments, the MMLV replication recognition sequence comprises a sequence selected from the group consisting of SEQ REF NOs: 12-15. In some embodiments, the 3' nucleic acid motif comprises SEQ REF NOs: 1, 2, 3, 5, 6, or 7.
[0009] As provided herein, PEgRNA comprises a spacer, a gRNA core, an editing template, a PBS, and a 3' nucleic acid motif in a 5' to 3' order. In some embodiments, PEgRNA also comprises a 5' joint immediately following the 3' nucleic acid motif. The length of the joint can be 2 to 12 nucleotides, such as 8 nucleotides in length. In some embodiments, the joint does not form a secondary structure. In some embodiments, the joint does not have complete complementarity with the PBS sequence, editing template, scaffold, and / or extension arm. In some embodiments, the joint has no more than 90%, no more than 85%, no more than 80%, no more than 75%, no more than 70%, no more than 65%, no more than 60%, no more than 55%, no more than 50%, no more than 45%, no more than 40%, no more than 35%, no more than 30%, no more than 25%, no more than 20%, or no more than 15% complementarity with the extension arm.
[0010] In some aspects, provided herein is a lead editing guide RNA (PEgRNA) comprising: (a) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; (b) an extension arm comprising: (i) an editing template comprising an expected edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and (c) a guide RNA (gRNA) core having at least 80% identity to SEQ REF NO: 16 and having a sequence identity to SEQ REF NO: 17. NO:16 contains one or more modifications, wherein the one or more modifications include: (A) a first insertion between nucleotides 12 and 13 and a second insertion between nucleotides 16 and 17, wherein the first insertion is the reverse complement of the second insertion; (B) a first insertion between nucleotides 52 and 53 and a second insertion between nucleotides 56 and 57, wherein the first insertion is the reverse complement of the second insertion; (C) complementary substitutions of nucleotides 2 and 29, 3 and 28, 4 and 27, 51 and 58, or a combination thereof; (D) replacement of nucleotides 11-12 with replacement sequence 1 and replacement of nucleotides 17-18 with replacement sequence 2, wherein the length of replacement sequence 1 is at least 3 nucleotides and wherein replacement sequence 2 is the reverse complement of replacement sequence 1; (E) a T to G substitution or a T to C substitution at nucleotide 5 and a complementary substitution at nucleotide 26; or (F) any combination thereof.
[0011] In some embodiments, the gRNA core comprises a first insertion between nucleotides 12 and 13 and a second insertion between nucleotides 16 and 17. The length of the insertion can be 1 to 6 nucleotides. In some embodiments, the first insertion comprises the sequence UGCUG. In some embodiments, the second insertion comprises the sequence CAGCA.
[0012] In some embodiments, the one or more modifications include replacing nucleotides 49-52 with replacement sequence 1 and replacing nucleotides 57-60 with replacement sequence 2, wherein replacement sequence 2 is the reverse complement of replacement sequence 1; optionally, wherein the length of replacement sequence 1 is 7-11 nucleotides; optionally, wherein the length of replacement sequence 1 is 7-9 nucleotides; optionally, wherein replacement sequence 1 comprises GCGUCUC, GCGUCCC, GCGUCCA, GCGUGUGA, GCGUAGCC, GCGUGCAGA, GCGUACCCU or GCGUUGUCG.
[0013] In some embodiments, the first insertion is 1 to 3 nucleotides in length, for example, the first insertion may comprise a sequence selected from the group consisting of C, CC, CA, CG, A, AC, AA, AG, CCC, CCAC, CCAAC, and CCACAC.
[0014] In some embodiments, the gRNA core comprises a first insertion between nucleotides 52 and 53 and a second insertion between nucleotides 56 and 57. The length of the first insertion can be 1 to 8 nucleotides. In some embodiments, the gRNA core comprises complementary substitutions of nucleotides 2 and 29, 3 and 28, 4 and 27, 11 and 18, 12 and 17, 51 and 58, or a combination thereof. In some embodiments, the gRNA core comprises a U to A substitution at nucleotide 2. In some embodiments, the gRNA core comprises a U to A substitution at nucleotide 3. In some embodiments, the gRNA core comprises a U to A substitution at nucleotide 4. In some embodiments, the gRNA core comprises a U to G substitution at nucleotide 51 and an A to C substitution at optional nucleotide 58.
[0015] In some embodiments, the gRNA core comprises replacement of nucleotides 11-12 with replacement sequence 1 and replacement of nucleotides 17-18 with replacement sequence 2.
[0016] In some embodiments, the length of replacement sequence 1 is 3 to 5 nucleotides, for example, replacement sequence 1 may include a sequence selected from the group consisting of CAGC, CCGC, GGAC, UGC, UCC, GAGGC, AGC, GGC, CGCA, GCACA, GGUC, and GGG. In some embodiments, the gRNA core further includes a U to A substitution at nucleotide 5 and an A to U substitution at nucleotide 26. In some embodiments, the gRNA core includes complementary substitutions at nucleotides 52 and 57. In some embodiments, the gRNA core includes a U to G substitution at nucleotide 52 and an A to C substitution at nucleotide 57. In some embodiments, the gRNA core includes a U to C substitution at nucleotide 52 and an A to G substitution at nucleotide 57. In some embodiments, the gRNA core includes complementary substitutions at nucleotides 49 and 60. In some embodiments, the gRNA core includes an A to G substitution at nucleotide 49 and a U to C substitution at nucleotide 60.
[0017] In some aspects, provided herein is a lead editing guide RNA (PEgRNA) comprising: (a) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; (b) an extension arm comprising: (i) an editing template comprising an expected edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and (c) a guide RNA (gRNA) core having at least 80% identity to SEQ REF NO: 16 and having a sequence identity to SEQ REF NO: 17. NO:16 contains one or more modifications, the one or more modifications comprising: (A) a U to A substitution at nucleotide 5 and an A to U substitution at nucleotide 26, and (B) a modification selected from the group consisting of: a. a first insertion between nucleotides 12 and 13 having the sequence UGCUG and a second insertion between nucleotides 16 and 17 having the sequence CAGCA; b. a first insertion between nucleotides 12 and 13 having the sequence UGCUG and a second insertion between nucleotides 16 and 17 having the sequence CAGCA, an A to G substitution at nucleotide 49, a U to C substitution at nucleotide 60, a U to G substitution at nucleotide 51, and an A to C substitution at nucleotide 58; c. replacement of nucleotides 11-12 with replacement sequence 1 and replacement of nucleotides 17-18 with replacement sequence 2, wherein replacement sequence 1 comprises GGG and wherein replacement sequence 2 comprises UCC; d. replacing nucleotides 11-12 with replacement sequence 1 and nucleotides 17-18 with replacement sequence 2, wherein replacement sequence 1 comprises GGG and wherein replacement sequence 2 comprises UCC; an A to G substitution at nucleotide 49, a U to C substitution at nucleotide 60, a U to G substitution at nucleotide 51, and an A to C substitution at nucleotide 58; or e. replacing nucleotides 11-12 with replacement sequence 1 and nucleotides 17-18 with replacement sequence 2, wherein replacement sequence 1 and replacement sequence 2 comprise the sequences CAGC and GCUG, CCGC and GCGG, GGAC and GUCC, GC and GC, CC and GG, GAGGC and GUCUC, AGC and GCU, GGC and GCC, CGCA and UGCG, GCACA and UUGGC, or GGUC and GGCC.
[0018] In some embodiments, the gRNA core comprises nucleotides 62-76 of SEQ REF NO:16.
[0019] In some embodiments, the one or more modifications include replacing nucleotides 49-52 with replacement sequence 1 and replacing nucleotides 57-60 with replacement sequence 2, wherein replacement sequence 2 is the reverse complement of replacement sequence 1; optionally, wherein the length of replacement sequence 1 is 7-11 nucleotides; optionally, wherein the length of replacement sequence 1 is 7-9 nucleotides; optionally, wherein replacement sequence 1 comprises GCGUCUC, GCGUCCC, GCGUCCA, GCGUGUGA, GCGUAGCC, GCGUGCAGA, GCGUACCCU or GCGUUGUCG.
[0020] In some aspects, provided herein is a lead editing guide RNA (PEgRNA) comprising: a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; an extension arm comprising: an editing template comprising an expected edit compared to the double-stranded target DNA, and a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and a guide RNA (gRNA) core comprising a sequence selected from the group consisting of SEQ REF NO: 17-61, 3860-4253, 4255-4349, 4351-4359 and 4452.
[0021] In some embodiments, the gRNA core comprises a sequence selected from the group consisting of SEQ REF NOs: 4294, 4319, 4322, 4286, 4290, 4346, 4271, 4264, 4317, 4330, 4312, 4356, 4280, and 4452. In some embodiments, the gRNA core comprises SEQ REF NO: 4354.
[0022] In some embodiments, the PEgRNA comprises a 3' nucleic acid motif selected from the group consisting of SEQ REF NO 1-15, such as SEQ REF NO: 1, 2, 3, 5, 6 or 7. In some embodiments, the PEgRNA comprises a 3' nucleic acid motif, wherein the 3' nucleic acid motif comprises a sequence selected from the group consisting of: a G-quadruplex or a C-quadruplex derived from a VEGF gene promoter, a pseudoknot derived from a potato leaf roll virus (PLRV), an MS2 protein binding sequence, a Moloney murine leukemia virus (MMLV) reverse transcriptase recruitment sequence, or a Moloney murine leukemia virus (MMLV) replication recognition sequence.
[0023] In some embodiments, the selected 3' nucleic acid motif is a G-quadruplex or C-quadruplex derived from the VEGF gene promoter. The G-quadruplex may comprise SEQ REF NO: 10. The C-quadruplex may comprise SEQ REF NO: 11. In some embodiments, the selected 3' nucleic acid motif is a pseudoknot derived from potato leaf roll virus (PLRV). The pseudoknot may comprise SEQ REF NO: 4. In some embodiments, the 3' nucleic acid motif comprises an MS2 protein binding sequence, such as SEQ REF NO: 9. In some embodiments, the 3' nucleic acid motif comprises an MMLV reverse transcriptase recruitment sequence, such as an MMLV reverse transcriptase recruitment sequence comprising SEQ REF NO: 8. In some embodiments, the selected 3' nucleic acid motif comprises an MMLV replication recognition sequence, such as a sequence selected from the group consisting of SEQ REF NO: 12-15.
[0024] In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, a PBS, and a 3' nucleic acid motif in 5' to 3' order. In some embodiments, the PEgRNA further comprises a 5' linker immediately adjacent to the 3' nucleic acid motif. The length of the linker is 2 to 12 nucleotides, such as 8 nucleotides in length. In some embodiments, the linker does not form a secondary structure. In some embodiments, the linker does not have complete complementarity with the PBS sequence, editing template, scaffold, and / or extension arm.
[0025] The joint may have no more than 90%, no more than 85%, no more than 80%, no more than 75%, no more than 70%, no more than 65%, no more than 60%, no more than 55%, no more than 50%, no more than 45%, no more than 40%, no more than 35%, no more than 30%, no more than 25%, no more than 20% or no more than 15% complementarity with the extension arm.
[0026] In some aspects, provided herein is a lead editing guide RNA (PEgRNA) comprising: (a) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; (b) a guide RNA (gRNA) core capable of binding to a Cas protein; (c) an extension arm comprising: (i) an editing template comprising an expected edit compared to the double-stranded target DNA; and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA, and (d) a tag sequence that is the reverse complement of a sequence within the editing template.
[0027] In any embodiments disclosed herein, the length of the tag sequence can be 4 nucleotides to 22 nucleotides, such as 4 nucleotides to 10 nucleotides in length, 4 nucleotides to 9 nucleotides in length, 6 nucleotides to 8 nucleotides in length, 6 nucleotides in length, or 8 nucleotides in length.
[0028] In some embodiments, the tag sequence does not have complete complementarity with the PBS, gRNA core and / or spacer. In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, a PBS, and a tag sequence in a 5' to 3' order. In some embodiments, the PEgRNA comprises an editing template, a PBS, a tag sequence, a spacer, and a gRNA core in a 5' to 3' order.
[0029] In some embodiments, the PEgRNA comprises a joint between the PBS and the tag sequence. The length of the joint can be 2 to 12 nucleotides, such as 4 to 8 nucleotides in length, 4 to 6 nucleotides in length, 8 nucleotides in length, 6 nucleotides in length, or 4 nucleotides in length.
[0030] In some embodiments, the linker does not have complete complementarity with the PBS, gRNA core and / or spacer.In some embodiments, the linker does not form a secondary structure.
[0031] In some embodiments, the gRNA core comprises a sequence selected from the group consisting of SEQ REF NOs: 16-60, 3860-4359, and 4452.
[0032] Also provided herein is a lead editing system comprising: (a) PEgRNA disclosed herein or one or more polynucleotides encoding PEgRNA disclosed herein; and (b) a lead editor comprising a Cas protein and a DNA polymerase or one or more polynucleotides encoding a lead editor. In some embodiments, the Cas protein has nickase activity. The Cas protein is Cas9, which may include mutations in the HNH domain.
[0033] In some embodiments, the Cas9 is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ REF NO: 4442. The Cas protein can be Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14a, Cas14b, Cas14c, Cas14d, Cas14e, Cas14f, Cas14g, Cas14h, Cas14u, or
[0034] In some embodiments, the DNA polymerase is a reverse transcriptase, such as a retroviral reverse transcriptase. In some embodiments, the reverse transcriptase has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ REF NO: 4444. In some embodiments, the Cas protein and the DNA polymerase are fused or connected in a fusion protein. In some embodiments, the fusion protein comprises the sequence of SEQ REF NO: 4440.
[0035] In some embodiments, the one or more polynucleotides comprise (a) a first sequence encoding the N-terminal portion of the Cas protein and an intein-N and (b) a second sequence encoding an intein-C, a C-terminal portion of the Cas protein, and a DNA polymerase.
[0036] In some embodiments, the lead editing system comprises one or more vectors, the one or more vectors comprising one or more polynucleotides encoding PEgRNA and one or more polynucleotides encoding lead editors. One or more vectors can be, for example, AAV vectors. One or more polynucleotides can be mRNA.
[0037] Also provided herein are lipid nanoparticles (LNPs) or ribonucleoproteins (RNPs) comprising the lead editing systems disclosed herein.
[0038] In some aspects, provided herein is a method for editing a double-stranded target DNA, the method comprising contacting the target DNA with (a) a PEgRNA disclosed herein and a lead editor comprising a Cas9 nickase and a reverse transcriptase, (b) a lead editing system disclosed herein, or (c) an LNP or RNP disclosed herein. The target DNA disclosed herein may be in a cell.
[0039] In some embodiments, the editing efficiency of editing the double-stranded target DNA is at least 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.1 times, 2.2 times, 2.3 times, 2.4 times, or 2.5 times higher than the editing efficiency of a control PEgRNA having the same spacer and extension arm, wherein the control PEgRNA contains a gRNA core having a sequence of SEQ REFNO: 16 and does not contain a 3' nucleic acid motif or tag.
[0040] In some embodiments, the gRNA core comprises a sequence selected from the group consisting of: SEQ REF NO: 4352, 3860, 3862, 3865, 3908, 3915, 3982, 3991, 4035, 4261, 4262, 4263, 4264, 4265, 4266, 4268, 4277, 4278, 4280, 4283, 4284, 4285, 4286, 4269, 4287, 4288, 4289, 4290, 4291, 4270, 4271, 4272, 4274, 4275, 4276, 4292, 4301, 4302, 4303, 4304, 4305, 4306, 4307, 4308, 4309, 4310, 4311, 4312, 4313, 4314, 4315 4302, 4304, 4305, 4306, 4309, 4293, 4311, 4312, 4313, 4315, 4316, 4317, 4319, 4320, 4294, 4321, 4322, 4323, 4295, 4296, 4297, 4299, 4324, 4333, 4334, 4338, 4339, 4341, 4342, 4343, 4345, 4346, 4348, 4349, 4328, 4329, 4330, and 4332.
[0041] In certain aspects, the PEgRNA provided herein comprises i) a spacer region comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a guide RNA (gRNA) core comprising a direct repeat, a first stem loop, and a second stem loop; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; and iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nick site in a non-target strand of the double-stranded target DNA, wherein the PEgRNA comprises one or more nucleic acid portions at its 3' end. In some embodiments, the PEgRNA comprises a spacer region, a gRNA core, an editing template, and a PBS in a 5' to 3' order.
[0042] In some embodiments, one or more (e.g., two or more, three or more, four or more, or five or more) nucleic acid portions comprise a hairpin (e.g., a hairpin comprising a self-complementary region, optionally, wherein the self-complementary region comprises 2, 3, 4, 5, 6, 7, 8, 9, or 10 consecutive complementary base pairs), a quadruplex (e.g., a G-quadruplex or a C-quadruplex, optionally, wherein the G-quadruplex or the C-quadruplex is derived from a VEGF gene promoter), a tRNA sequence (e.g., a tRNA sequence, optionally, wherein the tRNA sequence is a tRNA(proline) sequence), an aptamer (e.g., an aptamer derived from a viral protein binding sequence, optionally, wherein the aptamer comprises a viral reverse transcriptase recruitment sequence, optionally, wherein the aptamer comprises an MS2 protein binding sequence or a Moloney murine leukemia (MMLV) reverse transcriptase recruitment sequence), and / or a pseudoknot (e.g., a pseudoknot derived from potato leaf roll virus (PLRV)), or any combination thereof. In some embodiments, one or more nucleic acid portions comprise a structure derived from a replication recognition sequence of a retrovirus, optionally wherein the retrovirus is Moloney murine leukemia (MMLV). For example, one or more nucleic acid portions may comprise a configuration as shown in Table 4. In some embodiments, one or more nucleic acid portions comprise a nucleic acid sequence selected from SEQ REF NO 1-15.
[0043] In certain embodiments, the PEgRNA provided herein comprises a 5' joint immediately adjacent to one or more nucleic acid portions. In some embodiments, the length of the joint is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. In some embodiments, the length of the joint is 2 to 13 nucleotides. In some embodiments, the joint is 8 nucleotides long. In some embodiments, the joint does not form a secondary structure. In some embodiments, the joint does not have a region complementary to the PBS sequence. In some embodiments, the joint does not have a region complementary to the editing template.
[0044] In certain embodiments, the gRNA core of the PEgRNA provided herein comprises one or more sequence modifications compared to SEQ REF NO.16. In some embodiments, one or more (e.g., two or more, three or more, four or more or five or more) sequence modifications include the gRNA core differences listed in Table 1. In some embodiments, the gRNA core of the PEgRNA includes a gRNA core sequence as listed in Table 1 or Table 2. In some embodiments, one or more sequence modifications include sequence modifications in the same direction repeat. For example, the same direction repeat may include the flipping of at least one A / U base pair in the lower stem of the same direction repeat, optionally, wherein the lower stem does not contain 2, 3, 4 or more continuous AU base pairs; and / or the flipping of at least one A / U base pair in the same direction repeat includes the flipping of the fourth A / U base pair in the lower stem of the same direction repeat. Fig.12 An exemplary PEgRNA gRNA core structure is shown in , which has a flip of one AU base pair in the lower stem of the direct repeat.
[0045] In some embodiments, the sequence modification in the same direction repeat includes an extension in the upper stem of the same direction repeat. The length of the extension in the upper stem of the same direction repeat can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 base pairs. In some embodiments, the same direction repeat includes a sequence selected from SEQ REF NO: 26-37. In some embodiments, one or more sequence modifications include a modification in the second stem loop. In some embodiments, the modification in the second stem loop includes the flip of the G / C base pair in the second stem loop. In some embodiments, the gRNA core includes a nucleic acid sequence selected from SEQ REF NO: 21, 22 or 25. In some embodiments, the gRNA core includes a sequence selected from SEQ REF NO: 16-61.
[0046] In certain aspects, the PEgRNA provided herein comprises i) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a guide RNA (gRNA) core comprising a direct repeat, a first stem loop, and a second stem loop; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; and iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA, wherein the gRNA core comprises one or more sequence modifications compared to SEQ REF NO.16.
[0047] In some embodiments, PEgRNA comprises a spacer, a gRNA core, an editing template, and a PBS in a 5' to 3' order. In some embodiments, one or more (e.g., two or more, three or more, four or more, or five or more) sequence modifications include the gRNA core differences listed in Table 1. In some embodiments, the gRNA core of PEgRNA includes the gRNA core sequence listed in Table 1 or Table 2. In some embodiments, one or more sequence modifications include sequence modifications in the same direction repeat. For example, the same direction repeat may include the flipping of at least one AU base pair in the lower stem of the same direction repeat, optionally, wherein the lower stem does not contain 2, 3, 4 or more continuous AU base pairs; and / or the flipping of at least one A / U base pair in the same direction repeat includes the flipping of the fourth A / U base pair in the lower stem of the same direction repeat. In some embodiments, the sequence modification in the same direction repeat includes an extension in the upper stem of the same direction repeat. The extension in the upper stem of the direct repeat can be from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 base pairs. In some embodiments, the direct repeat comprises a sequence selected from SEQ REF NO: 26-37. In some embodiments, one or more sequence modifications include modifications in the second stem loop. In some embodiments, the modification in the second stem loop includes the flipping of the G / C base pair in the second stem loop. In some embodiments, the gRNA core comprises a nucleic acid sequence selected from SEQ REF NO: 21, 22 or 25. In some embodiments, the gRNA core comprises a sequence selected from SEQ REF NO: 16-61.
[0048] In certain embodiments, the PEgRNA provided herein comprises i) a spacer region comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a guide RNA (gRNA) core comprising a direct repeat, a first stem loop, and a second stem loop; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; and iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nick site in a non-target strand of the double-stranded target DNA, and v) a tag sequence comprising a region complementary to a PBS and / or editing template. In some embodiments, the PEgRNA comprises a spacer region, a gRNA core, an editing template, and a PBS in a 5' to 3' order. In some embodiments, the PEgRNA comprises an editing template, a spacer region, a tag sequence, a spacer region, and a gRNA core in a 5' to 3' order.
[0049] In some embodiments, the gRNA core comprises a first gRNA core sequence containing the 5' half of the gRNA core and a second gRNA core sequence containing the 3' half of the gRNA core, and wherein the PEgRNA comprises in 5' to 3' order: a spacer, a first gRNA core sequence, an editing template, a PBS, a tag sequence, and a second gRNA core sequence. In some embodiments, the spacer comprises a first spacer sequence containing the 5' half of the spacer and a second spacer sequence containing the 3' half of the spacer, wherein the tag sequence is between the first spacer sequence and the second spacer sequence. In some embodiments, the tag sequence comprises a region complementary to the editing template. In some embodiments, the tag sequence includes a region complementary to the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no substantial complementarity with the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no complementarity with the PBS. In some embodiments, the tag sequence and the editing template each comprise a region complementary to each other, wherein the 3' half of the complementary region in the editing template is located between 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 bases 5' of the 3' half of the editing template, wherein the complementary region in the tag sequence is located at the 5' portion of the tag sequence. In some embodiments, the tag sequence has no substantial complementarity with the spacer. In some embodiments, the tag has no complementarity with the spacer. In some embodiments, the length of the tag sequence is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. In some embodiments, the length of the tag sequence is at least 4, at least 6, at least 8 nucleotides. In some embodiments, the tag sequence comprises a nucleic acid sequence selected from SEQ REF NO 62-1960. In some embodiments, the PEgRNA comprises one or more nucleic acid portions in its 3' half. In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, and a PBS in 5' to 3' order.
[0050] In some embodiments, one or more nucleic acid portions comprise a hairpin (e.g., a hairpin comprising a self-complementary region, optionally, wherein the self-complementary region comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive complementary base pairs), a quadruplex (e.g., a G-quadruplex or a C-quadruplex, optionally, wherein the G-quadruplex or the C-quadruplex is derived from a VEGF gene promoter), a tRNA sequence (e.g., a tRNA sequence, optionally, wherein the tRNA sequence is a tRNA(proline) sequence), an aptamer (e.g., an aptamer derived from a viral protein binding sequence, optionally, wherein the aptamer comprises a viral reverse transcriptase recruitment sequence, optionally, wherein the aptamer comprises an MS2 protein binding sequence or a Moloney murine leukemia (MMLV) reverse transcriptase recruitment sequence), and / or a pseudoknot (e.g., a pseudoknot derived from potato leaf roll virus (PLRV)), or any combination thereof. In some embodiments, one or more nucleic acid portions comprise a structure derived from a replication recognition sequence of a retrovirus, optionally, wherein the retrovirus is Moloney murine leukemia (MMLV). For example, one or more nucleic acid portions may comprise a configuration as listed in Table 3. In some embodiments, one or more nucleic acid portions comprise a nucleic acid sequence selected from SEQ REF NOs 1-15.
[0051] In some embodiments, the PEgRNA comprises a joint. In some embodiments, the joint: i) is immediately adjacent to the 5' of one or more nucleic acid portions, ii) is immediately adjacent to the 5' of the tag sequence, iii) is immediately adjacent to the 3' of the tag sequence, iv) is immediately adjacent to the 3' of the spacer, v) is immediately adjacent to the 5' of the spacer, vi) is immediately adjacent to the 3' of the gRNA core, and / or vii) is immediately adjacent to the 5' of the gRNA core. In some embodiments, the length of the joint is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. In some embodiments, the length of the joint is 2 to 12 nucleotides. In some embodiments, the joint is 8 nucleotides long. In some embodiments, the joint does not form a secondary structure. In some embodiments, the joint does not have a region complementary to the PBS sequence. In some embodiments, the joint does not have a region complementary to the editing template. In some embodiments, the joint comprises a nucleic acid sequence selected from SEQREF NO 1961-3859.
[0052] In certain embodiments, the gRNA core of the PEgRNA provided herein comprises one or more sequence modifications compared to SEQ REF NO.16. In some embodiments, one or more (e.g., two or more, three or more, four or more or five or more) sequence modifications include the gRNA core differences listed in Table 1. In some embodiments, the gRNA core of the PEgRNA includes the gRNA core sequences listed in Table 1 or Table 2. In some embodiments, one or more sequence modifications include sequence modifications in the same direction repeat. For example, the same direction repeat may include the flipping of at least one AU base pair in the lower stem of the same direction repeat, optionally, wherein the lower stem does not contain 2, 3, 4 or more continuous AU base pairs; and / or the flipping of at least one A / U base pair in the same direction repeat includes the flipping of the fourth A / U base pair in the lower stem of the same direction repeat. In some embodiments, the sequence modification in the same direction repeat includes an extension in the upper stem of the same direction repeat. The extension in the upper stem of the direct repeat can be from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 base pairs. In some embodiments, the direct repeat comprises a sequence selected from SEQ REF NO: 26-37. In some embodiments, one or more sequence modifications include modifications in the second stem loop. In some embodiments, the modification in the second stem loop includes the flipping of the G / C base pair in the second stem loop. In some embodiments, the gRNA core comprises a nucleic acid sequence selected from SEQ REF NO: 21, 22 or 25. In some embodiments, the gRNA core comprises a sequence selected from SEQ REF NO: 16-61.
[0053] In some aspects, the PEgRNA provided herein comprises in 5' to 3' order: i) a spacer region comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a 5' portion of a guide RNA (gRNA) core comprising direct repeats and a first stem loop; iii) an editing template comprising an expected edit compared to a double-stranded target DNA; iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nick site in a non-target strand of a double-stranded target DNA; and v) a 3' portion of a gRNA core comprising a second stem loop. In some embodiments, the PEgRNA further comprises a tag sequence comprising a region complementary to a PBS and / or an editing template. In some embodiments, the tag sequence is located at 3' of the 3' portion of the gRNA core.
[0054] In some embodiments, the tag sequence comprises a region complementary to the editing template. In some embodiments, the tag sequence includes a region complementary to the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no substantial complementarity with the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no complementarity with the PBS. In some embodiments, the 5' end of the tag sequence comprises a region complementary to the position between 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 bases of the 5' of the 3' end of the editing template. In some embodiments, the tag sequence has no substantial complementarity with the spacer. In some embodiments, the tag has no complementarity with the spacer. In some embodiments, the length of the tag sequence is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. The length of the tag sequence can be at least 4, at least 6, or at least 8 nucleotides. In some embodiments, the tag sequence comprises a nucleic acid sequence selected from SEQ REF NO 62-1960. In some embodiments, the PEgRNA comprises one or more nucleic acid moieties at its 3' end. In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, and a PBS in a 5' to 3' order.
[0055] In some embodiments, one or more nucleic acid portions comprise a hairpin (e.g., a hairpin comprising a self-complementary region, optionally, wherein the self-complementary region comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive complementary base pairs), a quadruplex (e.g., a G-quadruplex or a C-quadruplex, optionally, wherein the G-quadruplex or the C-quadruplex is derived from a VEGF gene promoter), a tRNA sequence (e.g., a tRNA sequence, optionally, wherein the tRNA sequence is a tRNA(proline) sequence), an aptamer (e.g., an aptamer derived from a viral protein binding sequence, optionally, wherein the aptamer comprises a viral reverse transcriptase recruitment sequence, optionally, wherein the aptamer comprises an MS2 protein binding sequence or a Moloney murine leukemia (MMLV) reverse transcriptase recruitment sequence), and / or a pseudoknot (e.g., a pseudoknot derived from potato leaf roll virus (PLRV)), or any combination thereof. In some embodiments, one or more nucleic acid portions comprise a structure derived from a replication recognition sequence of a retrovirus, optionally, wherein the retrovirus is Moloney murine leukemia (MMLV). For example, one or more nucleic acid portions may comprise a configuration as listed in Table 2. In some embodiments, one or more nucleic acid portions (eg, the nucleic acid portion at the 3' end of the PEgRNA) comprise a nucleic acid sequence selected from SEQ REF NOs 1-15.
[0056] In some embodiments, the PEgRNA comprises a joint. In some embodiments, the joint: i) is immediately adjacent to the 5' of one or more nucleic acid portions, ii) is immediately adjacent to the 5' of the tag sequence, iii) is immediately adjacent to the 3' of the tag sequence, iv) is immediately adjacent to the 3' of the spacer, v) is immediately adjacent to the 5' of the spacer, vi) is immediately adjacent to the 3' of the gRNA core, and / or vii) is immediately adjacent to the 5' of the gRNA core. In some embodiments, the length of the joint is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. The length of the joint can be 2-12 nucleotides. The length of the joint can be 8 nucleotides. In some embodiments, the joint does not form a secondary structure. In some embodiments, the joint does not have a region complementary to the PBS sequence. In some embodiments, the joint does not have a region complementary to the editing template.
[0057] In some embodiments, the 5' portion of the gRNA core and the 3' portion of the guide RNA (gRNA) core comprise one or more sequence modifications compared to SEQ REF NO. 16. In some embodiments, the one or more sequence modifications include the gRNA core differences listed in Table 1 or Table 2.
[0058] In some embodiments, one or more sequence modifications include sequence modifications in the same direction repeat. For example, the same direction repeat may include the flip of at least one AU base pair in the lower stem of the same direction repeat, optionally, wherein the lower stem does not contain 2, 3, 4 or more continuous AU base pairs; and / or the flip of at least one A / U base pair in the same direction repeat includes the flip of the fourth A / U base pair in the lower stem of the same direction repeat. In some embodiments, the sequence modification in the same direction repeat includes the extension in the upper stem of the same direction repeat. The extension in the upper stem of the same direction repeat can be from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 base pairs. In some embodiments, the same direction repeat includes a sequence selected from SEQ REF NO: 26-37. In some embodiments, one or more sequence modifications include modifications in the second stem loop. In some embodiments, the modification in the second stem loop includes the flip of the G / C base pair in the second stem loop. In some embodiments, the gRNA core comprises a nucleic acid sequence selected from SEQ REF NO: 21, 22 or 25. In some embodiments, the gRNA core comprises a sequence selected from SEQ REF NO: 16-61. In some embodiments, the linker comprises a nucleic acid sequence selected from SEQ REF NO 1961-3859.
[0059] In some aspects, the PEgRNA provided herein comprises: i) a first sequence comprising a spacer containing a region complementary to a search target sequence in a target strand of a double-stranded target DNA, and the first half of a gRNA core; and ii) a second sequence comprising the second half of the gRNA core, an editing template comprising the expected editing compared to the double-stranded target DNA; a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and wherein the gRNA core comprises a direct repeat, a first stem loop, and a second stem loop.
[0060] In certain aspects, the PEgRNA provided herein comprises: i) a first sequence comprising an editing template comprising an expected edit compared to a double-stranded target DNA; a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; a spacer comprising a region complementary to a search target sequence in a target strand of the double-stranded target DNA; and the first half of a gRNA core; and ii) a second sequence comprising the second half of the gRNA core, wherein the gRNA core comprises a direct repeat, a first stem loop, and a second stem loop.
[0061] In some embodiments, the first sequence is on the first RNA molecule, and the second sequence is on the second RNA molecule. In some embodiments, the spacer and the first sequence and the second sequence are on the same RNA molecule. In some embodiments, the first half of the gRNA core and the second half of the gRNA core are selected from the first half gRNA core sequence and the second half gRNA sequence of the pairing provided in Table 2.
[0062] In certain embodiments, the PEgRNA further comprises a tag sequence comprising a region complementary to the PBS and / or editing template. In some embodiments, the PEgRNA comprises a spacer, the first half of the gRNA core, the second half of the gRNA core, an editing template, a PBS, and a tag sequence in a 5' to 3' order. In some embodiments, the PEgRNA comprises an editing template, a spacer, a tag sequence, a spacer, the first half of the gRNA core, and the second half of the gRNA core in a 5' to 3' order.
[0063] In some embodiments, the tag sequence comprises a region complementary to the editing template and has no substantial complementarity with the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no complementarity with the PBS. In some embodiments, the 5' end of the tag sequence comprises a region complementary to a position between 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 bases of the 5' of the 3' end of the editing template. In some embodiments, the tag sequence has no substantial complementarity with the spacer. In some embodiments, the tag has no complementarity with the spacer. In some embodiments, the length of the tag sequence is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. The length of the tag sequence can be at least 4 nucleotides, at least 6 nucleotides, or at least 8 nucleotides. The length of the tag sequence can be 2-12 nucleotides. In some embodiments, the tag sequence comprises a nucleic acid sequence selected from SEQ REF NO 62-1960. In some embodiments, the PEgRNA comprises one or more nucleic acid moieties in its 3' half. In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, and a PBS in 5' to 3' order.
[0064] In some embodiments, one or more nucleic acid portions comprise a hairpin (e.g., a hairpin comprising a self-complementary region, optionally, wherein the self-complementary region comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 consecutive complementary base pairs), a quadruplex (e.g., a G-quadruplex or a C-quadruplex, optionally, wherein the G-quadruplex or the C-quadruplex is derived from a VEGF gene promoter), a tRNA sequence (e.g., a tRNA sequence, optionally, wherein the tRNA sequence is a tRNA(proline) sequence), an aptamer (e.g., an aptamer derived from a viral protein binding sequence, optionally, wherein the aptamer comprises a viral reverse transcriptase recruitment sequence, optionally, wherein the aptamer comprises an MS2 protein binding sequence or a Moloney murine leukemia (MMLV) reverse transcriptase recruitment sequence), and / or a pseudoknot (e.g., a pseudoknot derived from potato leaf roll virus (PLRV)), or any combination thereof. In some embodiments, one or more nucleic acid portions comprise a structure derived from a replication recognition sequence of a retrovirus, optionally, wherein the retrovirus is Moloney murine leukemia (MMLV). For example, one or more nucleic acid portions may comprise a configuration as listed in Table 2. In some embodiments, one or more nucleic acid portions comprise a nucleic acid sequence selected from SEQ REF NOs 1-15.
[0065] In some embodiments, the PEgRNA comprises a joint. In some embodiments, the joint: i) is immediately adjacent to the 5' of one or more nucleic acid portions, ii) is immediately adjacent to the 5' of the tag sequence, iii) is immediately adjacent to the 3' of the tag sequence, iv) is immediately adjacent to the 3' of the spacer, v) is immediately adjacent to the 5' of the spacer, vi) is immediately adjacent to the 3' of the gRNA core, and / or vii) is immediately adjacent to the 5' of the gRNA core. In some embodiments, the length of the joint is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. In some embodiments, the joint does not form a secondary structure. In some embodiments, the joint does not have a region complementary to the PBS sequence. In some embodiments, the joint does not have a region complementary to the editing template.
[0066] In some embodiments, the 5' portion of the gRNA core and the 3' portion of the guide RNA (gRNA) core comprise one or more sequence modifications compared to SEQ REF NO. 16. In some embodiments, the one or more sequence modifications include the gRNA core differences listed in Table 1 or Table 2. In some embodiments, the linker comprises a nucleic acid sequence selected from SEQ REF NO 1961-3859.
[0067] In some embodiments, one or more sequence modifications include sequence modifications in the same direction repeat. For example, the same direction repeat may include the flip of at least one AU base pair in the lower stem of the same direction repeat, optionally, wherein the lower stem does not contain 2, 3, 4 or more continuous AU base pairs; and / or the flip of at least one A / U base pair in the same direction repeat includes the flip of the fourth A / U base pair in the lower stem of the same direction repeat. In some embodiments, the sequence modification in the same direction repeat includes the extension in the upper stem of the same direction repeat. The extension in the upper stem of the same direction repeat can be from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 base pairs. In some embodiments, the same direction repeat includes a sequence selected from SEQ REF NO: 26-37. In some embodiments, one or more sequence modifications include modifications in the second stem loop. In some embodiments, the modification in the second stem loop includes the flip of the G / C base pair in the second stem loop. In some embodiments, the gRNA core comprises a nucleic acid sequence selected from SEQ REF NO: 21, 22, or 25. In some embodiments, the gRNA core comprises a sequence selected from SEQ REF NO: 16-61.
[0068] In certain aspects, provided herein is a method of making a PEgRNA as described herein, the method comprising linking a first sequence to a second sequence.
[0069] In certain aspects, provided herein are methods of making a PEgRNA, the methods comprising synthesizing a polynucleotide comprising a sequence encoding a PEgRNA as described herein.
[0070] In certain aspects, provided herein are PEgRNA systems comprising a PEgRNA as described herein.
[0071] In certain aspects, provided herein is a lead editing complex comprising: (i) a PEgRNA disclosed herein or a PEgRNA system disclosed herein; and (ii) a lead editor comprising a DNA binding domain and a DNA polymerase domain. In some embodiments, the DNA binding domain is a CRISPR-associated (Cas) protein domain. In some embodiments, the Cas protein domain has nickase activity. In some embodiments, the Cas protein domain is Cas9. In some embodiments, Cas9 comprises a mutation in the HNH domain. In some embodiments, Cas9 comprises an H840A mutation in the HNH domain. In some embodiments, the Cas protein domain is Cas12b. In some embodiments, the Cas protein domain is Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14a, Cas14b, Cas14c, Cas14d, Cas14e, Cas14f, Cas14g, Cas14h, Cas14u or In some embodiments, the DNA polymerase domain is a reverse transcriptase. Many reverse transcriptases have DNA-dependent DNA synthesis ability in addition to RNA-dependent DNA synthesis ability (i.e., reverse transcription). In some embodiments, the reverse transcriptase is a retroviral reverse transcriptase. In some embodiments, the reverse transcriptase is a Moloney murine leukemia virus (M-MLV) reverse transcriptase. In some embodiments, the DNA polymerase and the programmable DNA binding domain are fused or connected to form a fusion protein. In some embodiments, the fusion protein comprises the sequence of SEQ REF NO:4440.
[0072] In certain aspects, provided herein are lipid nanoparticles (LNP) or ribonucleoproteins (RNP) comprising a lead editing complex or a component thereof. One embodiment provides a polynucleotide encoding a PEgRNA of the present disclosure, a PEgRNA system of the present disclosure, or a fusion protein of the present disclosure. In some embodiments, the polynucleotide is an mRNA. In some embodiments, the polynucleotide is operably linked to a regulatory element. In some embodiments, the regulatory element is an inducible regulatory element.
[0073] In certain aspects, provided herein are vectors comprising the polynucleotides of the above embodiments. In some embodiments, the vector is an AAV vector.
[0074] In certain aspects, provided herein is an isolated cell comprising a PEgRNA of the present disclosure, a PEgRNA system of the present disclosure, a lead editing complex of the present disclosure, an LNP or RNP of any of the above embodiments, a polynucleotide of any of the above embodiments, and / or a vector of any of the above embodiments. In some embodiments, the cell is a human cell.
[0075] In some aspects, provided herein is a pharmaceutical composition comprising at least one of: (i) a PEgRNA disclosed herein, a PEgRNA system disclosed herein, a lead editing complex disclosed herein, an LNP or RNP of an embodiment described herein, a polynucleotide of any of the foregoing embodiments, a vector of any of the foregoing embodiments, and / or a cell of any of the foregoing embodiments; and at least one (ii) a pharmaceutically acceptable carrier.
[0076] In certain aspects, provided herein is a method for editing a gene, the method comprising contacting the gene with any one of: (i) a PEgRNA disclosed herein or any PEgRNA system disclosed herein and (ii) a lead editor comprising a DNA binding domain and a DNA polymerase domain, wherein the PEgRNA guides the lead editor to incorporate the intended nucleotide edits into the gene, thereby editing the gene.
[0077] In certain aspects, the present invention also provides a method for editing a gene, the method comprising contacting the gene with a lead editing complex disclosed herein, wherein the PEgRNA guides the lead editor to incorporate the intended nucleotide edits into the gene, thereby editing the gene.
[0078] In some embodiments, the lead editor synthesizes a single-stranded DNA encoded by an editing template, wherein the single-stranded DNA replaces the editing target sequence and causes the expected nucleotide editing to be incorporated into the region corresponding to the editing target in the gene. In some embodiments, the gene is in a cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is a primary cell. In some embodiments, the cell is in a subject. In some embodiments, the subject is a human. In some embodiments, the method further comprises administering the cell to the subject after incorporating the expected nucleotide editing.
[0079] In certain embodiments, provided herein are cells generated by any of the methods described above. In certain embodiments, provided herein are a population of cells generated by any of the methods provided herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] The novel features of the methods and compositions provided herein are specifically set forth in the appended claims. The features and advantages of the methods and compositions provided herein will be better understood by reference to the following detailed description which sets forth illustrative embodiments, in which the principles of the methods and compositions provided herein are utilized, and in the accompanying drawings:
[0081] Figure 1 Exemplary nucleic acid portions (eg, contained on the 3' end of a PEgRNA disclosed herein) are shown.
[0082] Figure 2 3 graphs showing that nucleic acid moieties increase editing efficiency. Each violin plot represents a combination of 48 unique PEgRNAs (1 spacer, 3 unique edits, 4 PBS lengths, 4 RTT lengths).
[0083] Figure 3 An exemplary PEgRNA with a spacer and a PBS is shown.
[0084] Figure 4 An exemplary PEgRNA with a spacer, RTT, PBS, linker, and tag is shown.
[0085] Figure 5 An exemplary PEgRNA is shown with a spacer, RTT, PBS, linker, and tag, with arrows pointing to Figure 6 and 7 The "0" position used in .
[0086] Figure 6 is a graph showing the effect of tag start position on prime editing efficiency.
[0087] Figure 7 is a graph showing the effect of tag start position on prime editing efficiency.
[0088] Figure 8 An exemplary PEgRNA gRNA core is shown. The dashed lines and arrows represent two potential locations where the PEgRNA can be split into two RNA molecules for separate synthesis (e.g., before ligation).
[0089] Fig. 9 is a graph showing LegRNA editing efficiency.
[0090] Fig.10 A schematic diagram illustrating an exemplary oligonucleotide library design is shown.
[0091] Fig.11 A schematic diagram illustrating an exemplary amplified oligonucleotide library is shown.
[0092] Fig.12 An exemplary structure of the spacer and gRNA core of a PEgRNA is shown, wherein there is a flip of an AU base pair in the lower stem of the direct repeat and a 5-nucleotide extension in the upper stem of the direct repeat. The rest of the PEgRNA (e.g., editing template and PBS) is not shown.
[0093] Figures 13A to 13C is a graph showing the effect of the tag (Comp Tag) binding position on the efficiency of prime editing. Fig.13A The effect of the binding position of a 4-nucleotide-long tag on the efficiency of prime editing is shown. Fig. 13B The effect of the binding position of a 6-nucleotide tag on the efficiency of prime editing is shown. Fig. 13C The effect of the binding position of an 8-nucleotide-long tag on the efficiency of prime editing is shown.
[0094] Fig.14 is a graph showing the effect of tag (CompTag) length of the fully incorporated tag pool within the PEgRNA editing template on lead editing efficiency. DETAILED DESCRIPTION
[0095] In some embodiments, provided herein are compositions and methods related to modified lead editing guide RNA (PEgRNA), which can be used, for example, for lead editing applications. In certain embodiments, provided herein are compositions and methods for introducing intended nucleotide editing (e.g., correcting mutations in genes (including genes associated with diseases)) in target DNA. The compositions provided herein may include PEgRNA, which can guide a lead editor (PE) to a specific DNA target and introduce nucleotide editing on the target gene.
[0096] The following description and examples illustrate embodiments of the present disclosure in detail. It should be understood that the present disclosure is not limited to the specific embodiments described herein and is therefore subject to change. Those skilled in the art will recognize that there are many changes and modifications to the present disclosure that are encompassed within the scope of the present disclosure. Although the various features of the present disclosure can be described in the context of a single embodiment, these features can also be provided individually or in any suitable combination. On the contrary, although for clarity, the present disclosure can be described in the context of a separate embodiment, the present disclosure can also be implemented in a single embodiment.
[0097] definition
[0098] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
[0099] The terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting. As used herein, the singular forms "a / an", "a / an" and "the" are also intended to include the plural forms, unless the context clearly indicates otherwise. In addition, the terms "comprises", "comprising", "having", "having", "with" or variations thereof as used herein mean "comprising".
[0100] Unless stated otherwise, the words "comprising," "having," "including," and "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0101] Reference to "some embodiments," "an embodiment," "one embodiment," or "other embodiments" means that a particular feature or characteristic described in connection with the embodiments is included in at least one or more but not all embodiments of the present disclosure.
[0102] The term "about" or "approximately" means within 10% of a given value, rounded when only integers are applicable. For example, about 100 means 90 to 110, and about 7 means 6 to 8. When particular values are described in the application and claims, the value should be assumed to be modified by the term "about" unless otherwise indicated.
[0103] As used herein, "cell" may generally refer to a biological cell. A cell may be the basic structural, functional and / or biological unit of a living organism. A cell may be derived from any organism having one or more cells. Some non-limiting examples include: prokaryotic cells, eukaryotic cells, bacterial cells, archaeal cells, cells of unicellular eukaryotic organisms, protozoan cells, cells from plants, animal cells, cells from invertebrates (e.g., fruit flies, cnidarians, echinoderms, nematodes, etc.), cells from vertebrates (e.g., fish, amphibians, reptiles, birds, mammals), cells from mammals (e.g., pigs, cattle, goats, sheep, rodents, rats, mice, non-human primates, humans, etc.), etc. Sometimes a cell may not be derived from a natural organism (e.g., a cell may be made by synthesis, sometimes referred to as an artificial cell).
[0104] In some embodiments, the cell is a human cell. The cell may come from or be derived from different tissues, organs and / or cell types. In some embodiments, the cell is a primary cell. In some embodiments, the term primary cell means a cell separated from an organism (e.g., a mammal), which grows in a tissue culture (i.e., in vitro) for the first time before being subdivided and transferred to a subculture. In some non-limiting examples, mammalian primary cells can be modified and further subcultured by introducing one or more polynucleotides, polypeptides and / or lead editing compositions (e.g., by transfection, transduction, electroporation, etc.). Such modified mammalian primary cells include myocytes (e.g., cardiomyocytes, smooth muscle cells, muscle satellite cells), epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells, hepatocytes), endothelial cells, glial cells, neural cells, blood-forming elements (e.g., lymphocytes, bone marrow cells), precursors and stem cells of any of these somatic cell types. In some embodiments, the cell is a fibroblast. In some embodiments, the cell is a stem cell. In some embodiments, the cell is a pluripotent stem cell. In some embodiments, the cell is an induced pluripotent stem cell (iPSC). In some embodiments, the cell is a stem cell. In some embodiments, the cell is an embryonic stem cell (ESC). In some embodiments, the cell is a human stem cell. In some embodiments, the cell is a human pluripotent stem cell. In some embodiments, the cell is a human fibroblast. In some embodiments, the cell is a human induced pluripotent stem cell (iPSC). In some embodiments, the cell is a human stem cell. In some embodiments, the cell is a human embryonic stem cell.
[0105] In some embodiments, the cell is not separated from an organism, but forms a part of a tissue or organ of an organism (e.g., a mammal). In some non-limiting examples, mammalian cells include myocytes (e.g., cardiomyocytes, smooth muscle cells, muscle satellite cells), epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells, hepatocytes), endothelial cells, glial cells, nerve cells, the formation elements of blood (e.g., lymphocytes, bone marrow cells), precursors and stem cells of any of these somatic cell types. In some embodiments, the cell is a primary myocyte. In some embodiments, the cell is a muscle satellite cell (satellite cell). In some embodiments, the cell is a human muscle satellite cell (satellite cell). In some embodiments, the cell is a stem cell. In some embodiments, the cell is a human stem cell.
[0106] In some embodiments, the cell is a differentiated cell. In some embodiments, the cell is a fibroblast. In some embodiments, the cell is a differentiated muscle cell, a muscle satellite cell, a differentiated epithelial cell or a differentiated neuronal cell. In some embodiments, the cell is a skeletal muscle cell. In some embodiments, skeletal muscle cells are differentiated from iPSC, ESC or muscle satellite cells. In some embodiments, the cell is a differentiated human cell. In some embodiments, the cell is a human fibroblast. In some embodiments, the cell is a differentiated human muscle cell. In some embodiments, the cell is a human muscle satellite cell. In some embodiments, the cell is a human skeletal muscle cell. In some embodiments, human skeletal muscle cells are differentiated from human iPSC, human ESC or human muscle satellite cells. In some embodiments, the cell is differentiated from human iPSC or human ESC.
[0107] In some embodiments, the cell comprises a lead editor, a PEgRNA, an ngRNA, a lead editing system, or a lead editing complex. In some embodiments, the cell is from a human subject. In some embodiments, the human subject suffers from a disease or condition associated with a mutation to be corrected by lead editing. In some embodiments, the cell is from a human subject and comprises a lead editor, a PEgRNA, an ngRNA, a lead editing system, or a lead editing complex for correcting a mutation. In some embodiments, the cell is from a human subject, and the mutation has been edited or corrected by lead editing. In some embodiments, the cell is in a human subject and comprises a lead editor, a PEgRNA, an ngRNA, a lead editing system, or a lead editing complex for correcting a mutation. In some embodiments, the cell is from a human subject, and the mutation has been edited or corrected by lead editing.
[0108] As used herein, the term "substantially" may refer to a value that is close to 100% of a given value. In some embodiments, the term may refer to an amount that may be at least about 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 99.99% of the total amount. In some embodiments, the term may refer to an amount that may be about 100% of the total amount.
[0109] The terms "protein" and "polypeptide" are used interchangeably and refer to a polymer of two or more amino acids linked by covalent bonds (e.g., amide bonds), which can adopt a three-dimensional conformation. In some embodiments, a protein or polypeptide comprises at least 10 amino acids, 15 amino acids, 20 amino acids, 30 amino acids, or 50 amino acids linked by covalent bonds (e.g., amide bonds). In some embodiments, a protein comprises at least two amide bonds. In some embodiments, a protein comprises a plurality of amide bonds. In some embodiments, a protein comprises an enzyme, an enzyme precursor protein, a regulatory protein, a structural protein, a receptor, a nucleic acid binding protein, a biomarker, a member of a specific binding pair (e.g., a ligand or an aptamer), or an antibody. In some embodiments, a protein may be a full-length protein (e.g., a fully processed protein with a certain biological function). In some embodiments, a protein may be a variant or fragment of a full-length protein. For example, in some embodiments, compared to a naturally occurring Streptococcus pyogenes Cas9 protein, a Cas9 protein domain comprises an H840A amino acid substitution. Variants of a protein or enzyme (e.g., a variant reverse transcriptase) include polypeptides having an amino acid sequence that is about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, about 99.5% identical, or about 99.9% identical to the amino acid sequence of the reference protein.
[0110] In some embodiments, the protein comprises one or more protein domains or subdomains. As used herein, the term "polypeptide domain", "protein domain" or "domain" when used in the context of a protein or polypeptide refers to a polypeptide chain having one or more biological functions (e.g., catalytic function, protein-protein binding function or protein-DNA function). In some embodiments, the protein comprises multiple protein domains. In some embodiments, the protein comprises multiple naturally occurring protein domains. In some embodiments, the protein comprises multiple protein domains from different naturally occurring proteins. For example, in some embodiments, the lead editor can be a fusion protein comprising a Cas9 protein domain of Streptococcus pyogenes and a reverse transcriptase protein domain of Moloney murine leukemia virus. Proteins comprising amino acid sequences of proteins from different sources or naturally occurring proteins can be referred to as fusion proteins or chimeric proteins.
[0111] In some embodiments, the protein comprises a functional variant or functional fragment of a full-length wild-type protein. As used herein, a "functional fragment" or "functional portion" refers to any portion of a reference protein (e.g., a wild-type protein) that encompasses less than the entire amino acid sequence of the reference protein but retains one or more of the functions (e.g., catalytic or binding functions). For example, a functional fragment of a reverse transcriptase may encompass less than the entire amino acid sequence of a wild-type reverse transcriptase, but retains the ability to catalyze polynucleotide polymerization under at least one set of conditions. When the reference protein is a fusion of multiple functional domains, its functional fragment may retain one or more functions of at least one of the functional domains. For example, a functional fragment of Cas9 may encompass less than the entire amino acid sequence of a wild-type Cas9, but retains its DNA binding ability and partially or completely lacks its nuclease activity.
[0112] As used herein, "functional variant" or "functional mutant" refers to any variant or mutant of a reference protein (e.g., a wild-type protein) that encompasses one or more changes to the amino acid sequence of the reference protein but retains one or more of the functions (e.g., catalytic or binding functions). In some embodiments, one or more changes to the amino acid sequence include amino acid substitutions, insertions or deletions, or any combination thereof. In some embodiments, one or more changes to the amino acid sequence include amino acid substitutions. For example, compared to the amino acid sequence of a wild-type reverse transcriptase, a functional variant of a reverse transcriptase may include one or more amino acid substitutions, but retains the ability to catalyze polynucleotide polymerization under at least one set of conditions. When the reference protein is a fusion of multiple functional domains, its functional variant may retain one or more functions of at least one of the functional domains. For example, in some embodiments, compared to the amino acid sequence of a wild-type Cas9, a functional fragment of Cas9 may include one or more amino acid substitutions (e.g., H840A amino acid substitution) in the nuclease domain, but retains DNA binding ability and partially or completely lacks nuclease activity.
[0113] As used herein, the term "function" and its grammatical equivalents may refer to the ability to operate, have or serve the intended purpose. Function may include any percentage from baseline to 100% of the intended purpose. For example, a function may include or include about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to about 100% of the intended purpose. In some embodiments, the term function may mean more than 100% of normal function or more than about 100% of normal function, for example, 125%, 150%, 175%, 200%, 250%, 300%, 400%, 500%, 600%, 700% or up to about 1000% of the intended purpose. In some embodiments, the protein or polypeptide comprises naturally occurring amino acids (e.g., one of the twenty amino acids commonly found in peptides synthesized in nature and known by the single letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V). In some embodiments, the protein or polypeptide comprises non-naturally occurring amino acids (e.g., an amino acid that is not one of the twenty amino acids commonly found in peptides synthesized in nature, including synthetic amino acids, amino acid analogs, and amino acid mimetics). In some embodiments, the protein or polypeptide is modified.
[0114] In some embodiments, the protein includes an isolated polypeptide. The term "isolated" means free or removed to varying degrees from components that normally accompany it in its natural state or environment. For example, a polypeptide naturally present in a living animal is not isolated, but the same polypeptide partially or completely separated from coexisting materials in its natural state is isolated.
[0115] In some embodiments, the protein is present in a cell, tissue, organ or viral particle. In some embodiments, the protein is present in a cell or a portion of a cell (e.g., a bacterial cell, a plant cell or an animal cell). In some embodiments, the cell is in a tissue, a subject or a cell culture. In some embodiments, the cell is a microorganism (e.g., a bacterium, a fungus, a protozoa or a virus). In some embodiments, the protein is present in a mixture (e.g., a lysate) of an analyte. In some embodiments, the protein is present in a lysate from multiple cells or in a lysate from a single cell.
[0116] As used herein, the terms "homologous", "homology" or "percent homology" refer to the degree of sequence identity between an amino acid or polynucleotide sequence and a corresponding reference sequence. "Homology" can refer to a polymeric sequence, such as a similar polypeptide or DNA sequence. Homology can mean, for example, a nucleic acid sequence having at least about: 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In other embodiments, a "homologous sequence" of a nucleic acid sequence can exhibit 93%, 95% or 98% sequence identity to a reference nucleic acid sequence. For example, a "region having homology to a genomic region" can be a DNA region having a similar sequence to a given genomic region in a genome. The region of homology can be any length sufficient to facilitate binding of the spacer, primer binding site, or protospacer sequence to the genomic region. For example, the region of homology can comprise at least 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, , 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100 or more bases in length such that the region with homology has sufficient homology to bind to the corresponding genomic region.
[0117] When specifying the percentage of sequence homology or identity, in the context of two nucleic acid sequences or two peptide sequences, the percentage of homology or identity generally refers to the comparison of two or more sequences on a portion of their length when comparing and comparing to obtain maximum correspondence. When the position in the compared sequence is occupied by the same base or amino acid, these molecules can be homologous at the position. Unless otherwise stated, sequence homology or identity is assessed on the specified length of nucleic acid, polypeptide or its part. In some embodiments, homology or identity is assessed on the functional part or specified part of the length.
[0118] Sequence alignments for assessing sequence homology can be performed by algorithms known in the art, such as the Basic Local Alignment Search Tool (BLAST) algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410, 1990. A public Internet interface for performing BLAST analysis can be accessed through the National Center for Biotechnology Information. Additional known algorithms include those published in Smith & Waterman, "Comparison of Bio sequences", Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, "A general method applicable to the search for similarities in the amino acid sequence of two proteins" J. Mol. Biol. 48:443, 1970; Pearson & Lipman "Improved tools for biological sequence comparison", Proc. Natl. Acad. Sci. USA 85:2444, 1988; or automated implementations of these or similar algorithms. Global alignment programs can also be used to compare similar sequences of roughly equal size. Examples of global alignment programs include NEEDLE (available at www.ebi.ac.uk / Tools / psa / emboss_needle / ), which is a part of the EMBOSS package (Rice P et al., Tr ends Genet., 2000; 16: 276-277); and GGSEARCH program https: / / fasta.bioch.virginia.edu / fasta_www2 / , which is a part of the FASTA package (Pearson W and Lipman D, 1988, Proc. Natl. Acad. Sci. USA, 85: 2444-2448). Both programs are based on the Needleman-Wunsch algorithm, which is used to find the best alignment (including gaps) along the entire length of the two sequences. A detailed discussion of sequence analysis can also be found in Unit 19.3 of Ausubel et al. ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-1998, Chapter 15, 1998).Unless otherwise stated, percent identity should be determined based on an alignment of the query sequence to the reference sequence performed with a Needleman-Wunsch alignment with gap penalties set to existence: 11 extension: 1, where percent identity is calculated by dividing the number of identities by the length of the alignment.
[0119] A skilled artisan understands that amino acid (or nucleotide) positions can be determined in homologous sequences based on alignment, for example, "H840" in a reference Cas9 sequence can correspond to H839, or another position in a Cas9 homolog.
[0120] The term "polynucleotide" or "nucleic acid molecule" can be any polymeric form of nucleotides, including DNA, RNA, hybrids thereof, or RNA-DNA chimeric molecules. In some embodiments, the polynucleotide includes cDNA, genomic DNA, mRNA, tRNA, rRNA, or microRNA. In some embodiments, the polynucleotide is double-stranded, such as double-stranded DNA in a gene. In some embodiments, the polynucleotide is single-stranded or substantially single-stranded, such as single-stranded DNA or mRNA. In some embodiments, the polynucleotide is a cell-free nucleic acid molecule. In some embodiments, the polynucleotide circulates in the blood. In some embodiments, the polynucleotide is a cellular nucleic acid molecule. In some embodiments, the polynucleotide is a cellular nucleic acid molecule in a cell that circulates in the blood.
[0121] The polynucleotide may have any three-dimensional structure. The following are non-limiting examples of polynucleotides: a gene or gene fragment (e.g., a probe, primer, EST or SAGE tag), an exon, an intron, an intergenic DNA (including but not limited to heterochromatic DNA), a messenger RNA (mRNA), a transfer RNA (tRNA), a ribosomal RNA (rRNA), a ribozyme, a cDNA, a recombinant polynucleotide, a branched polynucleotide, a plasmid, a vector, an isolated DNA, an isolated RNA, a sgRNA, a guide RNA, a nucleic acid probe, a primer, a snRNA, a long non-coding RNA, a snoRNA, a siRNA, a miRNA, a tRNA-derived small RNA (tsRNA), an antisense RNA, a shRNA, or a small rDNA-derived RNA (srRNA).
[0122] In some embodiments, polynucleotides include deoxyribonucleotides, ribonucleotides or their analogs. In some embodiments, polynucleotides may include modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, the nucleotide structure may be modified before or after polynucleotide assembly. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides may be further modified such as by conjugation with a labeling component.
[0123] In some embodiments, the polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and when the polynucleotide is RNA, uracil (U) replaces thymine. In some embodiments, the polynucleotide may include one or more other nucleotide bases, such as inosine (I), which is read as guanine (G) by the translation mechanism. Consistent with the ST.26 standard, the RNA sequence provided herein (e.g., PEgRNA sequence) may contain "T" instead of "U".
[0124] In some embodiments, polynucleotides may be modified. As used herein, the term "modified" or "modification" refers to chemical modifications of A, C, G, T, and U nucleotides. In some embodiments, the modification may be on the sugar moiety of the nucleoside bases and / or nucleosides that make up the polynucleotides. In some embodiments, the modification may be on the internucleoside linkage (e.g., phosphate backbone). In some embodiments, a variety of modifications are included in the modified nucleic acid molecules. In some embodiments, a single modification is included in the modified nucleic acid molecules.
[0125] The terms "complementary", "complementary" or "complementarity" as used herein refer to the ability of two polynucleotide molecules to base pair with each other. Complementary polynucleotides can base pair by hydrogen bonding, which can be Watson Crick hydrogen bonding, Hoogsteen hydrogen bonding or anti-Hoogsteen hydrogen bonding. For example, an adenine on one polynucleotide molecule will base pair with a thymine or uracil on a second polynucleotide molecule, a cytosine on one polynucleotide molecule will base pair with a guanine on a second polynucleotide molecule, a guanine on one polynucleotide molecule will base pair with a cytosine or uracil on a second polynucleotide molecule, and a thymine or uracil on one polynucleotide molecule will base pair with an adenine or guanine on a second polynucleotide molecule. Two polynucleotide molecules are complementary to each other when a first polynucleotide molecule comprising a first nucleotide sequence can base pair with a second polynucleotide molecule comprising a second nucleotide sequence. For example, two DNA molecules 5'-ATGC-3' and 5'-GCAT-3' are complementary, and the complement of the DNA molecule 5'-ATGC-3' is 5'-GCAT-3'. The complementarity percentage represents the percentage of nucleotides in a polynucleotide molecule that can be base-paired with a second polynucleotide molecule (for example, 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90% and 100% complementary, respectively). "Completely complementary" means that all consecutive nucleotides of a polynucleotide molecule will be base-paired with the same number of consecutive nucleotides in a second polynucleotide molecule. "Substantially complementary" as used herein means that the degree of complementarity of all or part of two polynucleotide molecules can be 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99%. In some embodiments, the complementary portion can be a region of 10, 15, 20, 25, 30, 35, 40, 45, 50 or more nucleotides. "Substantially complementary" may also refer to 100% complementarity of a portion of two polynucleotide molecules. In some embodiments, the complementary portion between two polynucleotide molecules is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% of the length of at least one of the two polynucleotide molecules or a functional portion or defined portion thereof.
[0126] As used herein, "expression" refers to the process of polynucleotide transcription into mRNA and / or the process of polynucleotide (e.g., transcribed mRNA) translation into peptides, polypeptides or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing mRNA in eukaryotic cells. In some embodiments, the expression of a polynucleotide (e.g., a gene or a DNA encoding a protein) is determined by the amount of the protein encoded by the gene after gene transcription and translation. In some embodiments, the expression of a polynucleotide (e.g., a gene or a DNA encoding a protein) is determined by the amount of the functional form of the protein encoded by the gene after gene transcription and translation. In some embodiments, the expression of a gene is determined by the amount of the mRNA or transcript encoded by the gene after gene transcription. In some embodiments, the expression of a polynucleotide (e.g., mRNA) is determined by the amount of the protein encoded by the mRNA after mRNA translation. In some embodiments, the expression of a polynucleotide (e.g., mRNA or coding RNA) is determined by the amount of the functional form of the protein encoded by the polypeptide after polynucleotide translation.
[0127] The term "sequencing" as used herein may include capillary sequencing, bisulfite-free sequencing, bisulfite sequencing, TET-assisted bisulfite (TAB) sequencing, ACE sequencing, high-throughput sequencing, Maxam-Gilbert sequencing, massively parallel signature sequencing, Polony sequencing, 454 pyrosequencing, Sanger sequencing, Illumina sequencing, SOLiD sequencing, Ion Torrent semiconductor sequencing, DNA nanoball sequencing, Heliscope single molecule sequencing, single molecule real-time (SMRT) sequencing, nanopore sequencing, shotgun sequencing, RNA sequencing, or any combination thereof.
[0128] The terms "equivalent" or "bioequivalent" are used interchangeably when referring to specific molecules or biological or cellular materials and refer to molecules that have minimal homology to another molecule while still retaining the desired structure or function.
[0129] When the term "encoding" is applied to a polynucleotide, it means that if a polynucleotide can be used as a polynucleotide synthesis template in its native state or when operated by methods well known to those skilled in the art, for example, transcribed into RNA, reverse transcribed into DNA or cDNA, and / or translated to produce an amino acid or polypeptide or a fragment thereof, the polynucleotide is said to "encode" another polynucleotide, polypeptide or amino acid. In some embodiments, a polynucleotide comprising three consecutive nucleotides forms a codon encoding a specific amino acid. In some embodiments, a polynucleotide comprises one or more codons encoding a polypeptide. In some embodiments, a polynucleotide comprising one or more codons comprises a mutation in the codon compared to a wild-type reference polynucleotide. In some embodiments, a mutation in a codon encodes an amino acid substitution in a polypeptide encoded by the polynucleotide compared to a wild-type reference polypeptide.
[0130] The term "mutation" as used herein refers to changes and / or variations in the amino acid sequence of a protein or the nucleic acid sequence of a polynucleotide. Such changes and / or variations may include substitutions, insertions, deletions and / or truncations of one or more amino acids (with respect to amino acid sequences) and / or nucleotides (with respect to nucleic acid sequences) compared to a reference amino acid or nucleic acid sequence. In some embodiments, the reference sequence is a wild-type sequence. In some embodiments, the mutation in the nucleic acid sequence of a polynucleotide encodes a mutation in the amino acid sequence of a polypeptide. In some embodiments, the mutation in the amino acid sequence of a polypeptide or the mutation in the nucleic acid sequence of a polynucleotide is a mutation associated with a disease state.
[0131] As used herein, the term "subject" and its grammatical equivalents may refer to a human or a non-human. A subject may be a mammal. A human subject may be male or female. A human subject may be of any age. A subject may be a human embryo. A human subject may be a newborn, infant, child, teenager, or adult. A human subject may be up to about 100 years old. A human subject may need treatment for a genetic disease or condition.
[0132] The term "treatment" or "treating" and its grammatical equivalents may refer to the medical management of a subject for the purpose of curing, improving a disease, condition or disorder, or improving its symptoms. Treatment may include active treatment, i.e., treatment specifically directed to improving a disease, condition or disorder. Treatment may include causal treatment, i.e., treatment directed to removing the cause of the disease, condition or disorder. In addition, such treatment may include palliative treatment, i.e., treatment designed to relieve symptoms rather than cure a disease, condition or disorder. Treatment may include supportive treatment, i.e., treatment used to supplement another specific therapy for improving a disease, condition or disorder. In some embodiments, the condition may be pathological. In some embodiments, treatment may not completely cure or prevent a disease, condition or disorder. In some embodiments, treatment improves but does not completely cure or prevent a disease, condition or disorder. In some embodiments, the subject can be treated for 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, indefinitely, or for the life of the subject.
[0133] The term "ameliorate" and its grammatical equivalents means to reduce, inhibit, attenuate, eliminate, arrest or stabilize the development or progression of a disease.
[0134] The term "prevent" or "preventing" means to delay, prevent in advance or avoid the occurrence or development of a disease, condition or illness for a period of time. Prevention also means to reduce the risk of developing a disease, condition or illness. Prevention includes minimizing or partially or completely inhibiting the development of a disease, condition or illness. In some embodiments, a composition (e.g., a pharmaceutical composition) prevents a disease by delaying the onset of a disease for 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, indefinitely or for the lifetime of the subject.
[0135] The term "effective amount" or "therapeutically effective amount" can refer to an amount of a composition (e.g., a composition comprising a construct) that is sufficient to produce a desired activity as disclosed herein after introduction into a subject. An effective amount of a lead editing composition can be provided to a target gene or cell, whether the cell is ex vivo or in vivo.
[0136] The effective amount can be an amount that induces a target nucleic acid regulation amount (e.g., gene expression to produce a functional protein) observed relative to a negative control, such as at least about a 2-fold change (increase or decrease) or more. The effective amount or dosage can induce a target gene regulation (e.g., target gene expression to produce a functional protein) such as about a 2-fold increase, about a 3-fold increase, about a 4-fold increase, about a 5-fold increase, about a 6-fold increase, about a 7-fold increase, about a 8-fold increase, about a 9-fold increase, about a 10-fold increase, about a 25-fold increase, about a 50-fold increase, about a 100-fold increase, about a 200-fold increase, about a 500-fold increase, about a 700-fold increase, about a 1000-fold increase, about a 5000-fold increase, or about a 10,000-fold increase.
[0137] The amount of target gene regulation can be measured by any suitable method known in the art. In some embodiments, an "effective amount" or "therapeutically effective amount" is the amount of the composition required to improve disease symptoms relative to an untreated patient. In some embodiments, an effective amount is the amount of the composition sufficient to introduce an altered gene of interest into a cell (e.g., a cell in vitro or in vivo).
[0138] Lead Editor
[0139] The term "lead editing" refers to programmable editing of target DNA using a lead editor compounded with PEgRNA to incorporate the expected nucleotide editing into the target DNA by target-lead DNA synthesis. The target polynucleotide (e.g., target gene) of the lead editing may include a double-stranded DNA molecule with two complementary strands: a first strand that may be referred to as a "target strand" or "non-editing strand", and a second strand that may be referred to as a "non-target strand" or "editing strand". In some embodiments, in the lead editing guide RNA (PEgRNA), the spacer sequence is complementary or substantially complementary to a specific sequence on the target strand (which may be referred to as a "search target sequence"). In some embodiments, the spacer sequence anneals to the target strand at the search target sequence. The target strand may also be referred to as a "non-protospacer adjacent motif (non-PAM strand)". In some embodiments, the non-target strand may also be referred to as a "PAM strand". In some embodiments, the PAM strand comprises a protospacer sequence and an optional protospacer adjacent motif (PAM) sequence. In the lead editing using a lead editor based on Cas protein, the PAM sequence refers to a short DNA sequence immediately following the prototype spacer sequence on the PAM chain of the target gene. The PAM sequence can be specifically recognized by a programmable DNA binding protein (e.g., Cas nickase or Cas nuclease). In some embodiments, a specific PAM is a feature of a specific programmable DNA binding protein (e.g., Cas nickase or Cas nuclease). The prototype spacer sequence refers to a specific sequence complementary to the search target sequence in the PAM chain of the target gene. In PEgRNA, the spacer sequence may have a sequence substantially identical to the prototype spacer sequence on the target gene editing chain, except that the spacer sequence may contain uracil (U), and the prototype spacer sequence may contain thymine (T).
[0140] In some embodiments, the double-stranded target DNA includes a nicking site on a PAM strand (or non-target strand). As used herein, "nicking site" refers to a specific position between two nucleotides or two base pairs of a double-stranded target DNA. In some embodiments, the position of the nicking site is determined relative to the position of a specific PAM sequence. In some embodiments, the nicking site is a specific position where a nick will occur when the double-stranded target DNA contacts a nickase (e.g., Cas nickase) that recognizes a specific PAM sequence. In some embodiments, the nicking site is upstream of a specific PAM sequence on the PAM strand of the double-stranded target DNA. In some embodiments, the nicking site is downstream of a specific PAM sequence on the PAM strand of the double-stranded target DNA. In some embodiments, the nicking site is 3 base pairs upstream of the PAM sequence, and the PAM sequence is recognized by Streptococcus pyogenes Cas9 nickase, P. lavamentivorans Cas9 nickase, C. diphtheriae Cas9 nickase, N. cinerea Cas9, Staphylococcus aureus Cas9 or N. lari Cas9 nickase. In some embodiments, the nicking site is 3 base pairs upstream of the PAM sequence, and the PAM sequence is recognized by the Cas9 nickase, wherein the Cas9 nickase comprises a nuclease active HNH domain and a nuclease inactivation RuvC domain. In some embodiments, the nicking site is located 2 base pairs upstream of the PAM sequence, and the PAM sequence is recognized by the thermophilic Streptococcus Cas9 nickase.
[0141] In some embodiments, PEgRNA is compounded with the lead editor and guides the lead editor to bind to the search target sequence of the target gene. In some embodiments, the bound lead editor generates a nick on the editing strand (PAM strand) of the target gene at the nick site. In some embodiments, the primer binding site (PBS) of PEgRNA anneals with the free 3' end formed at the nick site, and the lead editor uses the free 3' end as a primer to initiate DNA synthesis from the nick site. Subsequently, a single-stranded DNA encoded by the editing template of PEgRNA is synthesized. In some embodiments, compared with the endogenous target gene sequence, the newly synthesized single-stranded DNA includes one or more expected nucleotide edits. In some embodiments, in addition to one or more mismatches at the expected nucleotide editing position in the editing template, the editing template of PEgRNA is complementary to the sequence in the editing strand, and the sequence partially complementary to the editing template can be referred to as "editing target sequence". Therefore, in some embodiments, in addition to one or more insertions, deletions or substitutions at the expected nucleotide editing position, the newly synthesized single-stranded DNA has identity or substantial identity with the sequence in the editing target sequence.
[0142] In some embodiments, the newly synthesized single-stranded DNA is balanced with the editing target on the editing strand of the target gene to pair with the target strand of the target gene. In some embodiments, the editing target sequence of the target gene is excised by a flap endonuclease (FEN) such as FEN1. In some embodiments, FEN is an endogenous FEN, for example, in a cell comprising a target gene. In some embodiments, FEN is provided as part of a lead editor, and the FEN is connected to other components of the lead editor or provided in trans. In some embodiments, the newly synthesized single-stranded DNA comprising the expected nucleotide editing replaces the endogenous single-stranded editing target sequence on the target gene editing strand. In some embodiments, the newly synthesized single-stranded DNA and the endogenous DNA on the target strand form a heteroduplex DNA structure in the region corresponding to the editing target sequence of the target gene. In some embodiments, the newly synthesized single-stranded DNA comprising nucleotide editing is paired with the target strand of the target DNA not comprising nucleotide editing in the heteroduplex, thereby generating a mismatch between two originally complementary strands. In some embodiments, the mismatch is recognized by a DNA repair mechanism (e.g., an endogenous DNA repair mechanism). In some embodiments, the intended nucleotide edits are incorporated into the target gene through DNA repair.
[0143] Modified PEgRNA
[0144] In certain aspects, modified PEgRNA is provided herein. The term "lead editing guide RNA" or "PEgRNA" refers to a guide polynucleotide comprising one or more expected nucleotide edits to be incorporated into a target DNA. In some embodiments, PEgRNA associates with a lead editor and guides the lead editor to incorporate one or more (e.g., two or more, three or more, four or more, or five or more) expected nucleotide edits into a target gene by a lead editor. "Nucleotide editing" or "expected nucleotide editing" refers to a specific deletion of one or more nucleotides at a specific position in the sequence to be incorporated into a target gene, an insertion of one or more nucleotides at a specific position, a substitution of a single nucleotide, or other changes at a specific position. Expected nucleotide editing may refer to editing on an editing template compared to a sequence on the target strand of a target gene, or may refer to editing encoded on a newly synthesized single-stranded DNA of a replacement editing target sequence by an editing template compared to an editing target sequence. In some embodiments, PEgRNA comprises a spacer sequence complementary or substantially complementary to a search target sequence on a target strand of a target gene. In some embodiments, the PEgRNA comprises a gRNA core associated with a DNA binding domain (e.g., a CRISPR-Cas protein domain) of a lead editor. In some embodiments, the PEgRNA further comprises an extended nucleotide sequence, the extended nucleotide sequence comprising one or more expected nucleotide edits compared to the endogenous sequence of the target gene, wherein the extended nucleotide sequence may be referred to as an extension arm. In certain embodiments, the PEgRNA comprises a primer binding site sequence (PBS) that can initiate DNA synthesis of the target leader. In some embodiments, the PEgRNA comprises an editing template, the editing template comprising one or more expected nucleotide edits to be incorporated into the target gene by the lead editor. In some embodiments, the extension arm comprises a PBS. In some embodiments, the extension arm comprises an editing template, the editing template comprising one or more expected nucleotide edits to be incorporated into the target gene by the lead editor.
[0145] A "primer binding site" (PBS or primer binding site sequence) is a single-stranded portion of the PEgRNA that includes a region complementary to the PAM strand (ie, non-target strand or editing strand). The PBS is complementary or substantially complementary to a sequence on the PAM strand of the double-stranded target DNA, which is immediately upstream of the nicking site. In some embodiments, during the lead editing process, the PEgRNA is compounded with the lead editor and guides the lead editor to bind to the search target sequence on the target strand of the double-stranded target DNA, and to generate a nick at the nicking site on the non-target strand of the double-stranded target DNA. In some embodiments, the PBS is complementary or substantially complementary to the free 3' end on the non-target strand of the double-stranded target DNA at the nicking site, and can anneal with it. In some embodiments, the PBS annealed to the free 3' end on the non-target strand can initiate DNA synthesis of the target leader.
[0146] The "editing template" of PEgRNA is a single-stranded portion of PEgRNA at the 5' of PBS, and includes a region complementary to the PAM strand (i.e., a non-target strand or an editing strand), and includes one or more expected nucleotide edits compared to the endogenous sequence of the double-stranded target DNA. In some embodiments, the editing template and the PBS are adjacent to each other. Therefore, in some embodiments, the PEgRNA in the lead editing comprises a single-stranded portion, which comprises a PBS and an editing template adjacent to each other. In some embodiments, in addition to one or more non-complementary nucleotides at the expected nucleotide editing position, the single-stranded portion of the PEgRNA comprising both the PBS and the editing template is complementary or substantially complementary to the endogenous sequence on the PAM strand (i.e., a non-target strand or an editing strand) of the double-stranded target DNA. As used herein, regardless of the relative 5'-3' positioning in other contexts, the relative position between the PBS and the editing template and the relative position between the elements of the PEgRNA are determined by the 5' to 3' order of the PEgRNA as a single molecule, regardless of the position of the sequence in the double-stranded target DNA that may have complementarity or identity with the elements of the PEgRNA. In some embodiments, the editing template is complementary or substantially complementary to a sequence on the PAM strand immediately downstream of the nicking site, except for one or more non-complementary nucleotides at the expected nucleotide editing position. An endogenous (e.g., genomic) sequence that is complementary or substantially complementary to the editing template, except for one or more non-complementary nucleotides at the position corresponding to the expected nucleotide editing, may be referred to as an "editing target sequence". In some embodiments, the editing template has identity or substantial identity to a sequence on the target strand, except for one or more insertions, deletions, or substitutions at the expected nucleotide editing position, and the sequence on the target strand is complementary to the editing target sequence or has the same position in the genome as the editing target sequence. In some embodiments, the editing template encodes a single-stranded DNA, wherein the single-stranded DNA has identity or substantial identity to the editing target sequence, except for one or more insertions, deletions, or substitutions at the position of one or more expected nucleotide editing.
[0147] Spacer
[0148] In the lead editing process, the spacer can guide the lead editing complex to the genomic locus with the same or substantially the same sequence. In some embodiments, the PEgRNA includes a spacer. In some embodiments, the length of the spacer varies from at least 10 nucleotides to 100 nucleotides. For example, the spacer can be at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides. In some embodiments, the length of the spacer is 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides or 25 nucleotides. In some embodiments, the length of the spacer is 15 nucleotides to 30 nucleotides, 15 to 25 nucleotides, 18 to 22 nucleotides, 10 to 20 nucleotides, 20 to 30 nucleotides, 30 to 40 nucleotides, 40 to 50 nucleotides, 50 to 60 nucleotides, 60 to 70 nucleotides, 70 to 80 nucleotides, or 90 nucleotides to 100 nucleotides. In some embodiments, the length of the spacer is 20 nucleotides. In some embodiments, the length of the spacer is 17 to 18 nucleotides.
[0149] In some embodiments, the spacer sequence comprises a region having substantial complementarity with a search target sequence on a target strand of a double-stranded target DNA. In some embodiments, the spacer sequence of the PEgRNA is identical or substantially identical to the prototype spacer sequence on the target gene editing strand (except that the prototype spacer sequence comprises thymine and the spacer sequence may comprise uracil). In some embodiments, the spacer sequence is at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% complementary to the search target sequence in the target gene. In some embodiments, the spacer is a sequence substantially complementary to the search target sequence.
[0150] In some embodiments, the length of the spacer varies from at least 10 nucleotides to 100 nucleotides. For example, the spacer can be at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides. In some embodiments, the length of the spacer is 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides. In some embodiments, the length of the spacer is 15 nucleotides to 30 nucleotides, 15 to 25 nucleotides, 18 to 22 nucleotides, 10 to 20 nucleotides, 20 to 30 nucleotides, 30 to 40 nucleotides, 40 to 50 nucleotides, 50 to 60 nucleotides, 60 to 70 nucleotides, 70 to 80 nucleotides, or 90 nucleotides to 100 nucleotides. In some embodiments, the length of the spacer is 20 nucleotides. In some embodiments, the length of the spacer is 17 to 18 nucleotides.
[0151] As used herein in PEgRNA or nicked guide RNA sequences or fragments thereof (such as spacers, PBSs or RTT sequences), unless otherwise indicated, the letter "T" or "thymine" should be understood to represent a nucleobase in the DNA sequence encoding the PEgRNA or guide RNA sequence, and is intended to refer to the uracil (U) nucleobase of the PEgRNA or guide RNA or any chemically modified uracil nucleobase known in the art, such as 5-methoxyuracil.
[0152] Primer Binding Site (PBS)
[0153] The PEgRNA may comprise a primer binding site (PBS) and an editing template (e.g., RTT). The extension arm of the PEgRNA may comprise a PBS and an editing template. In some embodiments, the PBS may be partially complementary to the spacer. In some embodiments, the editing template (e.g., RTT) is partially complementary to the spacer. In some embodiments, the editing template (e.g., RTT) and the primer binding site (PBS) are each partially complementary to the spacer.
[0154] The extension arm of PEgRNA may include a primer binding site sequence (PBS or PBS sequence), which is hybridized with the free 3' end of the single-stranded DNA in the target gene generated by the lead editor. The length of the PBS sequence may vary, depending on, for example, the lead editor component, the search target sequence, and other components of PEgRNA. In some embodiments, the length of the primer binding site (PBS) varies from at least 2 nucleotides to 50 nucleotides. For example, the length of the primer binding site (PBS) can be at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, or at least 50 nucleotides. In some embodiments, the length of PBS is at least 6 nucleotides. In some embodiments, the length of the PBS is about 4 to 16 nucleotides, about 6 to 16 nucleotides, about 6 to 18 nucleotides, about 6 to 20 nucleotides, about 8 to 20 nucleotides, about 10 to 20 nucleotides, about 12 to 20 nucleotides, about 14 to 20 nucleotides, about 16 to 20 nucleotides, or about 18 to 20 nucleotides. In some embodiments, the length of the PBS is about 7 to 15 nucleotides. In some embodiments, the length of the PBS is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides. In some embodiments, the length of the PBS is 8, 9, 10, 11, 12, 13, or 14 nucleotides.
[0155] PBS may be complementary or substantially complementary to the DNA sequence in the target gene editing strand. By annealing the editing strand at the free hydroxyl group (e.g., the free 3' end generated by the lead editor nick), PBS can initiate the synthesis of new single-stranded DNA encoded by the editing template at the nick site. In some embodiments, PBS is at least about 70%, 75%, 80%, 85%, 90%, 95% or 100% complementary to the editing strand region of the target gene. In some embodiments, PBS is completely complementary or 100% complementary to the editing strand region of the target gene.
[0156] The extension arm of the PEgRNA can contain an editing template, which serves as a DNA synthesis template for the DNA polymerase in the lead editor during lead editing.
[0157] The length of the editing template may vary, depending on, for example, the lead editor components, the search target sequence, and other components of the PEgRNA. In some embodiments, the editing template serves as a DNA synthesis template for a reverse transcriptase, and the editing template is referred to as a reverse transcription editing template (RTT).
[0158] In some embodiments, the editing template (e.g., RTT) is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In some embodiments, the RTT is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In some embodiments, the RTT is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.
[0159] In some embodiments, the editing template (e.g., RTT) sequence is about 70%, 75%, 80%, 85%, 90%, 95% or 99% complementary to the editing target sequence on the editing strand of the target gene. In some embodiments, the editing template sequence (e.g., RTT) is substantially complementary to the editing target sequence. In some embodiments, the editing template sequence (e.g., RTT) is complementary to the editing target sequence, except for the position of the expected nucleotide editing to be incorporated into the target gene. In some embodiments, the editing template comprises a nucleotide sequence having about 85% to about 95% complementarity with the editing target sequence in the editing strand in the target gene. In some embodiments, the editing template has about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% complementarity with the editing target sequence in the editing strand of the target gene.
[0160] In some embodiments, PEgRNA only comprises RNA nucleotides and forms RNA polynucleotides. In some embodiments, PEgRNA is a chimeric polynucleotide comprising RNA and DNA nucleotides. For example, PEgRNA may include DNA in a spacer sequence, a gRNA core, or an extension arm. In some embodiments, PEgRNA includes DNA in a spacer sequence. In some embodiments, the entire spacer sequence of PEgRNA is a DNA sequence. In some embodiments, PEgRNA includes DNA in a gRNA core (for example, in a stem region of a gRNA core). In some embodiments, PEgRNA includes DNA in an extension arm (for example, in an editing template). An editing template comprising a DNA sequence can serve as a DNA synthesis template for a DNA polymerase (for example, a DNA-dependent DNA polymerase) in a lead editor. Therefore, PEgRNA can be a chimeric polynucleotide comprising RNA, a gRNA core, and / or a PBS sequence in a spacer and a DNA in an editing template.
[0161] The components of PEgRNA can be arranged in a modular manner. In some embodiments, the spacer and the extension arm comprising the primer binding site sequence (PBS) and the editing template (e.g., reverse transcriptase template (RTT)) are interchangeably located in the middle of the 5' portion of the PEgRNA, the 3' portion of the PEgRNA, or the gRNA core. For example, in some embodiments, the PEgRNA comprises from 5' to 3': the spacer, the gRNA core, the editing template, and the PBS. In some embodiments, the PEgRNA comprises from 5' to 3': the editing template, the PBS, the spacer, and the gRNA core. In some embodiments, the PBS and / or the editing template are located within the gRNA core, that is, flanked by the first half of the gRNA core and the second half of the gRNA core.
[0162] In certain embodiments, the PEgRNA provided herein comprises i) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a guide RNA (gRNA) core comprising a direct repeat, a first stem loop, and a second stem loop; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; and iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA, wherein the PEgRNA further comprises one or more nucleic acid portions at its 3' end.
[0163] In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, and a PBS in 5' to 3' order.
[0164] In certain embodiments, the PEgRNA provided herein comprises i) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a guide RNA (gRNA) core comprising a direct repeat, a first stem loop, and a second stem loop; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; and iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA, wherein the gRNA core comprises one or more sequence modifications compared to SEQ REFNO.16.
[0165] In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, and a PBS in 5' to 3' order.
[0166] In certain embodiments, the PEgRNA provided herein comprises i) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a guide RNA (gRNA) core comprising a direct repeat, a first stem loop, and a second stem loop; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; and iv) a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in a non-target strand of the double-stranded target DNA, and v) a tag sequence comprising a region complementary to the PBS and / or the editing template.
[0167] In some embodiments, the PEgRNA comprises a spacer, a gRNA core, an editing template, a PBS, and a tag sequence in 5' to 3' order.
[0168] In some embodiments, the PEgRNA comprises an editing template, a PBS, a tag sequence, a spacer, and a gRNA core in 5' to 3' order.
[0169] In certain embodiments, the PEgRNA provided herein comprises, in 5' to 3' order: i) a spacer region comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a 5' portion of a guide RNA (gRNA) core; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nick site in a non-target strand of a double-stranded target DNA; and v) a 3' portion of a gRNA core. In some embodiments, the 5' portion of the gRNA core and the 3' portion of the gRNA core form a complete functional gRNA core that can be associated with a programmable DNA binding protein (e.g., Cas9 nickase) of a lead editor. In some embodiments, the 5' portion of the gRNA core comprises a 5' half of a direct repeat, a first stem loop, and a second stem loop. In some embodiments, the 3' portion of the gRNA core comprises a 3' half of a second stem loop and a third stem loop. In some embodiments, the PEgRNA further comprises a tag sequence comprising a region complementary to a PBS and / or an editing template.
[0170] In certain embodiments, the PEgRNA provided herein comprises: i) a first sequence comprising a spacer containing a region complementary to a search target sequence in a target strand of a double-stranded target DNA, and the first half of the gRNA core; and ii) a second sequence comprising the second half of the gRNA core, an editing template comprising the expected editing compared to the double-stranded target DNA; a primer binding site (PBS) comprising a region complementary to a region upstream of a nick site in a non-target strand of the double-stranded target DNA; and wherein the gRNA core comprises direct repeats, a first stem loop, and a second stem loop. In certain embodiments, the PEgRNA provided herein comprises: i) a first sequence comprising an editing template comprising the expected editing compared to the double-stranded target DNA; a primer binding site (PBS) comprising a region complementary to a region upstream of a nick site in a non-target strand of the double-stranded target DNA; a spacer comprising a region complementary to a search target sequence in a target strand of the double-stranded target DNA; and the first half of the gRNA core; and ii) a second sequence comprising the second half of the gRNA core, wherein the gRNA core comprises direct repeats, a first stem loop, and a second stem loop. In some embodiments, the first half of the gRNA core comprises a 5' half of a direct repeat, a first stem loop, and a second stem loop. In some embodiments, the second portion of the gRNA core comprises a 3' half of a second stem loop and a third stem loop. In some embodiments, the first half of the gRNA core comprises the first half of a direct repeat. In some embodiments, the second half of the gRNA core comprises the second half of a direct repeat, a first stem loop, a second stem loop, and a third stem loop.
[0171] In some embodiments, the first sequence is on a first molecule and the second sequence is on a second molecule.
[0172] In some embodiments, the first sequence and the second sequence are on the same molecule.
[0173] In some embodiments, the first half of the gRNA core and the second half of the gRNA core are selected from the paired first half gRNA core sequence and second half gRNA sequence provided in Table 2.
[0174] In some embodiments, provided herein are example sequences of PEgRNA spacers, PBS, RTT, and ngRNA spacers of a lead editing system comprising a nuclease that recognizes the PAM sequence "NGG". In some embodiments, the PAM motif on the editing strand comprises an "NGG" motif, where N is any nucleotide. In some embodiments, the PEgRNA of the present disclosure is part of a lead editing system that recognizes the PAM motif CGG. In some embodiments, the PEgRNA of the present disclosure is part of a lead editing system that recognizes the PAM motif AGG.
[0175] Modified gRNA Core
[0176] In some embodiments, the gRNA core of PEgRNA is associated with a programmable DNA binding domain in a lead editor. In some embodiments, the gRNA core comprises a unidirectional repeat, a first stem loop, and a second stem loop. In some embodiments, the gRNA core also comprises a third stem loop. The guide RNA core of PEgRNA (also referred to herein as a gRNA core, a gRNA scaffold, or a gRNA backbone sequence) may contain a polynucleotide sequence bound to a DNA binding domain (e.g., Cas9) of a lead editor. The gRNA core may interact with a lead editor as described herein, for example, by associating with a DNA binding domain (such as a DNA nickase of a lead editor).
[0177] Those skilled in the art will recognize that different lead editors with different DNA binding domains from different DNA binding proteins may require different gRNA core sequences specific for the DNA binding proteins. In some embodiments, the gRNA core can bind to a lead editor based on Cas9. In some embodiments, the gRNA core can bind to a lead editor based on Cpf1. In some embodiments, the gRNA core can bind to a lead editor based on Cas12b.
[0178] In some embodiments, the gRNA core includes regions and secondary structures involved in binding to a specific CRISPR Cas protein. For example, in a Cas9-based lead editing system, the gRNA core of a PEgRNA may include regions of one or more base pairing regions. In some embodiments, the gRNA core capable of binding to Cas9 includes from 5' to 3': a repeat sequence, a loop structure, an anti-repeat sequence, a first stem loop, a second stem loop, and a third stem loop. An exemplary structure of the gRNA core is shown in Figure 8 ; Figure 8 The sequence in is the canonical SpCas9 sgRNA scaffold. As used herein, repeat sequences and anti-repeat sequences refer to nucleic acid secondary structures formed by the same direction repeat region formed by base pairing between the crRNA and tracrRNA sequences equivalent to the Cas9 guide RNA. The repeat sequence and the anti-repeat sequence can be connected by a ring structure, and the secondary structure formed by base pairing between the repeat sequence and the anti-repeat sequence can be called a same direction repeat region (or, the repeat, anti-repeat and connecting ring structure can be called a tetraloop). In some embodiments, the same direction repeat region of the gRNA core includes one or more base pairing regions: a base pairing "lower stem" adjacent to the spacer sequence ( Figure 8 G1 to A6 and U25 to U30 in the lower stem) and the base-paired "upper stem" ( Figure 8 G9 to A12 and U17 to C20 in the gRNA core), wherein the lower stem and the upper stem may be connected by a "bump" comprising unpaired RNA. As used herein, the position of the gRNA core change can be referred to in the context of the secondary structure of the gRNA core. For example, the "first base pair in the direct repeat (or lower stem)" refers to the base pair between the 5' nucleotide in the repeat sequence and the complementary nucleotide that is the 3' nucleotide in the anti-repeat sequence ( Figure 8 G1 and A30 in the direct repeat (or lower stem) and the "second base pair in the direct repeat (or lower stem)" refers to the base pair between the second 5' nucleotide in the repeat sequence and the complementary nucleotide in the anti-repeat sequence ( Figure 8 Similarly, the "starting" or "starting" base pair of the second stem-loop refers to the base pair formed between the 5'-most nucleotide in the second stem-loop and the complementary nucleotide in the complementary portion of the second stem-loop ( Figure 8 The "terminal" or "last" base pair of the second stem-loop is when the second stem-loop is formed by base pairing of the 5' portion of the stem connected by the loop with the 3' portion of the stem, the base pair being formed between the 3'-most nucleotide in the 5' portion of the stem and the complementary nucleotide in the complementary 3' portion of the stem ( Figure 8 U52 and A57 in ).
[0179] The gRNA core may also include 3', the first stem loop, the second stem loop and the third stem loop of the same direction repeat. In some embodiments, the gRNA core may include same direction repeats, and at least one, at least two or at least three stem loops. As used herein, a stem loop (or hairpin loop) is a base pairing pattern that may appear in a single-stranded nucleic acid. In some embodiments, when two regions of the same nucleic acid chain are at least partially complementary in the nucleotide sequence when read in opposite directions, a stem loop may be formed, so that the base pair may form a double helix comprising an unpaired loop. The stem loops in the gRNA core described herein may be numbered from the 5' end of the gRNA core to the 3' end. For example, the "first stem loop" is the first stem loop at the 5' end of the proximal end of the same direction repeat of the gRNA core sequence (excluding any same direction repeats). The "second stem loop" is the second stem loop (excluding any same direction repeats) that follows the first stem loop in the 5' to 3' direction, and so on.
[0180] In some embodiments, the gRNA core comprises a nucleotide change compared to a wild-type gRNA core (e.g., a canonical SpCas9 gRNA scaffold as listed in SEQ REF NO: 16). For example, in some embodiments, one or more nucleotides in the gRNA core are deleted, inserted, and / or substituted compared to the canonical SpCas9 gRNA scaffold as listed in SEQ REF NO: 16. In some embodiments, the gRNA core of the PEgRNA is capable of binding to the Cas9 (e.g., nCas9) in the lead editor and comprises one or more nucleotide changes or modifications compared to the wild-type CRISPR-Cas9 guide RNA scaffold (e.g., a canonical SpCas9 gRNA scaffold as listed in SEQ REF NO: 16). In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions, and / or substitutions in the same repeat compared to the canonical SpCas9 gRNA scaffold as listed in SEQ REF NO: 16. Potential advantages associated with such modified gRNA cores may include improved lead editing efficiency and / or improved manufacturing by a split synthesis scheme.
[0181] In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions, and / or substitutions in the lower stem or upper stem of the direct repeat. In some embodiments, the gRNA core comprises one or more nucleotide substitutions in the lower stem of the direct repeat. In some embodiments, the gRNA core comprises one or more nucleotide insertions in the upper stem of the direct repeat. In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions, and / or substitutions in the first stem loop compared to the canonical SpCas9gRNA scaffold as listed in SEQ REF NO: 16. In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions, and / or substitutions in the second stem loop compared to the canonical SpCas9 gRNA scaffold as listed in SEQ REF NO: 16. In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions, and / or substitutions in the second stem loop. In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions, and / or substitutions in the third stem loop compared to the canonical SpCas9 gRNA scaffold as listed in SEQ REF NO: 16. In some embodiments, the gRNA core comprises one or more nucleotide insertions, deletions and / or substitutions compared to a wild-type CRISPR-Cas9 guide RNA scaffold (e.g., a canonical SpCas9 gRNA scaffold as set forth in SEQ REF NO: 16), and the gRNA core comprises a third stem-loop having a sequence identical to the third stem-loop of the wild-type CRISPR-Cas9 guide RNA scaffold.
[0182] In some embodiments, RNA nucleotides in the lower stem, upper stem, and / or stem-loop regions can be replaced by one or more DNA sequences. In some embodiments, the gRNA core comprises an unmodified or wild-type RNA sequence in the junction and / or bulge region. In some embodiments, the gRNA core does not comprise a long segment AU pair, such as a GUUUU-AAAAC pairing element. Exemplary gRNA core structures are shown in Figure 8 and Fig.12 .
[0183] In some embodiments, PEgRNA includes a guide RNA (gRNA) core associated with a DNA binding domain (e.g., CRISPR-Cas protein domain) of a lead editor. In some embodiments, PEgRNA includes a guide RNA (gRNA) core associated with a DNA binding domain (e.g., Cas9 domain) of a lead editor. In certain aspects, the gRNA core of the PEgRNA provided herein includes one or more sequence modifications compared to SEQ REF NO.16. In some embodiments, one or more (e.g., two or more, three or more, four or more or five or more) sequence modifications include the gRNA core differences listed in Table 1 or Table 2. In some embodiments, the gRNA core includes a sequence selected from SEQ REF NO: 16-61. In some embodiments, the gRNA core includes a first gRNA core sequence containing a 5' half of the gRNA core and a second gRNA core sequence containing a 3' half of the gRNA core, and wherein the PEgRNA is in a 5' to 3' order: a spacer, a first gRNA core sequence, an editing template, a PBS, a tag sequence, and a second gRNA core sequence. The 5' half and the 3' half can form a functional gRNA core for associating / binding with a programmable DNA binding protein (e.g., Cas protein). Those skilled in the art will recognize that different lead editors with different DNA binding domains from different DNA binding proteins may require different gRNA core sequences specific to DNA binding proteins. In some embodiments, the gRNA core can be bound to a lead editor based on Cas9. In some embodiments, the gRNA core can be bound to a lead editor based on Cpf1. In some embodiments, the gRNA core can be bound to a lead editor based on Cas12b.
[0184] In some embodiments, the gRNA core of the PEgRNA provided herein comprises one or more sequence modifications compared to SEQ REF NO. 16. In some embodiments, the one or more sequence modifications comprise a gRNA core change compared to SEQ REF No.: 16 listed in Table 1. In some embodiments, the gRNA core comprises a gRNA core sequence listed in Table 1 or Table 2.
[0185] In some embodiments, one or more sequence modifications include sequence modifications in the same direction repeat. In some embodiments, the sequence modification in the gRNA core of PEgRNA includes one or more nucleotide flips. As used herein, the term "flip" refers to the modification of a sequence so that the nucleotide bases that are base-paired with each other in a loop stem or hairpin structure are exchanged with each other. For example, the original unmodified stem structure may include an A / U base pair, wherein A is in the first strand (or region) of the stem structure, and U is in the complementary strand (or region) of the stem structure. A / U to U / A base pair flips replace adenosine in the first strand (or region) with uracil, and replaces uracil in the complementary strand (or region) with adenosine, thereby "flipping" the A / U base pair to a U / A base pair. In some embodiments, nucleotide flipping can be used, for example, to split a sequence containing the same base repeats present in a nucleic acid molecule (e.g., a sequence of at least 3, 4, 5, 6 or 7 continuous A nucleotides, U nucleotides, C nucleotides or G nucleotides) without destroying its secondary structure. Fig.12 An example of an A / U flip is described, which splits a series of 4 consecutive A nucleotides and U nucleotides at the fourth position in the lower stem of the direct repeat without disrupting the secondary structure of the gRNA core. In some embodiments, the original base pair is replaced with an alternative base pair (e.g., an A / U base pair is replaced with a C / G or G / C base pair) without flipping.
[0186] In some embodiments, the direct repeat of the gRNA core may include a flip of at least one AU base pair in the lower stem of the direct repeat, optionally wherein the lower stem does not contain 2, 3, 4 or more consecutive AU base pairs; and / or the flip of at least one A / U base pair in the direct repeat includes a flip of the fourth A / U base pair in the lower stem of the direct repeat.
[0187] In some embodiments, the sequence modification in the direct repeat includes the insertion of one or more nucleotides in the upper stem of the direct repeat of the gRNA core, resulting in an extension of the upper stem compared to the wild-type gRNA core (e.g., as listed in SEQ REF NO: 16). The extension in the upper stem can be from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 base pairs. In some embodiments, the gRNA core comprises a sequence selected from SEQ REF NO: 26-37.
[0188] In some embodiments, the one or more sequence modifications include a sequence modification in the second stem-loop.
[0189] In some embodiments, the modification in the second stem loop includes the flipping of the G / C base pair. In some embodiments, the modification in the second stem loop includes the flipping of the A / U base pair in the second stem loop. In some embodiments, the modification in the second stem loop includes replacing the A / U base pair with a G / C base pair. In some embodiments, the modification in the second stem loop includes replacing the U / A base pair with a G / C base pair. In some embodiments, the modification in the second stem loop includes replacing the A / U base pair with a G / C base pair, and also includes replacing the U / A base pair with a G / C base pair. In some embodiments, the gRNA core comprises a nucleic acid sequence selected from SEQREF NO: 21, 22 or 25.
[0190] Exemplary gRNA core sequences and sequence modifications are shown in Tables 1 and 2. In some embodiments, the gRNA core comprises a sequence selected from SEQ REF NOs: 16-61, 3860-4359, and 4452.
[0191] In some embodiments, one or more sequence modifications include modifications in the third stem loop of the gRNA core. In some embodiments, the modifications in the third stem loop include flipping of G / C base pairs. In some embodiments, the modifications in the third stem loop include flipping of A / U base pairs.
[0192] The gRNA core may comprise any one of the modifications described in Table 1 or Table 2, or any combination thereof.
[0193] In some embodiments, the gRNA core has a flipped 1st AU base pair in the direct repeat. In some embodiments, the gRNA core has a flipped 2nd AU base pair in the direct repeat. In some embodiments, the gRNA core has a flipped 3rd AU base pair in the direct repeat. In some embodiments, the gRNA core has a flipped 4th AU base pair in the direct repeat.
[0194] In some embodiments, the gRNA core comprises replacing an AU base pair (bp) with a GC Bp at the fourth base pair of the second stem loop. In some embodiments, the gRNA core comprises replacing an AU Bp with a GC Bp at the fourth base pair of the second stem loop.
[0195] In some embodiments, the gRNA core comprises a five base pair extension of the upper stem of the direct repeat (tgctg and cagca). In some embodiments, the gRNA has "flip and extend" (M4 and E5), as described in Nelson, JW, Randolph, PB, Shen, SP et al. Engineered pegRNAs improve prime editing efficiency. Nat Biotechnol (2021). The M4 modification is the 4th AU base pair in the direct repeat of the gRNA core flipped. The E5 modification is to extend the upper stem end of the direct repeat with five bp sequences (tgctg and cagca).
[0196] In some embodiments, the gRNA core comprises an M4 modification. In some embodiments, the gRNA core comprises an E5 modification. In some embodiments, the gRNA core comprises an M4 modification and an E5 modification.
[0197] In some embodiments, the gRNA core comprises replacing an A / U base pair with a G / C base pair in the second stem loop. In some embodiments, the gRNA core comprises replacing an A / U base pair with a G / C base pair at the first base pair of the second stem loop.
[0198] In some embodiments, the gRNA core has 1 base pair extension (c and g) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 2 base pair extensions (cc and gg) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 2 base pair extensions (ca and tg) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 2 base pair extensions (cg and tg) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 1 base pair extension (a and t) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 2 base pair extensions (ac and gt) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 2 base pair extensions (aa and tt) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has 2 base pair extensions (ag and tt) in the upper stem of the same direction repeat sequence. In some embodiments, the gRNA core has a 3 base pair extension (ccc and ggg) in the upper stem of the same repeat sequence. In some embodiments, the gRNA core has a 4 base pair extension (ccac and gtgg) in the upper stem of the same repeat sequence. In some embodiments, the gRNA core has a 5 base pair extension (ccaac and gttgg) in the upper stem of the same repeat sequence. In some embodiments, the gRNA core has a 6 base pair extension (ccacac and gtgtgg) in the upper stem of the same repeat sequence.
[0199] In some embodiments, the gRNA core has a 1 base pair extension (c and g) in the second stem-loop sequence. In some embodiments, the gRNA core has a 2 base pair extension (cc and gg) in the second stem-loop sequence. In some embodiments, the gRNA core has a 2 base pair extension (ca and tg) in the second stem-loop sequence. In some embodiments, the gRNA core has a 2 base pair extension (cg and tg) in the second stem-loop sequence. In some embodiments, the gRNA core has a 1 base pair extension (a and t) in the second stem-loop sequence. In some embodiments, the gRNA core has a 2 base pair extension (ac and gt) in the second stem-loop sequence. In some embodiments, the gRNA core has a 2 base pair extension (aa and tt) in the second stem-loop sequence. In some embodiments, the gRNA core has a 2 base pair extension (ag and tt) in the second stem-loop sequence. In some embodiments, the gRNA core has a 3 base pair extension (ccc and ggg) in the second stem-loop sequence. In some embodiments, the gRNA core has a 4 base pair extension (ccac and gtgg) in the second stem-loop sequence. In some embodiments, the gRNA core has a 5 base pair extension in the second stem-loop sequence (ccaac and gttgg). In some embodiments, the gRNA core has a 6 base pair extension in the second stem-loop sequence (ccacac and gtgtgg).
[0200] In some embodiments, the gRNA core has 1 base pair extension (c and g) in the third stem-loop sequence. In some embodiments, the gRNA core has 2 base pair extensions (cc and gg) in the third stem-loop sequence. In some embodiments, the gRNA core has 2 base pair extensions (ca and tg) in the third stem-loop sequence. In some embodiments, the gRNA core has 2 base pair extensions (cg and tg) in the third stem-loop sequence. In some embodiments, the gRNA core has 1 base pair extension (a and t) in the third stem-loop sequence. In some embodiments, the gRNA core has 2 base pair extensions (ac and gt) in the third stem-loop sequence. In some embodiments, the gRNA core has 2 base pair extensions (aa and tt) in the third stem-loop sequence. In some embodiments, the gRNA core has 2 base pair extensions (ag and tt) in the third stem-loop sequence. In some embodiments, the gRNA core has 3 base pair extensions (ccc and ggg) in the third stem-loop sequence. In some embodiments, the gRNA core has a 4 base pair extension in the third stem-loop sequence (ccac and gtgg). In some embodiments, the gRNA core has a 5 base pair extension in the third stem-loop sequence (ccaac and gttgg). In some embodiments, the gRNA core has a 6 base pair extension in the third stem-loop sequence (ccacac and gtgtgg).
[0201] In some embodiments, the gRNA core modification increases the editing efficiency by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 110%, at least 120%, at least 130%, at least 140%, at least 150%, at least 160%, at least 170%, at least 180%, at least 190%, at least 200% compared to the editing efficiency of the control PEgRNA with an unmodified gRNA core. Exemplary nucleotide sequence modifications in the gRNA core of PEgRNA are provided in Table 1. Modifications compared to the canonical SpCas9 gRNA scaffold sequence are indicated in the third column ("modification description"). Although the gRNA core sequences provided in Table 1 are RNA sequences, "T" is used instead of "U" in the sequence to be consistent with the ST.26 standard.
[0202] Table 1: Exemplary gRNA core sequences
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211] Nucleic acid part
[0212] In some embodiments, in addition to the spacer, gRNA core, primer binding site, and editing template, the PEgRNA further comprises one or more nucleic acid portions (e.g., hairpins, pseudoknots, quadruplexes, tRNA sequences, aptamers). In some embodiments, such nucleic acid portions are located at the 3' end of the PEgRNA.
[0213] In some embodiments, the nucleic acid portion comprises a hairpin. In some embodiments, a hairpin is a nucleic acid secondary structure formed by intramolecular base pairing between two regions of the same chain, and when read in opposite directions, the two regions are generally complementary in the nucleotide sequence. The two regions base pair to form a double helix, which ends with an unpaired loop. As described herein, the length of the hairpin can be between 5 and 50 nucleotides, between 10 and 40 nucleotides, or between at least 15 and 30 nucleotides. The length of the hairpin can be at least 10 nucleotides, at least 15 nucleotides, at least 20 nucleotides, at least 25 nucleotides, or at least 30 nucleotides. In some embodiments, the length of the hairpin is 14 nucleotides. In some embodiments, the length of the hairpin is 18 nucleotides. In some embodiments, the length of the hairpin is 22 nucleotides. In some embodiments, the hairpin comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more continuous complementary base pairs. In some embodiments, the hairpin comprises 4, 5, 6, 7, 8, 9 or 10 consecutive complementary base pairs. In some embodiments, the hairpin comprises 4-8 consecutive complementary base pairs. In some embodiments, the hairpin comprises 5 consecutive complementary base pairs. In some embodiments, the hairpin comprises 7 consecutive complementary base pairs.
[0214] In some embodiments, the nucleic acid portion comprises a pseudoknot. As used herein, a pseudoknot includes, but is not limited to, a nucleic acid secondary structure containing at least two stem-loop structures, wherein one half of a stem is inserted between the two halves of another stem. There are several different folding topologies in a pseudoknot, such as an H-type. In an H-type fold, the bases in the hairpin loop form intramolecular pairs with the bases outside the stem. This results in the formation of a second stem and loop, thereby obtaining a pseudoknot with two stems and two loops. As described herein, the length of a pseudoknot can be between 5 and 50 nucleotides, between 10 and 40 nucleotides, or between at least 15 and 30 nucleotides. The length of a hairpin can be at least 10 nucleotides, at least 15 nucleotides, at least 20 nucleotides, at least 25 nucleotides, or at least 30 nucleotides. In some embodiments, the length of a pseudoknot is 22 nucleotides.
[0215] In some embodiments, the nucleic acid portion comprises a quadruplex. In some embodiments, a quadruplex is a non-standard four-stranded nucleic acid secondary structure, which can be formed in DNA and RNA sequences rich in guanine or rich in cysteine in some cases. As described herein, the length of the quadruplex can be between 5 and 50 nucleotides, between 10 and 40 nucleotides, or between at least 15 and 30 nucleotides. The length of the hairpin can be at least 10 nucleotides, at least 15 nucleotides, at least 20 nucleotides, at least 25 nucleotides, or at least 30 nucleotides. In some embodiments, the length of the quadruplex is 18 nucleotides. In some embodiments, the quadruplex is rich in guanine (G-quadruplex). In some embodiments, the quadruplex is rich in cytosine (C-quadruplex).
[0216] In some embodiments, the nucleic acid portion comprises an aptamer. In some embodiments, the aptamer comprises a short single-stranded nucleic acid oligomer that can be bound to a specific target molecule. Because aptamers tend to form spirals and single-stranded loops, they can present a variety of shapes. As described herein, the length of the aptamer can be between 5 and 50 nucleotides, between 10 and 40 nucleotides, or between at least 15 and 30 nucleotides. The length of the hairpin can be at least 10 nucleotides, at least 15 nucleotides, at least 20 nucleotides, at least 25 nucleotides, or at least 30 nucleotides. In some embodiments, the length of the aptamer is 19 nucleotides. In some embodiments, the length of the aptamer is 33 nucleotides.
[0217] In some embodiments, the nucleic acid portion comprises a tRNA sequence. The tRNA sequence can be very long (e.g., at least 25 nucleotides, at least 30 nucleotides, at least 35 nucleotides, at least 40 nucleotides, at least 45 nucleotides, at least 50 nucleotides, at least 55 nucleotides, at least 60 nucleotides, at least 65 nucleotides, at least 70 nucleotides, or at least 75 nucleotides). In some embodiments, the tRNA sequence can be very short (less than 25 nucleotides, less than 20 nucleotides, less than 15 nucleotides, or less than 10 nucleotides). As described herein, the length of the tRNA sequence can be between 5 and 80 nucleotides, between 10 and 70 nucleotides, or between at least 15 and 60 nucleotides. The length of the hairpin can be at least 10 nucleotides, at least 15 nucleotides, at least 20 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, or at least 70 nucleotides. In some embodiments, the length of the aptamer is 18 nucleotides. In some embodiments, the length of the aptamer is 61 nucleotides.
[0218] Exemplary moieties can be found in Table 4. One skilled in the art will appreciate that the present disclosure is not limited to the sequences and structures in Table 4, as the configurations in Table 4 are examples of a broader class of moieties encompassed by the present disclosure.
[0219] In some embodiments, one or more nucleic acid portions comprise a hairpin (e.g., a hairpin comprising a self-complementary region, optionally, wherein the self-complementary region comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more consecutive complementary base pairs), a quadruplex (e.g., a G-quadruplex or a C-quadruplex, optionally, wherein the G-quadruplex or the C-quadruplex is derived from a VEGF gene promoter), a tRNA sequence (e.g., a tRNA sequence, optionally, wherein the tRNA sequence is a tRNA(proline) sequence), an aptamer (e.g., an aptamer derived from a viral protein binding sequence, optionally, wherein the aptamer comprises a viral reverse transcriptase recruitment sequence, optionally, wherein the aptamer comprises an MS2 protein binding sequence or a Moloney murine leukemia (MMLV) reverse transcriptase recruitment sequence), and / or a pseudoknot (e.g., a pseudoknot derived from a potato leaf roll virus (PLRV)), or any combination thereof.
[0220] In some embodiments, one or more nucleic acid portions comprise a structure derived from a replication recognition sequence of a retrovirus. In some embodiments, the nucleic acid portion comprises a sequence derived from a replication recognition sequence of Moloney murine leukemia virus (MMLV). In some embodiments, one or more nucleic acid portions comprise a nucleic acid sequence selected from SEQ REF NO 12-15.
[0221] In some embodiments, the one or more nucleic acid portions comprise a hairpin. In some embodiments, the hairpin comprises the sequence of any one of SEQ REF No: 1-3 or 5-7.
[0222] In some embodiments, one or more nucleic acid portions comprise a pseudoknot. In some embodiments, the pseudoknot is derived from potato leaf roll virus. In some embodiments, the pseudoknot comprises the sequence of SEQ REF NO: 4. In some embodiments, one or more nucleic acid portions comprise an MS2 hairpin. In some embodiments, the nucleotide sequence of the MS2 hairpin (or also referred to as an "MS2 aptamer") is: GCCAACATGAGGATCACCCATGTCTGCAGGGC C (SEQ REF NO: 4446). In some embodiments, the nucleotide sequence of the MS2 aptamer comprises the sequence of SEQ REF NO: 9. In some embodiments, the MS2 coat protein (MCP) recognizes the MS2 hairpin. In some embodiments, the amino acid sequence of MCP is: GSASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAY KVTCSVRQSSAQNRKYTIKVEVPKVATQTVGGEELPVAGWRSYL NMELTIPIFATNSDCELIVKAMQGLLKDGNPIPSAIA ANSGIY (SEQ REF NO: 4447).
[0223] In some embodiments, one or more nucleic acid portions comprise a G-quadruplex or a C-quadruplex. In some embodiments, one or more nucleic acid portions comprise a quadruplex from a VEGF gene promoter. In some embodiments, the quadruplex comprises a sequence of SEQ REF NO: 10 or 11.
[0224] In some embodiments, the PEgRNA comprises one or more nucleic acid moieties at its 3' end. In some embodiments, the PEgRNA comprises one or more nucleic acid moieties at its 5' end.
[0225] Table 3: Exemplary nucleic acid motif sequences
[0226]
[0227]
[0228] Table 4: Exemplary nucleic acid motif structural configurations
[0229]
[0230]
[0231] Tag sequence
[0232] In some embodiments, in addition to the spacer, gRNA core, primer binding site and editing template, the PEgRNA further comprises a tag sequence. In some embodiments, the tag sequence comprises a region complementary to the editing template. In some embodiments, the tag sequence includes a region complementary to the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and / or the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no substantial complementarity with the PBS. In some embodiments, the tag sequence comprises a region complementary to the editing template and has no complementarity with the PBS. In some embodiments, the tag sequence and the editing template each comprise a region complementary to each other, wherein the 3' end of the complementary region in the editing template is located at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more base positions of the 5' of the 3' half of the editing template. In some embodiments, the complementary region in the tag sequence is located at the 5' portion of the tag sequence. In some embodiments, the tag sequence has no substantial complementarity with the spacer. In some embodiments, the tag has no complementarity with the spacer. In some embodiments, the length of the tag sequence is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. In some embodiments, the length of the tag sequence is at least 4, at least 6, at least 8 nucleotides. In some embodiments, the tag sequence comprises a nucleic acid sequence selected from SEQ REF NO 62-1960. Exemplary tag sequences can be found in Table 5.
[0233]
[0234]
[0235]
[0236]
[0237]
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
[0244]
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254]
[0255]
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277]
[0278]
[0279]
[0280]
[0281]
[0282]
[0283]
[0284]
[0285]
[0286]
[0287]
[0288]
[0289]
[0290]
[0291]
[0292]
[0293]
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321]
[0322]
[0323]
[0324]
[0325]
[0326]
[0327]
[0328]
[0329]
[0330]
[0331]
[0332]
[0333]
[0334]
[0335]
[0336]
[0337]
[0338]
[0339]
[0340]
[0341]
[0342]
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356]
[0357]
[0358]
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369]
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
[0376]
[0377]
[0378]
[0379]
[0380]
[0381]
[0382]
[0383]
[0384]
[0385]
[0386]
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398]
[0399]
[0400]
[0401]
[0402]
[0403]
[0404]
[0405]
[0406]
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413]
[0414]
[0415]
[0416]
[0417]
[0418]
[0419]
[0420]
[0421]
[0422]
[0423]
[0424]
[0425]
[0426]
[0427]
[0428]
[0429]
[0430]
[0431]
[0432]
[0433]
[0434]
[0435]
[0436]
[0437]
[0438]
[0439]
[0440]
[0441]
[0442]
[0443]
[0444]
[0445]
[0446]
[0447]
[0448]
[0449]
[0450]
[0451]
[0452]
[0453]
[0454]
[0455]
[0456]
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471]
[0472]
[0473]
[0474]
[0475]
[0476]
[0477]
[0478]
[0479]
[0480]
[0481]
[0482]
[0483]
[0484]
[0485]
[0486]
[0487]
[0488]
[0489]
[0490]
[0491]
[0492]
[0493]
[0494]
[0495]
[0496]
[0497]
[0498]
[0499]
[0500]
[0501]
[0502]
[0503]
[0504]
[0505]
[0506]
[0507]
[0508]
[0509]
[0510]
[0511]
[0512]
[0513]
[0514]
[0515]
[0516]
[0517]
[0518]
[0519]
[0520]
[0521]
[0522]
[0523]
[0524]
[0525]
[0526]
[0527]
[0528]
[0529]
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569]
[0570]
[0571]
[0572]
[0573]
[0574]
[0575]
[0576]
[0577]
[0578]
[0579]
[0580]
[0581]
[0582]
[0583]
[0584]
[0585]
[0586]
[0587]
[0588]
[0589]
[0590]
[0591]
[0592]
[0593]
[0594]
[0595]
[0596]
[0597]
[0598]
[0599]
[0600]
[0601]
[0602]
[0603]
[0604]
[0605]
[0606]
[0607]
[0608]
[0609]
[0610]
[0611]
[0612]
[0613]
[0614]
[0615]
[0616]
[0617]
[0618]
[0619]
[0620]
[0621]
[0622]
[0623]
[0624]
[0625]
[0626]
[0627]
[0628]
[0629]
[0630]
[0631]
[0632]
[0633]
[0634]
[0635]
[0636]
[0637]
[0638]
[0639]
[0640]
[0641]
[0642]
[0643]
[0644]
[0645]
[0646]
[0647]
[0648]
[0649]
[0650]
[0651]
[0652]
[0653]
[0654]
[0655]
[0656]
[0657]
[0658]
[0659]
[0660]
[0661]
[0662]
[0663]
[0664]
[0665]
[0666]
[0667]
[0668]
[0669]
[0670]
[0671]
[0672]
[0673]
[0674]
[0675]
[0676]
[0677]
[0678]
[0679]
[0680]
[0681]
[0682]
[0683]
[0684]
[0685]
[0686]
[0687]
[0688]
[0689]
[0690]
[0691]
[0692]
[0693]
[0694]
[0695]
[0696]
[0697]
[0698]
[0699]
[0700]
[0701]
[0702]
[0703]
[0704]
[0705]
[0706]
[0707]
[0708]
[0709]
[0710]
[0711]
[0712]
[0713]
[0714]
[0715]
[0716]
[0717]
[0718]
[0719]
[0720]
[0721]
[0722]
[0723] Connectors
[0724] In some embodiments, the PEgRNA comprises a joint. In some embodiments, the joint: i) is immediately adjacent to the 5' of one or more nucleic acid portions, ii) is immediately adjacent to the 5' of the tag sequence, iii) is immediately adjacent to the 3' of the tag sequence, iv) is immediately adjacent to the 3' of the spacer, v) is immediately adjacent to the 5' of the spacer, vi) is immediately adjacent to the 3' of the gRNA core, or vii) is immediately adjacent to the 5' of the gRNA core. In some embodiments, the length of the joint is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides. In some embodiments, the length of the joint is 2 to 12 nucleotides. In some embodiments, the length of the joint is 5 to 20 nucleotides. In some embodiments, the length of the joint is 3 to 10, 3 to 15, 3 to 20, 3 to 25, 3 to 30, 3 to 35, 3 to 40, or 3 to 50 nucleotides. In some embodiments, the length of the joint is 8 nucleotides. In some embodiments, the joint does not form a secondary structure. In some embodiments, the linker does not have a region complementary to the PBS sequence. In some embodiments, the linker does not have a region complementary to the editing template. In some embodiments, the linker comprises a sequence selected from SEQ REF NO 1961-3859. As used herein, a linker can be any chemical group or molecule connecting two molecules / parts (e.g., components of PEgRNA).
[0725] LegRNA
[0726] Also provided herein is a legRNA. In some embodiments, the PEgRNA is a legRNA. As used herein, a "legRNA" is a PEgRNA comprising a spacer, a gRNA core, a PBS, and an editing template (e.g., an RTT sequence), wherein the PBS and the editing template are located within the gRNA core. The legRNA disclosed herein may include any 3' portion or other modification disclosed herein.
[0727] In certain embodiments, the legRNA comprises, in 5' to 3' order: i) a spacer comprising a region complementary to a search target sequence in a target strand of a double-stranded target DNA; ii) a 5' portion of a guide RNA (gRNA) core; iii) an editing template comprising an expected edit compared to the double-stranded target DNA; iv) a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and v) a 3' portion of the gRNA core. In some embodiments, the 5' portion of the gRNA core comprises a direct repeat, a first stem loop, and the 5' half of a second stem loop. In some embodiments, the 3' portion of the gRNA core comprises the 3' half of the second stem loop and a third stem loop. In some embodiments, the 5' portion of the gRNA core is within 3' of the 3' portion of the gRNA core of the complete gRNA core sequence. 第30th and 31st 个 , No. 31 With the 32nd 个 , No. 32 With the 33rd 个 , No. 33 With the 34th 个 , No. 34 With the 35th 个 , No. 35 With the 36th 个 , No. 36 With the 37th 个 , No. 37 With the 38th 个 , No. 38 With the 39th 个 or 39 With the 40th 个 The 5' portion of the gRNA core is "split" between nucleotides, wherein the position of the nucleotides is numbered as listed in SEQ REF NO: 16. In some embodiments, the 5' portion of the gRNA core is at the position of the 3' portion of the gRNA core in the entire gRNA core sequence. 第 50th and 51st 个 , No. 51 With the 52nd 个 , No. 52 With the 55th 个 , No. 55 With the 54th 个 , No. 54 With the 55th 个 , No. 55 With the 56th 个 , No. 56 With the 57th 个 , No. 57 With the 58th 个 , No. 58 With the 59th 个 or 59 With the 60th 个 In some embodiments, the 5' portion of the gRNA core and the 3' portion of the gRNA core are "split" between nucleotides, wherein the position numbering of the nucleotides is as listed in SEQ REF NO: 16. In some embodiments, the 5' portion of the gRNA core and the 3' portion of the gRNA core are split between the 54th and 55th nucleotides of the complete gRNA core sequence, wherein the position numbering of the nucleotides is as listed in SEQ REF NO: 16. In some embodiments, the 5' portion of the gRNA core comprises the sequence GTTTAAGAGCTAGAAATAGCAAGTTTAAATAAG GCTAGTCCGTTATCAGCGTGA. In some embodiments, the 3' portion of the gRNA core comprises the sequence AAACGCGGCACCGAGTCGGTGC.
[0728] Exemplary legRNAs are found in Table 6 below.
[0729] In some embodiments, the PEgRNA further comprises a tag sequence comprising a region complementary to the PBS and / or the editing template.
[0730] The legRNA may comprise a tag sequence, an aptamer, a hairpin, a quadruplex, a tRNA, a pseudoknot, a linker, or any nucleic acid portion as described herein. In some embodiments, the legRNA comprises a linker. In some embodiments, the linker: i) is immediately 5' to one or more nucleic acid portions, ii) is immediately 5' to the tag sequence, iii) is immediately 3' to the tag sequence, iv) is immediately 3' to the spacer, v) is immediately 5' to the spacer, vi) is immediately 3' to the gRNA core, and / or vii) is immediately 5' to the gRNA core. In some embodiments, the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides in length. In some embodiments, the linker does not form a secondary structure. In some embodiments, the linker does not have a region complementary to a PBS sequence. In some embodiments, the linker does not have a region complementary to an editing template. In some embodiments, the linker comprises a nucleic acid sequence selected from SEQ REF NO 1961-3859. As used herein, a linker can be any chemical group or molecule that connects two molecules or moieties (eg, components of a legRNA).
[0731]
[0732]
[0733]
[0734]
[0735]
[0736]
[0737]
[0738]
[0739]
[0740]
[0741]
[0742]
[0743]
[0744] Extended gRNA core
[0745] In some embodiments, the PEgRNA comprises a gRNA core that comprises one or more nucleotide insertions compared to a wild-type CRISPR guide RNA scaffold sequence (e.g., a canonical SpCa9 guide RNA scaffold), i.e., a gRNA core with an extended length. Potential advantages associated with such an extended gRNA core may include improved lead editing efficiency and / or improved manufacturing by a split synthesis scheme.
[0746] In some embodiments, the gRNA core comprises an insertion of one or more nucleotides in the direct repeat compared to the wild-type CRISPR guide RNA scaffold sequence as set forth in SEQ REF NO: 16. In some embodiments, the gRNA core comprises an insertion of one or more nucleotides in the second stem loop compared to the canonical SpCas9 guide RNA scaffold sequence as set forth in SEQ REF NO: 16. Exemplary extended gRNA cores are provided in Tables 1 and 2. Although the gRNA core sequences provided in Tables 1 and 2 are RNA sequences, "T" is used instead of "U" in the sequences to be consistent with the ST.26 standard.
[0747] The components of a PEgRNA (e.g., an extended PEgRNA) can be synthesized by split synthesis, which refers to synthesizing two (or more) parts of a PEgRNA (e.g., a 5' half of a PEgRNA and a 3' half of a PEgRNA) separately and ligating the first half to the second half to form a full-length PEgRNA. An exemplary "split" position between the 5' half and the 3' half (e.g., in the direct repeat or second stem-loop of the gRNA core) is shown in Figure 8 Exemplary gRNA core sequences and corresponding first and second halves for split synthesis are shown in Table 2.
[0748] In certain embodiments, the PEgRNA provided herein comprises: i) a first sequence comprising a spacer region containing a region complementary to a search target sequence in a target strand of a double-stranded target DNA, and the first half of a gRNA core; and ii) a second sequence comprising the second half of the gRNA core, an editing template containing the expected editing compared to the double-stranded target DNA; a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; and wherein the gRNA core comprises a direct repeat, a first stem loop, and a second stem loop.
[0749] In certain embodiments, the PEgRNA provided herein comprises: i) a first sequence comprising an editing template comprising an expected edit compared to a double-stranded target DNA; a primer binding site (PBS) comprising a region complementary to a region upstream of a nicking site in a non-target strand of the double-stranded target DNA; a spacer comprising a region complementary to a search target sequence in a target strand of the double-stranded target DNA; and the first half of a gRNA core; and ii) a second sequence comprising the second half of the gRNA core, wherein the gRNA core comprises a direct repeat, a first stem loop, and a second stem loop.
[0750] In some embodiments, the first sequence is on the first RNA molecule, and the second sequence is on the second RNA molecule. In some embodiments, the spacer and the first sequence and the second sequence are on the same RNA molecule. In some embodiments, the first half of the gRNA core and the second half of the gRNA core are selected from the first half gRNA core sequence and the second half gRNA sequence of the pairing provided in Table 2.
[0751] It should be understood that the length of the first half and the second half of the gRNA core may be equal or unequal. In some embodiments, the length of the first half of the gRNA core is at least 5, at least 10, at least 15, at least 20 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 35 nucleotides, at least 40 nucleotides, at least 45 nucleotides, at least 50 nucleotides, at least 55 nucleotides, at least 60 nucleotides, at least 65 nucleotides, at least 70 nucleotides or at least 75 nucleotides. In some embodiments, the length of the second half of the gRNA core is at least 5, at least 10, at least 15, at least 20 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 35 nucleotides, at least 40 nucleotides, at least 45 nucleotides, at least 50 nucleotides, at least 55 nucleotides, at least 60 nucleotides, at least 65 nucleotides, at least 70 nucleotides or at least 75 nucleotides.
[0752] In some embodiments, the first half of the gRNA core is at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identical to the sequences provided in Table 2. In some embodiments, the first half of the gRNA core is identical to the sequences provided in Table 2. In some embodiments, the second half of the gRNA core is at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identical to the sequences provided in Table 2. In some embodiments, the second half of the gRNA core is identical to the sequences provided in Table 2.
[0753] As previously discussed, the gRNA core may comprise direct repeats and / or one or more stem loops. In some embodiments, the gRNA core synthesized using split synthesis comprises the first half of the gRNA core containing the first half of the direct repeats and the second half of the gRNA core containing the second half of the direct repeats. In some embodiments, the gRNA core synthesized using split synthesis comprises the first half of the gRNA core containing the first half of the second stem loop and the second half of the gRNA core containing the second stem loop.
[0754]
[0755]
[0756]
[0757]
[0758]
[0759]
[0760]
[0761]
[0762]
[0763]
[0764]
[0765]
[0766]
[0767]
[0768]
[0769]
[0770]
[0771]
[0772]
[0773]
[0774]
[0775]
[0776]
[0777]
[0778]
[0779]
[0780]
[0781]
[0782]
[0783]
[0784]
[0785]
[0786]
[0787]
[0788]
[0789]
[0790]
[0791]
[0792]
[0793]
[0794]
[0795]
[0796]
[0797]
[0798]
[0799]
[0800]
[0801]
[0802]
[0803]
[0804]
[0805]
[0806]
[0807]
[0808]
[0809]
[0810]
[0811]
[0812]
[0813]
[0814]
[0815]
[0816]
[0817]
[0818]
[0819]
[0820]
[0821]
[0822]
[0823]
[0824]
[0825]
[0826]
[0827]
[0828]
[0829]
[0830]
[0831]
[0832]
[0833]
[0834]
[0835]
[0836]
[0837]
[0838]
[0839]
[0840]
[0841]
[0842]
[0843]
[0844]
[0845]
[0846]
[0847]
[0848]
[0849]
[0850]
[0851]
[0852]
[0853]
[0854]
[0855]
[0856]
[0857]
[0858]
[0859]
[0860]
[0861]
[0862]
[0863]
[0864]
[0865]
[0866]
[0867]
[0868]
[0869]
[0870]
[0871]
[0872]
[0873]
[0874]
[0875]
[0876]
[0877]
[0878]
[0879]
[0880]
[0881]
[0882]
[0883]
[0884]
[0885]
[0886]
[0887]
[0888]
[0889]
[0890]
[0891]
[0892]
[0893]
[0894]
[0895]
[0896]
[0897]
[0898]
[0899]
[0900]
[0901]
[0902]
[0903]
[0904]
[0905]
[0906]
[0907]
[0908]
[0909]
[0910]
[0911]
[0912]
[0913]
[0914]
[0915]
[0916]
[0917]
[0918]
[0919]
[0920]
[0921]
[0922]
[0923]
[0924]
[0925]
[0926]
[0927] Nucleotide editing
[0928] Provided herein are exemplary PEgRNAs with modifications disclosed herein for nucleotide editing. Compared to the target gene sequence, the expected nucleotide editing in the editing template of the PEgRNA may include various types of changes. In some embodiments, compared to the target gene sequence, the nucleotide editing is a single nucleotide substitution. In some embodiments, compared to the target gene sequence, the nucleotide editing is a deletion. In some embodiments, compared to the target gene sequence, the nucleotide editing is an insertion. In some embodiments, compared to the target gene sequence, the editing template comprises one to ten expected nucleotide editings. In some embodiments, compared to the target gene sequence, the editing template comprises one or more expected nucleotide editings. In some embodiments, compared to the target gene sequence, the editing template comprises two or more expected nucleotide editings. In some embodiments, compared to the target gene sequence, the editing template comprises three or more expected nucleotide editings. In some embodiments, compared to the target gene sequence, the editing template comprises four or more, five or more, or six or more expected nucleotide editings. In some embodiments, compared to the target gene sequence, the editing template comprises two single nucleotide substitutions, insertions, deletions, or any combination thereof. In some embodiments, compared to the target gene sequence, the editing template comprises three single nucleotide substitutions, insertions, deletions, or any combination thereof. In some embodiments, the editing template comprises four, five or six single nucleotide substitutions, insertions, deletions or any combination thereof compared to the target gene sequence. In some embodiments, the nucleotide substitutions include adenine (A) to thymine (T) substitutions. In some embodiments, the nucleotide substitutions include A to guanine (G) substitutions. In some embodiments, the nucleotide substitutions include A to cytosine (C) substitutions. In some embodiments, the nucleotide substitutions include TA substitutions. In some embodiments, the nucleotide substitutions include TG substitutions. In some embodiments, the nucleotide substitutions include TC substitutions. In some embodiments, the nucleotide substitutions include G to A substitutions. In some embodiments, the nucleotide substitutions include G to T substitutions. In some embodiments, the nucleotide substitutions include G to C substitutions. In some embodiments, the nucleotide substitutions include C to A substitutions. In some embodiments, the nucleotide substitutions include C to T substitutions. In some embodiments, the nucleotide substitutions include C to G substitutions.
[0929] In some embodiments, the length of the nucleotide insertion is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, or at least 20 nucleotides. In some embodiments, the length of the nucleotide insertion is 1 to 2 nucleotides, 1 to 3 nucleotides, 1 to 4 nucleotides, 1 to 5 nucleotides, 2 to 5 nucleotides, 3 to 5 nucleotides, 3 to 6 nucleotides, 3 to 8 nucleotides, 4 to 9 nucleotides, 5 to 10 nucleotides, 6 to 11 nucleotides, 7 to 12 nucleotides, 8 to 13 nucleotides, 9 to 14 nucleotides, 10 to 15 nucleotides, 11 to 16 nucleotides, 12 to 17 nucleotides, 13 to 18 nucleotides, 14 to 19 nucleotides, 15 to 20 nucleotides. In some embodiments, the nucleotide insertion is a single nucleotide insertion. In some embodiments, the nucleotide insertion comprises an insertion of two nucleotides.
[0930] Compared to the gene to be edited, the editing template of the PEgRNA may include one or more expected nucleotide edits. The position of the expected nucleotide edits associated with other components of the PEgRNA or specific nucleotides (e.g., mutations) in the target gene may be different. In some embodiments, the nucleotide edits are in a PEgRNA region corresponding to or homologous to the protospacer sequence. In some embodiments, the nucleotide edits are in a PEgRNA region corresponding to a gene region outside the protospacer sequence.
[0931] In some embodiments, the position of the incorporation of nucleotide edits in the target gene can be determined based on the position of the protospacer adjacent motif (PAM). For example, the expected nucleotide edits can be set in a sequence corresponding to the protospacer adjacent motif (PAM) sequence. In some embodiments, the nucleotide edits in the editing template are located at the position corresponding to the 5' most nucleotide of the PAM sequence. In some embodiments, the nucleotide edits in the editing template are located at the position corresponding to the 3' most nucleotide of the PAM sequence. In some embodiments, the position of the expected nucleotide edits in the editing template can be referred to by aligning the editing template with the partially complementary editing strands of the target gene and referring to the nucleotide position on the editing strand where the expected nucleotide edits are incorporated. In some embodiments, the nucleotide edits are incorporated into a position that is about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 base pairs upstream of the 5'-most nucleotide of the PAM sequence in the target gene editing strand. 0 base pairs upstream or downstream of a reference position means that the intended nucleotide is immediately upstream or downstream of the reference position. In some embodiments, the nucleotide edits are incorporated approximately 0 to 2 base pairs, 0 to 4 base pairs, 0 to 6 base pairs, 0 to 8 base pairs, 0 to 10 base pairs, 2 to 4 base pairs, 2 to 6 base pairs, 2 to 8 base pairs, 2 to 10 base pairs, 2 to 12 base pairs, 4 to 6 base pairs, 4 to 8 base pairs, 4 to 10 base pairs, upstream of the 5'-most nucleotide of the PAM sequence. base pairs, 4 to 12 base pairs, 4 to 14 base pairs, 6 to 8 base pairs, 6 to 10 base pairs, 6 to 12 base pairs, 6 to 14 base pairs, 6 to 16 base pairs, 8 to 10 base pairs, 8 to 12 base pairs, 8 to 14 base pairs, 8 to 16 base pairs, 8 to 18 base pairs, 10 to 12 base pairs, 10 to 14 base pairs, 10 to 16 base pairs base pairs, 10 to 18 base pairs, 10 to 20 base pairs, 12 to 14 base pairs, 12 to 16 base pairs, 12 to 18 base pairs, 12 to 20 base pairs, 12 to 22 base pairs, 14 to 16 base pairs, 14 to 18 base pairs, 14 to 20 base pairs, 14 to 22 base pairs, 14 to 24 base pairs, 16 to 18 base pairs, 16 to 20 base pairs, 16 to 22 base pairs, 16 to 24 base pairs, 16 to 26 base pairs, 18 to 20 base pairs, 18 to 22 base pairs, 18 to 24 base pairs, 18 to 26 base pairs, 18 to 28 base pairs, 20 to 22 base pairs, 20 to 24 base pairs, 20 to 26 base pairs, 20 to 28 base pairs, or 20 to 30 base pairs.In some embodiments, the nucleotide edit is incorporated at a position corresponding to 3 base pairs upstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edit is incorporated at a position corresponding to 4 base pairs upstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edit is incorporated at a position corresponding to 5 base pairs upstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edit in the editing template is located at a position corresponding to 6 base pairs upstream of the 5'-most nucleotide of the PAM sequence.
[0932] In some embodiments, the nucleotide edits are intended to be incorporated at a position that corresponds to about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 base pairs downstream of the 5'-most nucleotide of the PAM sequence in the target gene editing strand. In some embodiments, the nucleotide edits are incorporated approximately 0 to 2 base pairs, 0 to 4 base pairs, 0 to 6 base pairs, 0 to 8 base pairs, 0 to 10 base pairs, 2 to 4 base pairs, 2 to 6 base pairs, 2 to 8 base pairs, 2 to 10 base pairs, 2 to 12 base pairs, 4 to 6 base pairs, 4 to 8 base pairs, 4 to 10 base pairs, downstream of the 5'-most nucleotide of the PAM sequence. base pairs, 4 to 12 base pairs, 4 to 14 base pairs, 6 to 8 base pairs, 6 to 10 base pairs, 6 to 12 base pairs, 6 to 14 base pairs, 6 to 16 base pairs, 8 to 10 base pairs, 8 to 12 base pairs, 8 to 14 base pairs, 8 to 16 base pairs, 8 to 18 base pairs, 10 to 12 base pairs, 10 to 14 base pairs, 10 to 16 base pairs base pairs, 10 to 18 base pairs, 10 to 20 base pairs, 12 to 14 base pairs, 12 to 16 base pairs, 12 to 18 base pairs, 12 to 20 base pairs, 12 to 22 base pairs, 14 to 16 base pairs, 14 to 18 base pairs, 14 to 20 base pairs, 14 to 22 base pairs, 14 to 24 base pairs, 16 to 18 base pairs, 16 to 20 In some embodiments, the nucleotide edits are incorporated at a position corresponding to 3 base pairs downstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edits are incorporated at a position corresponding to 4 base pairs downstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edits are incorporated at a position corresponding to 5 base pairs downstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edits are incorporated at a position corresponding to 5 base pairs downstream of the 5'-most nucleotide of the PAM sequence. In some embodiments, the nucleotide edits are incorporated at a position corresponding to 6 base pairs downstream of the 5'-most nucleotide of the PAM sequence. "Upstream" and "downstream" are intended to define the relative positions of at least two regions or sequences oriented in a 5' to 3' direction in a nucleic acid molecule. For example, a first sequence is upstream of a second sequence in a DNA molecule, wherein the first sequence is located 5' of the second sequence. Thus, the second sequence is downstream of the first sequence.
[0933] When referred to in a PEgRNA, the position of one or more expected nucleotide edits may be referred to in relation to the components of the PEgRNA. For example, the expected nucleotide edit may be at 5' or 3' of the PBS. In some embodiments, the PEgRNA comprises a structure from 5' to 3': a spacer, a gRNA core, an editing template, and a PBS. In some embodiments, the expected nucleotide edit is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 base pairs upstream of the 5' nucleotide of the PBS. In some embodiments, the nucleotide edit is intended to be 0 to 2 base pairs, 0 to 4 base pairs, 0 to 6 base pairs, 0 to 8 base pairs, 0 to 10 base pairs, 2 to 4 base pairs, 2 to 6 base pairs, 2 to 8 base pairs, 2 to 10 base pairs, 2 to 12 base pairs, 4 to 6 base pairs, 4 to 8 base pairs, 4 to 10 base pairs upstream of the 5'-most nucleotide of the PBS. , 4 to 12 base pairs, 4 to 14 base pairs, 6 to 8 base pairs, 6 to 10 base pairs, 6 to 12 base pairs, 6 to 14 base pairs, 6 to 16 base pairs, 8 to 10 base pairs, 8 to 12 base pairs, 8 to 14 base pairs, 8 to 16 base pairs, 8 to 18 base pairs, 10 to 12 base pairs, 10 to 14 base pairs, 10 to 16 bases 10 to 18 base pairs, 10 to 20 base pairs, 12 to 14 base pairs, 12 to 16 base pairs, 12 to 18 base pairs, 12 to 20 base pairs, 12 to 22 base pairs, 14 to 16 base pairs, 14 to 18 base pairs, 14 to 20 base pairs, 14 to 22 base pairs, 14 to 24 base pairs, 16 to 18 base pairs, 16 to 2 or 20 to 30 base pairs.
[0934] The corresponding position of the expected nucleotide editing incorporated into the target gene may also refer to the base at the nick position generated by the lead editor based on sequence homology and complementarity. For example, in an embodiment, when the spacer is hybridized with the search target sequence and the extension arm is hybridized with the editing target sequence, the distance between the nucleotide editing to be incorporated into the target gene and the nick generated by the lead editor can be determined. In certain embodiments, the position of the nucleotide editing may be at any position downstream of the nick site on the editing strand (or PAM strand) generated by the lead editor, so that the distance length between the nick site and the expected nucleotide editing is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides. In some embodiments, the position of the nucleotide edit is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides upstream of the nick site on the edited strand. In some embodiments, the position of the nucleotide edit is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides downstream of the nick site on the edited strand. In some embodiments, the position of the nucleotide edit is 0 base pairs away from the nick site on the edited strand, that is, the editing position is at the same position as the nick site. As used herein, the distance between the nick site and the nucleotide edit (e.g., when the nucleotide edit includes an insertion or deletion) refers to the 5'most position of the nucleotide edit that produces the nick of the 3' free end on the edited strand (i.e., the "proximal position" of the nucleotide edit and the nick site). Similarly, as used herein, the distance between the nick site and the PAM position edit (e.g., when the nucleotide edit includes the insertion, deletion or substitution of two or more consecutive nucleotides) refers to the 5'most position of the nucleotide edit and the 5'most position of the PAM sequence.
[0935] PEgRNA may also include optional modifiers, for example, 3' terminal modifier region and / or 5' terminal modifier region. In some embodiments, PEgRNA includes at least one nucleotide that is not part of a spacer, gRNA core or extension arm. Optional sequence modifiers may be located in or between any other regions shown, and are not limited to being located at 3' and 5' ends. In certain embodiments, PEgRNA includes secondary RNA structures, such as but not limited to aptamers, hairpins, stem / loops, toe loops and / or RNA binding protein recruitment domains (e.g., MS2 aptamers that recruit and bind to MS2cp proteins). In some embodiments, PEgRNA includes a short segment of uracil at the 5' end or 3' end. For example, in some embodiments, a PEgRNA comprising a 3' extension arm includes a "UUU" sequence at the 3' end of the extension arm. In some embodiments, PEgRNA includes a toe loop sequence at the 3' end. In some embodiments, PEgRNA includes a 3' extension arm and a toe loop sequence at the 3' end of the extension arm. In some embodiments, the PEgRNA comprises a 5' extension arm and a toe loop sequence at the 5' end of the extension arm. In some embodiments, the PEgRNA comprises a toe loop element having a sequence 5'-GAAANNNNN-3', wherein N is any nucleobase. In some embodiments, the secondary RNA structure is located in the spacer. In some embodiments, the secondary structure is located in the extension arm. In some embodiments, the secondary structure is located in the gRNA core. In some embodiments, the secondary structure is located between the spacer and the gRNA core, between the gRNA core and the extension arm, or between the spacer and the extension arm. In some embodiments, the secondary structure is located between the PBS and the editing template. In some embodiments, the secondary structure is located at the 3' end or the 5' end of the PEgRNA. In some embodiments, the PEgRNA comprises a transcription termination signal at the 3' end of the PEgRNA. In addition to the secondary RNA structure, the PEgRNA may also include a chemical linker or a poly (N) linker or tail, wherein "N" may be any nucleobase. In some embodiments, the chemical linker may serve to prevent the reverse transcription of the gRNA core.
[0936] In some embodiments, the lead editing system or composition further comprises a nicking guide polynucleotide, such as a nicking guide RNA (ngRNA). Without being bound by any particular theory, the non-editing strand of the double-stranded target DNA in the target gene can be nicked by the CRISPR-Cas nickase guided by ngRNA. In some embodiments, the nick on the non-editing strand guides the endogenous DNA repair mechanism to use the editing strand as a template for non-editing strand repair, which can increase the efficiency of the lead editing. In some embodiments, the non-editing strand is positioned to the lead editor nick of the non-editing strand by ngRNA. Therefore, a PEgRNA system comprising at least one PEgRNA and at least one ngRNA is also provided herein.
[0937] In some embodiments, ngRNA is a guide RNA containing a variable spacer sequence and a guide RNA scaffold or core region that interacts with a DNA binding domain (e.g., Cas9 of a lead editor). In some embodiments, ngRNA comprises a spacer sequence (referred to herein as ng spacer or second spacer) that is substantially complementary to a second search target sequence (or ng search target sequence) located on an editing strand or a non-target strand. Therefore, in some embodiments, the search target sequence recognized by the ng spacer and the search target sequence recognized by the spacer sequence of the PEgRNA are on opposite strands of the double-stranded target DNA of the target gene (e.g., the gene).
[0938] A lead editing system or composition that does not include ngRNA may be referred to as a "PE2" lead editing system. A lead editing system or composition that includes ngRNA may be referred to as a "PE3" lead editing system or a PE3 lead editing complex.
[0939] In some embodiments, the ng search target sequence is located on the non-target strand, within 10 base pairs to 100 base pairs of the expected nucleotide edited by the PEgRNA on the editing strand. In some embodiments, the ng target search target sequence is within 10bp, 20bp, 30bp, 40bp, 50bp, 60bp, 70bp, 80bp, 90bp, 91bp, 92bp, 93bp, 94bp, 95bp, 96bp, 97bp, 98bp, 99bp or 100bp of the expected nucleotide edited by the PEgRNA on the editing strand. In some embodiments, the 5' ends of the ng search target sequence and the PEgRNA search target sequence are within 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10bp of each other. In some embodiments, the 5' ends of the ng search target sequence and the PEgRNA search target sequence are within 10bp, 20bp, 30bp, 40bp, 50bp, 60bp, 70bp, 80bp, 90bp, 91bp, 92bp, 93bp, 94bp, 95bp, 96bp, 97bp, 98bp, 99bp or 100bp of each other.
[0940] In some embodiments, the ng spacer sequence is complementary to the second search target sequence and can hybridize with the second search target sequence only after the expected nucleotide editing is incorporated into the editing strand by the editing template of the PEgRNA. Such a lead editing system may be referred to as a "PE3b" lead editing system or composition. In some embodiments, the ngRNA comprises a spacer sequence that only matches the editing strand after the nucleotide editing is incorporated, but does not match the endogenous target gene sequence on the editing strand. Therefore, in some embodiments, the expected nucleotide editing is incorporated into the ng search target sequence. In some embodiments, the expected nucleotide editing is incorporated into about 1-10 nucleotides corresponding to the position of the PAM of the ng search target sequence.
[0941] In some embodiments, the PEgRNA and / or ngRNA of the present disclosure may comprise modified nucleotides, e.g., chemically modified DNA or RNA nucleobases, and may comprise one or more nucleobase analogs (e.g., modifications that may increase functionality such as temperature resilience). In some embodiments, the PEgRNA and / or ngRNA as described herein may be chemically modified. As used herein, the phrase "chemical modification" may include modifications that introduce chemical properties different from those found in naturally occurring DNA or RNA, e.g., covalent modifications, such as the introduction of modified nucleotides (e.g., nucleotide analogs, or side groups that are not naturally present in DNA or RNA molecules).
[0942] In some embodiments, the PEgRNA and / or ngRNA provided in the present disclosure may have undergone chemical or biological modification. Modifications may be performed at any position within the PEgRNA or ngRNA, and may include modifications to the nucleobase or phosphate backbone of the PEgRNA or ngRNA. In some embodiments, the chemical modification may be a structurally guided modification. In some embodiments, the chemical modification is located at the 5' end and / or the 3' end of the PEgRNA. In some embodiments, the chemical modification is located at the 5' end and / or the 3' end of the ngRNA. In some embodiments, the chemical modification may be within the primer binding site of the spacer sequence, extension arm, editing template sequence, or PEgRNA. In some embodiments, the chemical modification may be within the spacer sequence or gRNA core of the PEgRNA or ngRNA. In some embodiments, the chemical modification may be within the most 3' nucleotide of the PEgRNA or ngRNA. In some embodiments, the chemical modification may be within the most 3' of the PEgRNA or ngRNA. In some embodiments, the chemical modification may be within the most 5' of the PEgRNA or ngRNA. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chemically modified nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chemically modified nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, or 5 or more chemically modified nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, or 5 or more chemically modified nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, or 3 or more chemically modified nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, or 3 or more chemically modified nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chemically modified consecutive nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more chemically modified consecutive nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, or 5 chemically modified consecutive nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, or 5 chemically modified consecutive nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, or 3 chemically modified consecutive nucleotides at the 3' end.In some embodiments, the PEgRNA or ngRNA comprises 1, 2 or 3 chemically modified consecutive nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 3 chemically modified consecutive nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5 or more chemically modified nucleotides near the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 3 chemically modified consecutive nucleotides at the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 3 chemically modified consecutive nucleotides at the 5' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5 or more chemically modified nucleotides near the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5 or more chemically modified consecutive nucleotides near the 3' end. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5, or more chemically modified nucleotides near the 3' end, wherein the 3'-most nucleotide is unmodified and 1, 2, 3, 4, 5, or more chemically modified nucleotides precede the 3'-most nucleotide in a 5' to 3' order. In some embodiments, the PEgRNA or ngRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more chemically modified nucleotides near the 3' end, wherein the 3'-most nucleotide is unmodified and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more chemically modified nucleotides precede the 3'-most nucleotide in a 5' to 3' order.
[0943] In some embodiments, the PEgRNA or ngRNA comprises one or more chemically modified nucleotides in the gRNA core. Figure 8 As illustrated, the gRNA core of PEgRNA may include the region of one or more base-paired lower stems, base-paired upper stems, wherein the lower stem and upper stem may be connected by a protrusion comprising unpaired RNA. The gRNA core may also include a connection point away from the spacer sequence. In some embodiments, the gRNA core includes one or more chemically modified nucleotides in the lower stem, upper stem, and / or hairpin region. In some embodiments, all nucleotides in the lower stem, upper stem, and / or hairpin region are chemically modified.
[0944] Chemical modifications to PEgRNA or ngRNA may include 2'-O-thiocarbamate protected nucleoside phosphoramidites, 2'-O-methyl (M), 3' thiophosphate 2'-O-methyl ester (MS) or 2'-O-methyl 3' thioPACE (MSP), or any combination thereof. In some embodiments, chemically modified PEgRNA and / or ngRNA may include 2'-O-methyl (M) RNA, 3' thiophosphate 2'-O-methyl ester (MS) RNA, 2'-O-methyl 3' thioPACE (MSP) RNA, 2'-F RNA, thiophosphate bond modification, any other chemical modification known in the art, or any combination thereof. Chemical modifications may also include, for example, incorporating non-nucleotide linkages or modified nucleotides into PEgRNA and / or ngRNA (e.g., modification of one or both of the 3' and 5' ends of the guide RNA molecule). Such modifications can include adding bases to the RNA sequence, complexing the RNA with an agent (e.g., a protein or a complementary nucleic acid molecule), and including elements that alter the structure of the RNA molecule (e.g., that form secondary structures).
[0945] Lead Editor
[0946] The term "lead editor (PE)" refers to a polypeptide or polypeptide component involved in the lead editing, or any polynucleotide encoding the polypeptide or polypeptide component. In various embodiments, the lead editor comprises a polypeptide domain having DNA binding activity and a polypeptide domain having DNA polymerase activity. In some embodiments, the lead editor also comprises a polypeptide domain having nuclease activity. In some embodiments, the polypeptide domain with DNA binding activity comprises a nuclease domain or nuclease activity. In some embodiments, the polypeptide domain with nuclease activity comprises a nickase or a fully active nuclease. As used herein, the term "nickase" refers to a nuclease that can cut only one strand of a double-stranded DNA target. In some embodiments, the lead editor comprises a polypeptide domain that is an inactivated nuclease. In some embodiments, the polypeptide domain with programmable DNA binding activity comprises a nucleic acid-guided DNA binding domain, for example, a CRISPR-Cas protein, for example, a Cas9 nickase, a Cpf1 nickase, or another CRISPR-Cas nuclease. In some embodiments, the polypeptide domain with DNA polymerase activity includes a template-dependent DNA polymerase, such as a DNA-dependent DNA polymerase or an RNA-dependent DNA polymerase. In some embodiments, the DNA polymerase is a reverse transcriptase. In some embodiments, the lead editor includes another polypeptide involved in the lead editing, such as a polypeptide domain with 5' endonuclease activity, for example, a 5' endogenous DNA flap endonuclease (e.g., FEN1), for helping to drive the lead editing process toward the formation of an edited product. In some embodiments, the lead editor also includes an RNA-protein recruitment polypeptide, such as an MS2 coat protein.
[0947] The lead editor can be engineered. In some embodiments, the polypeptide components of the lead editor do not naturally exist in the same organism or cell environment. In some embodiments, the polypeptide components of the lead editor may come from different sources or different organisms. In some embodiments, the lead editor comprises a DNA binding domain and a DNA polymerase domain derived from different species. In some embodiments, the lead editor comprises a Cas polypeptide and a reverse transcriptase polypeptide derived from different species. For example, the lead editor may comprise a Streptococcus pyogenes Cas9 polypeptide and a Moloney murine leukemia virus (M-MLV) reverse transcriptase polypeptide.
[0948] In some embodiments, the polypeptide domain of the lead editor can be fused or connected by a peptide linker to form a fusion protein. In other embodiments, the lead editor comprises one or more polypeptide domains provided in trans as a separate protein, which can be associated with each other by non-peptide linkage or by an aptamer or a recruitment sequence. For example, the lead editor may include a DNA binding domain and a reverse transcriptase domain, which are associated with each other by an RNA-protein recruitment aptamer (e.g., an MS2 aptamer) that can be connected to a PEgRNA. The lead editor polypeptide component may be encoded in whole or in part by one or more polynucleotides. In some embodiments, a single polynucleotide, construct, or vector encodes a lead editor fusion protein. In some embodiments, a plurality of polynucleotides, constructs, or vectors each encode a polypeptide domain or a portion of a domain of a lead editor, or a portion of a lead editor fusion protein. For example, the lead editor fusion protein may include an N-terminal portion fused to an intein-N and a C-terminal portion fused to an intein-C, each portion being encoded separately by an AAV vector.
[0949] Prime editor nucleotide polymerase domain
[0950] In some embodiments, the lead editor includes a nucleotide polymerase domain, for example, a DNA polymerase domain. The DNA polymerase domain may be a wild-type DNA polymerase domain, a full-length DNA polymerase protein domain, or may be a functional mutant, a functional variant, or a functional fragment thereof. In some embodiments, the polymerase domain is a template-dependent polymerase domain. For example, a DNA polymerase may rely on a template polynucleotide chain (e.g., an editing template sequence) for new strand DNA synthesis. In some embodiments, the lead editor includes a DNA-dependent DNA polymerase. For example, a lead editor with a DNA-dependent DNA polymerase may use a PEgRNA editing template comprising a DNA sequence as a template to synthesize new single-stranded DNA. In such cases, PEgRNA is a chimeric or hybrid PEgRNA and includes an extension arm containing a DNA chain. A chimeric or hybrid PEgRNA may include an RNA portion (including a spacer and a gRNA core) and a DNA portion (an extension arm comprising an editing template, wherein the editing template includes a DNA chain).
[0951] The DNA polymerase can be a wild-type polymerase from a eukaryotic, prokaryotic, archaeal, or viral organism, and / or the polymerase can be modified by genetic engineering, mutagenesis, or a directed evolution-based process. The polymerase can be T7 DNA polymerase, T5 DNA polymerase, T4 DNA polymerase, Klenow fragment DNA polymerase, DNA polymerase III, etc. The polymerase can be thermostable and can include Taq, Tne, Tma, Pfu, Tfl, Tth, Stoffel fragment, and DNA polymerase, KOD, Tgo, JDF3 and mutants, variants and derivatives thereof.
[0952] In order to synthesize longer nucleic acid molecules (e.g., nucleic acid molecules longer than about 3-5Kb in length), at least two DNA polymerases may be used. In certain embodiments, one of the polymerases may substantially lack 3' exonuclease activity, while the other may have 3' exonuclease activity. Such pairings may include identical or different polymerases. Examples of DNA polymerases substantially lacking 3' exonuclease activity include, but are not limited to, Taq, Tne (exo-), Tma (exo-), Pfu (exo-), Pwo (exo-), exo-KOD, and Tth DNA polymerases, and any functional mutants, functional variants, and functional fragments thereof.
[0953] In some embodiments, the DNA polymerase is a bacteriophage polymerase, such as T4, T7, or phi29 DNA polymerase. In some embodiments, the DNA polymerase is an archaeal polymerase, such as a pol I type archaeal polymerase or a pol II type archaeal polymerase. In some embodiments, the DNA polymerase comprises a thermostable archaeal DNA polymerase. In some embodiments, the DNA polymerase comprises a true bacterial DNA polymerase, such as Pol I, Pol II, or Pol III polymerase. In some embodiments, the DNA polymerase is a Pol I family DNA polymerase. In some embodiments, the DNA polymerase is an Escherichia coli Pol I DNA polymerase. In some embodiments, the DNA polymerase is a Pol II family DNA polymerase. In some embodiments, the DNA polymerase is Pyrococcus furiosus (Pfu) Pol II DNA polymerase. In some embodiments, the DNA polymerase is a Pol IV family DNA polymerase. In some embodiments, the DNA polymerase is an Escherichia coli Pol IV DNA polymerase.
[0954] In some embodiments, the DNA polymerase includes a eukaryotic DNA polymerase. In some embodiments, the DNA polymerase is a Pol-β DNA polymerase, a Pol-λ DNA polymerase, a Pol-σ DNA polymerase, or a Pol-μ DNA polymerase. In some embodiments, the DNA polymerase is a Pol-α DNA polymerase. In some embodiments, the DNA polymerase is a POLA1 DNA polymerase. In some embodiments, the DNA polymerase is a POLA2 DNA polymerase. In some embodiments, the DNA polymerase is a Pol-δ DNA polymerase. In some embodiments, the DNA polymerase is a POLD1 DNA polymerase. In some embodiments, the DNA polymerase is a POLD2 DNA polymerase. In some embodiments, the DNA polymerase is a human POLD1 DNA polymerase. In some embodiments, the DNA polymerase is a human POLD2 DNA polymerase. In some embodiments, the DNA polymerase is a POLD3 DNA polymerase. In some embodiments, the DNA polymerase is a POLD4 DNA polymerase. In some embodiments, the DNA polymerase is a Pol-ε DNA polymerase. In some embodiments, the DNA polymerase is a POLE1 DNA polymerase. In some embodiments, the DNA polymerase is a POLE2 DNA polymerase. In some embodiments, the DNA polymerase is a POLE3 DNA polymerase. In some embodiments, the DNA polymerase is a Pol-η (POLH) DNA polymerase. In some embodiments, the DNA polymerase is a Pol-ι (POLI) DNA polymerase. In some embodiments, the DNA polymerase is a Pol-κ (POLK) DNA polymerase. In some embodiments, the DNA polymerase is a Rev1 DNA polymerase. In some embodiments, the DNA polymerase is a human Rev1 DNA polymerase. In some embodiments, the DNA polymerase is a viral DNA-dependent DNA polymerase. In some embodiments, the DNA polymerase is a B family DNA polymerase. In some embodiments, the DNA polymerase is a herpes simplex virus (HSV) UL30 DNA polymerase. In some embodiments, the DNA polymerase is a cytomegalovirus (CMV) UL54 DNA polymerase.
[0955] In some embodiments, the DNA polymerase is an archaeal polymerase. In some embodiments, the DNA polymerase is a B family / pol I type DNA polymerase. For example, in some embodiments, the DNA polymerase is a homolog of Pfu from Pyrococcus furiosus. In some embodiments, the DNA polymerase is a pol II type DNA polymerase. For example, in some embodiments, the DNA polymerase is a homolog of the P. furiosus DP1 / DP2 2-subunit polymerase. In some embodiments, the DNA polymerase lacks 5' to 3' nuclease activity. Suitable DNA polymerases (pol I or pol II) can be derived from archaea having an optimal growth temperature similar to the desired assay temperature.
[0956] In some embodiments, the DNA polymerase comprises a thermostable archaeal DNA polymerase. In some embodiments, the thermostable DNA polymerase is isolated or derived from Pyrococcus species (furiosus, species GB-D, woesii, abysii, horikoshii), Thermococcus species (kodakaraensis KOD1, litoralis, 9°N species-7, species JDF-3, gorgonarius), Pyrodictium occultum, and Archaeoglobus fulgidus.
[0957] Polymerases may also be from true bacterial species. In some embodiments, the DNA polymerase is a Pol I family DNA polymerase. In some embodiments, the DNA polymerase is an Escherichia coli Pol I DNA polymerase. In some embodiments, the DNA polymerase is a Pol II family DNA polymerase. In some embodiments, the DNA polymerase is a Pyrococcus furiosus (Pfu) PolII DNA polymerase. In some embodiments, the DNA polymerase is a Pol III family DNA polymerase. In some embodiments, the DNA polymerase is a Pol IV family DNA polymerase. In some embodiments, the DNA polymerase is an Escherichia coli Pol IV DNA polymerase. In some embodiments, the Pol I DNA polymerase is a functional variant of a DNA polymerase lacking or having reduced 5' to 3' exonuclease activity.
[0958] Suitable thermostable pol I DNA polymerases can be isolated from a variety of thermophilic eubacteria, including Thermus species and Thermotoga maritima, such as Thermus aquaticus (Taq), Thermus thermophilus (Tth), and Thermotoga maritima (Tma Ul Tma).
[0959] In some embodiments, the lead editor includes an RNA-dependent DNA polymerase domain, such as a reverse transcriptase (RT). RT or RT domain may be a wild-type RT domain, a full-length RT domain, or may be a functional mutant, a functional variant, or a functional fragment thereof. The RT or RT domain of the lead editor may include a wild-type RT, or may be engineered or evolved to contain a specific amino acid substitution, truncation, or variant. The engineered RT may include a sequence or amino acid change different from a naturally occurring RT. In some embodiments, the engineered RT may have improved reverse transcription activity than a naturally occurring RT or RT domain. In some embodiments, the engineered RT may have improved features than a naturally occurring RT, for example, improved thermal stability, reverse transcription efficiency, or target fidelity. In some embodiments, the lead editor comprising an engineered RT has improved lead editing efficiency than the lead editor with reference to a naturally occurring RT.
[0960] In some embodiments, the lead editor comprises a viral RT, such as a retroviral RT. Non-limiting examples of viral RTs include Moloney murine leukemia virus (M-MLV or MLVRT); human T-cell leukemia virus type 1 (HTLV-1) RT; bovine leukemia virus (BLV) RT; Rous sarcoma virus (RSV) RT; human immunodeficiency virus (HIV) RT, M-MFVRT, avian sarcoma leukemia virus (ASLV) RT, Rous sarcoma virus (RSV) RT, avian myeloblastic leukemia virus (AMV) RT, avian polycythemia virus (AEV) helper virus MCAV RT, avian myelocytoma virus MC29 helper virus MCAV RT, avian reticuloendotheliosis virus (REV-T) helper virus REV-A RT, avian sarcoma virus UR2 helper virus (UR2AV) RT, avian sarcoma virus Y73 helper virus YAV RT, Rous associated virus (Rous Associated Virus) Virus) (RAV) RT and myeloblastosis-associated virus (MAV) RT, all of which may be suitable for use in the methods and compositions described herein.
[0961] In some embodiments, the lead editor comprises wild-type M-MLV RT. An exemplary sequence of wild-type M-MLV RT is provided in SEQ REF NO: 4448.
[0962] In some embodiments, the lead editor comprises an M-MMLV RT comprising one or more of the following amino acid substitutions compared to the wild-type M-MMLV RT set forth in SEQ REF NO:4448: P51X, S67X, E69X, L139X, T197X, D200X, H204X, F209X, E302X, T306X, F309X, W313X, T330X, L345X, L435X, N454X, D524X, E562X, D583X, H594X, L603X, E607X, or D653X, wherein X is any amino acid other than a wild-type amino acid. In some embodiments, the lead editor comprises an M-MMLV RT comprising one or more of the following amino acid substitutions compared to the wild-type M-MMLV RT set forth in SEQ REF NO:4448: P51L, S67K, E69K, L139P, T197A, D200N, H204R, F209N, E302K, E302R, T306K, F309N, W313F, T330P, L345G, L435G, N454K, D524G, E562Q, D583N, H594Q, L603W, E607K, and D653N. In some embodiments, the lead editor comprises an M-MLV RT comprising one or more amino acid substitutions D200N, T330P, L603W, T306K, and W313F compared to the wild-type M-MMLV RT set forth in SEQ REF NO: 4448. In some embodiments, the lead editor comprises an M-MLV RT comprising amino acid substitutions D200N, T330P, L603W, T306K, and W313F compared to the wild-type M-MMLV RT set forth in SEQ REF NO: 4448.
[0963] Exemplary wild-type Moloney murine leukemia virus reverse transcriptase:
[0964] (SEQ REF NO:4448). In some embodiments, the RT variant can be a functional fragment of a reference RT having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or up to 100, or up to 200, or up to 300, or up to 400, or up to 500 or more amino acid changes compared to a reference RT (e.g., wild-type RT).In some embodiments, the RT variant comprises a fragment of a reference RT (e.g., wild-type RT) such that the fragment is about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 96% identical, about 97% identical, about 98% identical, about 99% identical, about 99.5% identical, or about 99.9% identical to the corresponding fragment of the reference RT. In some embodiments, the fragment is 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% identical, 96%, 97%, 98%, 99% or 99.5% of the amino acid length of the corresponding wild-type RT (M-MLV reverse transcriptase) (e.g., SEQ REF NO: 4448).
[0965] In some embodiments, the length of the RT functional fragment is at least 100 amino acids. In some embodiments, the length of the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550 or up to 600 or more amino acids.
[0966] In other embodiments, functional RT variants are truncated a certain number of amino acids at the N-terminus or C-terminus or both, which results in truncated variants that still retain enough DNA polymerase function. In some embodiments, compared with a reference RT (e.g., wild-type RT), the RT truncated variants have at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 amino acids at the N-terminus. In some embodiments, the reference RT is a wild-type M-MLV RT. In other embodiments, the RT truncation variant has a truncation of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 amino acids at the C-terminus compared to the reference RT (e.g., wild-type RT). In some embodiments, the reference RT is a wild-type M-MLV RT. In other embodiments, compared with reference RT (e.g., wild-type RT), RT truncated variants have truncations at the N-terminus and the C-terminus. In some embodiments, the lengths of the N-terminal truncation and the C-terminal truncation are the same. In some embodiments, the lengths of the N-terminal truncation and the C-terminal truncation are different.
[0967] For example, the lead editor disclosed herein may include a functional variant of a wild-type M-MLV reverse transcriptase. In some embodiments, the lead editor includes a functional variant of a wild-type M-MLV RT, wherein the functional variant of M-MLV RT is truncated after amino acid position 502 compared to the wild-type M-MLV RT listed in SEQ REF NO: 4448. In some embodiments, compared to the wild-type M-ML V RT listed in SEQ REF NO: 4448, the functional variant of M-MLV RT further includes D200X, T306X, W313X and / or T330X amino acid substitutions, wherein X is any amino acid other than the original amino acid. In some embodiments, compared to the wild-type M-MLV RT listed in SEQ REF NO: 4448, the functional variant of M-MLV RT further includes D200N, T306K, W313F and / or T330P amino acid substitutions, wherein X is any amino acid other than the original amino acid. The nucleic acid sequence encoding the lead editor comprising this truncated RT is 522 nt smaller than the nucleic acid sequence encoding the lead editor comprising the full-length M-MLV RT, thus making it potentially useful in applications where delivery of DNA sequences is difficult due to their size (i.e., adeno-associated virus and lentiviral delivery).In some embodiments, the lead editor comprises an M-MLV RT variant, wherein the M-MLV RT consists of the following amino acid sequence: TLNIED EYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRAS AKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKG VLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDNSRLIN.
[0968] In some embodiments, the lead editor comprises a eukaryotic RT, such as a yeast, fruit fly, rodent, or primate RT. In some embodiments, the lead editor comprises a group II intron RT, such as a. Geobacillus stearothermophilus group II intron (GsI-IIC) RT or Eubacterium rectum group II intron (Eu.re.I2) RT. In some embodiments, the lead editor comprises an inversion sub-RT.
[0969] Programmable DNA binding domain
[0970] In some embodiments, the DNA binding domain of the lead editor is a programmable DNA binding domain.A programmable DNA binding domain refers to a protein domain designed to bind to a specific nucleic acid sequence (e.g., a target DNA or a target RNA). In some embodiments, the DNA binding domain is a polynucleotide programmable DNA binding domain, which may be associated with a guide polynucleotide (e.g., PEgRNA), and the guide polynucleotide guides the DNA binding domain to a specific DNA sequence, for example, a search target sequence in a target gene. In some embodiments, the DNA binding domain comprises a clustered regularly spaced short palindromic repeat (CRISPR)-related (Cas) protein. The Cas protein may include any Cas protein described herein or a functional fragment or functional variant thereof. In some embodiments, the DNA binding domain may also include a zinc finger protein domain. In other cases, the DNA binding domain includes a transcription activator-like effector domain (TALE). In some embodiments, the DNA binding domain includes a DNA nuclease. For example, the DNA binding domain of the lead editor may include an RNA-guided DNA endonuclease, such as a Cas protein. In some embodiments, the DNA binding domain comprises a zinc finger nuclease (ZFN) or a transcription activator-like effector domain nuclease (TALEN), wherein one or more zinc finger motifs or TALE motifs are associated with one or more nucleases (e.g., a FokI nuclease domain).
[0971] In some embodiments, the DNA binding domain has nuclease activity. In some embodiments, the DNA binding domain of the lead editor comprises an endonuclease domain having single-stranded DNA cleavage activity. For example, the endonuclease domain may include a FokI nuclease domain. In some embodiments, the DNA binding domain of the lead editor comprises a nuclease having full nuclease activity. In some embodiments, the DNA binding domain of the lead editor comprises a nuclease having a modified or reduced nuclease activity compared to the wild-type endonuclease domain. For example, the endonuclease domain may include one or more amino acid substitutions compared to the wild-type endonuclease domain. In some embodiments, the DNA binding domain of the lead editor has nickase activity. In some embodiments, the DNA binding domain of the lead editor comprises a Cas protein domain that is a nickase. In some embodiments, compared to the wild-type Cas protein, the Cas nickase comprises one or more amino acid substitutions in the nuclease domain, which reduces or eliminates its double-stranded nuclease activity but retains DNA binding activity. In some embodiments, the Cas nickase comprises an amino acid substitution in the HNH domain. In some embodiments, the Cas nickase comprises an amino acid substitution in the RuvC domain.
[0972] In some embodiments, the DNA binding domain comprises a CRISPR-associated protein (Cas protein) domain. The Cas protein can be a Class 1 or Class 2 Cas protein. The Cas protein can be a Type I, Type II, Type III, Type IV, Type V, or Type VI Cas protein. Non-limiting examples of Cas proteins include Cas9, Cas12a (Cpf1), Cas12e (CasX), Cas12d (CasY), Cas12b1 (C2c1), Cas12b2, Cas12c (C2c3), C2c4, C2c8, C2c5, C2c10, C2c9, Cas14a, Cas14b, Cas14c, Cas14d, Cas14e, Cas14f, Cas14g, Cas14h, Cas14u, Cns2, CasΦ, and homologs thereof, functional fragments, or modified versions. The Cas protein can be a chimeric Cas protein fused to other proteins or polypeptides. The Cas protein may be a chimera of various Cas proteins, for example, it comprises domains of Cas proteins from different organisms.
[0973] The Cas protein (e.g., Cas9) can be from any suitable organism. In some aspects, the organism is S. pyogenes. In some aspects, the organism is S. aureus. In some aspects, the organism is S. thermophilus. In some embodiments, the organism is Staphylococcus lugdunensis.
[0974] Cas protein (e.g., Cas9) can be a wild-type or modified form of Cas protein. Cas protein (e.g., Cas9) can be a nuclease activity variant, a nuclease inactivation variant, a nickase or a functional variant or a functional fragment of a wild-type Cas protein. Relative to the wild-type version of the Cas protein, the Cas protein (e.g., Cas9) may include amino acid changes, such as deletions, insertions, substitutions, fusions, chimeras, or any combination thereof. Cas protein can be a polypeptide having at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity or sequence similarity with a wild-type exemplary Cas protein.
[0975] Cas protein (e.g., Cas9) may include one or more domains. Non-limiting examples of Cas domains include guiding nucleic acid recognition and / or binding domains, nuclease domains (e.g., DNase or RNase domains, RuvC, HNH), DNA binding domains, RNA binding domains, helicase domains, protein-protein interaction domains, and dimerization domains. In various embodiments, Cas protein includes guiding nucleic acid recognition and / or binding domains that can interact with guiding nucleic acids, and one or more nuclease domains that include nucleic acid cleavage catalytic activity.
[0976] In some embodiments, the Cas protein (e.g., Cas9) comprises one or more nuclease domains. The Cas protein may comprise an amino acid sequence having at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the nuclease domain (e.g., RuvC domain, HNH domain) of a wild-type Cas protein. In some embodiments, the Cas protein comprises a single nuclease domain. For example, Cpf1 may comprise a RuvC domain but lacks an HNH domain. In some embodiments, the Cas protein comprises two nuclease domains, for example, the Cas9 protein may comprise an HNH nuclease domain and a RuvC nuclease domain.
[0977] In some embodiments, the lead editor comprises a Cas protein (e.g., Cas9), wherein all nuclease domains of the Cas protein are active. In some embodiments, the lead editor comprises a Cas protein with one or more inactivated nuclease domains. One or more nuclease domains (e.g., RuvC, HNH) of the Cas protein may be deleted or mutated so that they are no longer functional or have reduced nuclease activity. In some embodiments, the Cas protein (e.g., Cas9) comprising a mutation in the nuclease domain has reduced (e.g., nickase) or eliminated nuclease activity when compounded with a guide nucleic acid (e.g., PEgRNA), while maintaining its ability to target and search for nucleic acid loci at the target sequence.
[0978] In some embodiments, the lead editor comprises a Cas nickase, which can bind to the target gene in a sequence-specific manner and generate single-strand breaks at the prototype spacer within the double-stranded DNA in the target gene, but does not generate double-strand breaks. For example, the Cas nickase can cut the editing strand or the non-editing strand of the target gene, but cannot cut both at the same time. In some embodiments, the lead editor comprises a Cas nickase (e.g., Cas9) containing two nuclease domains, wherein one of the two nuclease domains is modified to lack catalytic activity or is missing. In some embodiments, the Cas nickase of the lead editor comprises a nuclease inactivation RuvC domain and a nuclease activity HNH domain. In some embodiments, the Cas nickase of the lead editor comprises a nuclease inactivation HNH domain and a nuclease activity RuvC domain. In some embodiments, the lead editor comprises a Cas9 nickase having an amino acid substitution in the RuvC domain. In some embodiments, compared to wild-type Streptococcus pyogenes Cas9, the Cas9 nickase comprises a D10X amino acid substitution, wherein X is any amino acid other than D. In some embodiments, the lead editor comprises a Cas9 nickase having an amino acid substitution in the HNH domain. In some embodiments, the Cas9 nickase comprises an H840X amino acid substitution compared to wild-type Streptococcus pyogenes Cas9, wherein X is any amino acid other than H.
[0979] In some embodiments, the lead editor includes a Cas protein, which can be bound to the target gene in a sequence-specific manner but lacks or has eliminated nuclease activity, and may not cut any strand of double-stranded DNA in the target gene. The activity eliminated or lack of activity may refer to enzyme activity compared to wild-type exemplary activity (e.g., wild-type Cas9 nuclease activity) is less than 1%, less than 2%, less than 3%, less than 4%, less than 5%, less than 6%, less than 7%, less than 8%, less than 9% or less than 10%. In some embodiments, the Cas protein of the lead editor completely lacks nuclease activity. Nucleases lacking nuclease activity (e.g., Cas9) may be referred to as nuclease inactivation or "nuclease death" (abbreviated as "d"). Nuclease death Cas proteins (e.g., dCas, dCas9) may be bound to target polynucleotides, but may not cut target polynucleotides. In some aspects, the dead Cas protein is a dead Cas9 protein. In some embodiments, the lead editor comprises a nuclease-dead Cas protein in which all nuclease domains (e.g., RuvC and HNH nuclease domains in Cas9 protein; RuvC nuclease domain in Cpf1 protein) are mutated to lack catalytic activity, or are deleted.
[0980] Cas proteins can be modified. Cas proteins (e.g., Cas9) can be modified to increase or decrease nucleic acid binding affinity, nucleic acid binding specificity, and / or enzymatic activity. Cas proteins can also be modified to change any other activity or property of the protein, such as stability. For example, one or more nuclease domains of the Cas protein can be modified, deleted, or inactivated, or the Cas protein can be truncated to remove domains that are not necessary for protein function, or to optimize (e.g., enhance or reduce) the activity of the Cas protein.
[0981] The Cas protein can be a fusion protein. For example, the Cas protein can be fused with a cleavage domain, an epigenetic modification domain, a transcriptional regulatory domain, or a polymerase domain. The Cas protein can also be fused with a heterologous polypeptide to provide increased or decreased stability. The fused domain or heterologous polypeptide can be located at the N-terminus, the C-terminus, or inside the Cas protein.
[0982] In some embodiments, the Cas protein of the lead editor is a Class 2 Cas protein. In some embodiments, the Cas protein is a Type II Cas protein. In some embodiments, the Cas protein is a Cas9 protein, a modified version of a Cas9 protein, a Cas9 protein homolog, a mutant, a variant, or a functional fragment thereof. As used herein, Cas9, Cas9 protein, Cas9 polypeptide, or Cas9 nuclease refers to an RNA-guided nuclease comprising one or more Cas9 nuclease domains and a Cas9 gRNA binding domain having the ability to bind to a guide polynucleotide (e.g., PEgRNA). Cas9 protein may refer to a wild-type Cas9 protein from any organism, or a homolog, ortholog, or paralog from any organism; any functional mutant or functional variant thereof; or any functional fragment or domain thereof. In some embodiments, the lead editor comprises a full-length Cas9 protein. In some embodiments, the Cas9 protein may generally have at least about 50%, 60%, 70%, 80%, 90%, 100% sequence identity with a wild-type reference Cas9 protein (e.g., Cas9 from Streptococcus pyogenes). In some embodiments, the Cas9 comprises amino acid changes such as deletions, insertions, substitutions, fusions, chimeras, or any combination thereof compared to a wild-type reference Cas9 protein.
[0983] In some embodiments, the Cas9 protein may include a Cas9 protein from Streptococcus pyogenes (Sp), Staphylococcus aureus (Sa), Streptococcus canis (Sc), Streptococcus thermophilus (St), Staphylococcus lugdunensis (Slu), Neisseria meningitidis (Nm), Campylobacter jejuni (Cj), Francisella novicida (Fn), or Treponema denticola (Td), or any Cas9 homolog or ortholog from an organism known in the art. In some embodiments, the Cas9 polypeptide is a SpCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a SaCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a ScCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a StCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a SluCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a NmCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a CjCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a FnCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a TdCas9 polypeptide. In some embodiments, the Cas9 polypeptide is a chimera comprising domains from two or more organisms described herein or those known in the art. In some embodiments, the Cas9 polypeptide is a Cas9 polypeptide from Streptococcus cynomolgus. In some embodiments, the Cas9 polypeptide is a Cas9 polypeptide generated by replacing the PAM interaction domain of SpCas9 with the PAM interaction domain of Streptococcus cynomolgus Cas9 (Spy-mac Cas9).
[0984] An exemplary Streptococcus pyogenes Cas9 (SpCas9) amino acid sequence is provided in SEQ REF NO:4449.
[0985] Exemplary Streptococcus pyogenes Cas9 (SpCas9) amino acid sequence:
[0986]
[0987] In some embodiments, the lead editor comprises a Cas9 protein from Staphylococcus lugdunensis (Slu Cas9). An exemplary amino acid sequence of Slu Cas9 is provided in SEQ REF NO: 4450.
[0988] Exemplary Staphylococcus lugdunensis Cas9 (Slu Cas9) amino acid sequence WP_002460848.1:
[0989]
[0990] In some embodiments, the Cas9 protein includes a variant Cas9 protein containing one or more amino acid substitutions. In some embodiments, the wild-type Cas9 protein includes a RuvC domain and an HNH domain. In some embodiments, the lead editor includes a nuclease activity Cas9 protein that can cut two chains of a double-stranded target DNA sequence. In some embodiments, the nuclease activity Cas9 protein includes a functional RuvC domain and a functional HNH domain. In some embodiments, the lead editor includes a Cas9 nickase that can bind to a guide polynucleotide and recognize a target DNA, but can only cut one chain of a double-stranded target DNA. In some embodiments, the Cas9 nickase includes only one functional RuvC domain or one functional HNH domain. In some embodiments, the lead editor includes a Cas9 with a non-functional HNH domain and a functional RuvC domain. In some embodiments, the lead editor can cut the editing chain (ie, PAM chain), but cannot cut the non-editing chain of the double-stranded target DNA sequence. In some embodiments, the lead editor comprises a Cas9 with a non-functional RuvC domain, which can cut the target strand (ie, the non-PAM strand) but cannot cut the editing strand of the double-stranded target DNA sequence. In some embodiments, the lead editor comprises a Cas9 with neither a functional RuvC domain nor a functional HNH domain, which may not be able to cut any strand of the double-stranded target DNA sequence.
[0991] In some embodiments, the lead editor comprises a Cas9 having a mutation in the RuvC domain, the mutation reducing or eliminating the nuclease activity of the RuvC domain. In some embodiments, the Cas9 comprises a mutation at amino acid D10, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449. In some embodiments, the Cas9 comprises a D10A mutation, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449. In some embodiments, the Cas9 polypeptide comprises a mutation at amino acid D10, G12, and / or G17, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449. In some embodiments, the Cas9 polypeptide comprises a D10A mutation, a G12A mutation, and / or a G17A mutation, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449.
[0992] In some embodiments, the lead editor comprises a Cas9 polypeptide having a mutation in the HNH domain, the mutation reducing or eliminating the nuclease activity of the HNH domain. In some embodiments, the Cas9 polypeptide comprises a mutation at amino acid H840, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449. In some embodiments, the Cas9 polypeptide comprises an H840A mutation, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449. In some embodiments, the Cas9 polypeptide comprises a mutation at amino acid E762, D839, H840, N854, N856, N863, H982, H983, A984, D986, and / or A987, or a corresponding mutation thereof, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449. In some embodiments, the Cas9 polypeptide comprises E762A, D839A, H840A, N854A, N856A, N863A, H982A, H983A, A984A and / or D986A mutations, or their corresponding mutations, compared to the wild-type SpCas9 set forth in SEQ REF NO:4449.
[0993] In some embodiments, the lead editor comprises a Cas9 having one or more amino acid substitutions in both the HNH domain and the RuvC domain, wherein the one or more amino acid substitutions reduce or eliminate the nuclease activity of both the HNH domain and the RuvC domain. In some embodiments, the lead editor comprises a nuclease-inactivated Cas9, or a nuclease-dead Cas9 (dCas9). In some embodiments, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449, the dCas9 comprises an H840X substitution and a D10X mutation, or a corresponding mutation thereof, wherein for the H840X substitution, X is any amino acid other than H, and for the D10X substitution, X is any amino acid other than D. In some embodiments, compared to the wild-type SpCas9 listed in SEQ REF NO: 4449, the dead Cas9 comprises H840A and D10A mutations, or a corresponding mutation thereof.
[0994] In some embodiments, the N-terminal methionine is removed from the Cas9 nickase or from any Cas9 variant, ortholog, or equivalent disclosed or contemplated herein. For example, the methionine-minus Cas9 nickase comprises the following sequence, or a variant thereof having an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.
[0995] In addition to dead Cas9 and Cas9 nickase variants, the Cas9 protein used herein may also include other Cas9 variants that are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any reference Cas9 protein (including any wild-type Cas9, or mutant Cas9 (e.g., dead Cas9 or Cas9 nickase), or fragment Cas9, or circular mutant Cas9, or other Cas9 variants disclosed herein or known in the art). In some embodiments, the Cas9 variant can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to a reference Cas9 (e.g., wild-type Cas9). In some embodiments, the Cas9 variant comprises a fragment of a reference Cas9 (e.g., a gRNA binding domain or a DNA cleavage domain) such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to a corresponding fragment of a reference Cas9 (e.g., a wild-type Cas9). In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid length of the corresponding wild-type Cas9.
[0996] In some embodiments, the Cas9 fragment is a functional fragment that retains one or more Cas9 activities. In some embodiments, the length of the Cas9 fragment is at least 100 amino acids. In some embodiments, the length of the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250 or at least 1300 amino acids.
[0997] In some embodiments, the lead editor comprises a Cas protein (e.g., Cas9) containing modifications that allow for altered PAM recognition. In lead editing using a lead editor based on a Cas protein, a "protospacer adjacent motif (PAM)", a PAM sequence, or a PAM-like motif can be used to refer to a short DNA sequence immediately adjacent to the protospacer sequence on the PAM chain of a target gene. In some embodiments, PAM is recognized by the Cas nuclease in the lead editor during the lead editing process. In certain embodiments, PAM is required for target binding of Cas proteins. The specific PAM sequence required for Cas protein recognition may depend on the specific type of Cas protein. The length of PAM may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides. In some embodiments, the length of PAM is between 2-6 nucleotides. In some embodiments, PAM may be a 5'PAM (i.e., upstream of the 5' end of the protospacer). In other embodiments, PAM may be a 3'PAM (i.e., downstream of the 5' end of the protospacer). In some embodiments, the Cas protein of the lead editor recognizes a canonical PAM, for example, SpCas9 recognizes 5'-NGG-3' PAM. In some embodiments, the Cas protein of the lead editor has an altered or non-canonical PAM specificity. Exemplary PAM sequences and corresponding Cas variants are described in Table 7 below. It should be understood that for each of the variants provided, the Cas protein comprises one or more of the amino acid substitutions shown compared to the wild-type Cas protein sequence (e.g., Cas9 listed in SEQ REF NO: 4449). The PAM motifs shown in Table 7 below are arranged in 5' to 3' order.
[0998] Table 7: Cas protein variants and corresponding PAM sequences
[0999]
[1000]
[1001] In some embodiments, the lead editor comprises a Cas9 polypeptide comprising one or more mutations selected from the group consisting of A61R, L111R, D1135V, R221K, A262T, R324L, N394K, S409I, S409I, E427G, E480K, M495V, N497A, Y515N, K526E, F539S, E543D, R654L, R661A, R661L, R691A, N692A, M694A, M694I, Q695A, H698A, R753G, M763I, K848A, K890N, Q926A, K1003A, R1060 319R, A1320V, P1321S, A1322R, I1322V, D1332G, R1332N, A1332R, R1333K, R1333P, R1335L, R1335Q, R1335V, T1337N, T1337R, S1338T, H1349R, and any combination thereof.
[1002] In some embodiments, the lead editor comprises a SaCas9 polypeptide. In some embodiments, the SaCas9 polypeptide comprises one or more of the mutations E782K, N968K, and R1015H compared to wild-type SaCas9. In some embodiments, the lead editor comprises an FnCas9 polypeptide, such as a wild-type FnCas9 polypeptide or an FnCas9 polypeptide comprising one or more of the mutations E1369R, E1449H, or R1556A compared to wild-type FnCas9. In some embodiments, the lead editor comprises Sc Cas9, such as a wild-type ScCas9 or an ScCas9 polypeptide comprising one or more of the mutations I367K, G368D, I369K, H371L, T375S, T376G, and T1227K compared to wild-type ScCas9. In some embodiments, the lead editor comprises a St1 Cas9 polypeptide, a St3 Cas9 polypeptide, or a Slu Cas9 polypeptide.
[1003] In some embodiments, the lead editor comprises a Cas polypeptide containing a circular mutant Cas variant. For example, the Cas9 polypeptide of the lead editor can be engineered so that the N-terminus and C-terminus of the Cas9 protein (e.g., a wild-type Cas9 protein or a Cas9 nickase) are locally rearranged to retain the ability to bind DNA when complexed with a guide RNA (gRNA). An exemplary circular arrangement configuration can be N-terminus-[original C-terminus]-[original N-terminus]-C-terminus. Any Cas9 protein described herein, including any variant, ortholog, or naturally occurring Cas9 or equivalent thereof, can be reconfigured into a circular arrangement variant.
[1004] In various embodiments, the circular arrangement of a Cas protein (e.g., Cas9) may have the following structure: N-terminus-[original C-terminus]-[optional linker]-[original N-terminus]-C-terminus. In some embodiments, the circular arrangement of Cas9 comprises any of the following structures:
[1005] N-terminus-[1268-1368]-[optional linker]-[1-1267]-C-terminus;
[1006] N-terminus-[1168-1368]-[optional linker]-[1-1167]-C-terminus;
[1007] N-terminus - [1068-1368] - [optional linker] - [1-1067] - C-terminus;
[1008] N-terminus - [968-1368] - [optional linker] - [1-967] - C-terminus;
[1009] N-terminus - [868-1368] - [optional linker] - [1-867] - C-terminus;
[1010] N-terminus - [768-1368] - [optional linker] - [1-767] - C-terminus;
[1011] N-terminus - [668-1368] - [optional linker] - [1-667] - C-terminus;
[1012] N-terminus - [568-1368] - [optional linker] - [1-567] - C-terminus;
[1013] N-terminus-[468-1368]-[optional linker]-[1-467]-C-terminus;
[1014] N-terminus-[368-1368]-[optional linker]-[1-367]-C-terminus;
[1015] N-terminus-[268-1368]-[optional linker]-[1-267]-C-terminus;
[1016] N-terminus-[168-1368]-[optional linker]-[1-167]-C-terminus;
[1017] N-terminus-[68-1368]-[optional linker]-[1-67]-C-terminus;
[1018] N-terminus - [10-1368] - [optional linker] - [1-9] - C-terminus, or corresponding circular arrangements of other Cas9 proteins (including other Cas9 orthologs, variants, etc.).
[1019] In some embodiments, the circularly arranged Cas9 comprises any of the following structures (amino acid positions listed in SEQ REF NO: 4449-1368 amino acids of UniProtKB-Q99ZW2):
[1020] N-terminus-[102-1368]-[optional linker]-[1-101]-C-terminus;
[1021] N-terminus-[1028-1368]-[optional linker]-[1-1027]-C-terminus;
[1022] N-terminus-[1041-1368]-[optional linker]-[1-1043]-C-terminus;
[1023] N-terminus-[1249-1368]-[optional linker]-[1-1248]-C-terminus; or
[1024] N-terminus - [1300-1368] - [optional linker] - [1-1299] - C-terminus, or corresponding circular arrangements of other Cas9 proteins (including other Cas9 orthologs, variants, etc.).
[1025] In some embodiments, the circularly arranged Cas9 comprises any of the following structures (amino acid positions listed in SEQ REF NO: 4449-1368 amino acids of UniProtKB-Q99ZW2): N-terminus-[103-1368]-[optional linker]-[1-102]-C-terminus;
[1026] N-terminus-[1029-1368]-[optional linker]-[1-1028]-C-terminus;
[1027] N-terminus-[1042-1368]-[optional linker]-[1-1041]-C-terminus;
[1028] N-terminus-[1250-1368]-[optional linker]-[1-1249]-C-terminus; or
[1029] N-terminus - [1301-1368] - [optional linker] - [1-1300] - C-terminus, or corresponding circular arrangements of other Cas9 proteins (including other Cas9 orthologs, variants, etc.).
[1030] In some embodiments, the circular arrangement can be formed by directly connecting the C-terminal fragment of Cas9 to the N-terminal fragment of Cas9 or by connecting to the N-terminal fragment of Cas9 using a linker (such as an amino acid linker). In some embodiments, the C-terminal fragment may correspond to 95% or more of the C-terminal amino acid of Cas9 (e.g., amino acids about 1300-1368 listed in SEQ REF No: 4449 or their corresponding amino acid positions), or 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5% or more of the C-terminal amino acid of Cas9 (e.g., SEQ REF No: 4449). The N-terminal portion may correspond to 95% or more of the N-terminal amino acid of Cas9 (e.g., amino acids about 1-1300 listed in SEQ REF No: 4449, or their corresponding amino acid positions), or 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5% or more of the N-terminal amino acid of Cas9 (e.g., as listed in SEQ REF No: 4449, or their corresponding amino acid positions).
[1031] In some embodiments, the circular arrangement can be formed by directly connecting the C-terminal fragment of Cas9 to the N-terminal fragment of Cas9 or by connecting to the N-terminal fragment of Cas9 using a linker (such as an amino acid linker). In some embodiments, the C-terminal fragment rearranged to the N-terminus includes or corresponds to 30% or less of the amino acids at the C-terminus of Cas9 (e.g., amino acids 1012-1368 listed in SEQ REF No: 4449 or their corresponding amino acid positions). In some embodiments, the C-terminal fragment rearranged to the N-terminus comprises or corresponds to the C-terminal 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the amino acids of Cas9 (e.g., as listed in SEQ REF No: 4449 or its corresponding amino acid positions). In some embodiments, the C-terminal fragment rearranged to the N-terminus comprises or corresponds to the C-terminal 410 residues or less of Cas9 (e.g., as listed in SEQ REF No: 4449 or its corresponding amino acid positions). In some embodiments, the C-terminal portion rearranged to the N-terminus comprises or corresponds to the C-terminal 410, 400, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10 residues of Cas9 (e.g., as set forth in SEQ REF No: 4449 or its corresponding amino acid positions). In some embodiments, the C-terminal portion rearranged to the N-terminus comprises or corresponds to the C-terminal 357, 341, 328, 120, or 69 residues (e.g., as set forth in SEQ REF No: 4449 or its corresponding amino acid positions) of Cas9.
[1032] In other embodiments, the circular arrangement Cas9 variant can be a topological rearrangement of the primary structure of Cas9 based on the following method, the method is based on SEQ REF NO: 4449 of Streptococcus pyogenes Cas9: (a) selecting a circular arrangement (CP) site corresponding to the internal amino acid residues of the primary structure of Cas9, which divides the original protein into two halves: an N-terminal region and a C-terminal region; (b) modifying the Cas9 protein sequence (e.g., by genetic engineering techniques) by moving the original C-terminal region (including the CP site amino acid) before the original N-terminal region, thereby forming the N-terminus of the new Cas9 protein, which now starts with the CP site amino acid residue. The CP site can be located in any domain of the Cas9 protein, including, for example, a helix-II domain, a RuvCIII domain, or a CTD domain. For example, the CP site may be located at (as listed in SEQ REF No: 4449 or its corresponding amino acid position) the original amino acid residue 181, 199, 230, 270, 310, 1010, 1016, 1023, 1029, 1041, 1247, 1249 or 1282. Therefore, once relocated to the N-terminus, the original amino acid 181, 199, 230, 270, 310, 1010, 1016, 1023, 1029, 1041, 1247, 1249 or 1282 will become the new N-terminal amino acid. These CP-Cas9 proteins may be referred to as Cas9-CP, respectively. 181 , Cas9-CP 199 , Cas9-CP 230 , Cas9-CP 270 , Cas9-CP 310 , Cas9-CP 1010 , Cas9-CP 1016 , Cas9-CP 1023 , Cas9-CP 1029 , Cas9-CP 1041 , Cas9-CP 1247 , Cas9-CP 1249 and Cas9-CP 1282 . This description is not intended to limit CP variants obtained from SEQ REF NO: 18, but can be implemented to obtain CP variants in any Cas9 sequence, whether at CP sites corresponding to these positions, or at other CP sites entirely. This description is not intended to limit specific CP sites in any way. Almost any CP site can be used to form CP-Cas9 variants.
[1033] In some embodiments, the lead editor comprises a Cas9 functional variant having a smaller molecular weight than the wild-type SpCas9 protein. In some embodiments, the smaller-sized Cas9 functional variant may be advantageous for delivery to cells, for example, by expression vectors, nanoparticles, or other delivery methods. In certain embodiments, the smaller-sized Cas9 functional variant is a Class II type Cas protein. In certain embodiments, the smaller-sized Cas9 functional variant is a Class V type Cas protein. In certain embodiments, the smaller-sized Cas9 functional variant is a Class VI type Cas protein.
[1034] In some embodiments, the lead editor comprises a SpCas9 having a length of 1368 amino acids and a predicted molecular weight of 158 kilodaltons. In some embodiments, the lead editor comprises a Cas9 functional variant or functional fragment having less than 1300 amino acids, less than 1290 amino acids, less than 1280 amino acids, less than 1270 amino acids, less than 1260 amino acids, less than 1250 amino acids, less than 1240 amino acids, less than 1230 amino acids, less than 1220 amino acids, less than 1210 amino acids, less than 1200 amino acids, less than 1190 amino acids, less than 1180 amino acids, less than 1170 amino acids, less than 1160 amino acids, less than 1150 amino acids, less than 114 ... 0 amino acids, less than 1130 amino acids, less than 1120 amino acids, less than 1110 amino acids, less than 1100 amino acids, less than 1050 amino acids, less than 1000 amino acids, less than 950 amino acids, less than 900 amino acids, less than 850 amino acids, less than 800 amino acids, less than 750 amino acids, less than 700 amino acids, less than 650 amino acids, less than 600 amino acids, less than 550 amino acids or less than 500 amino acids, but at least greater than about 400 amino acids and retains one or more functions of the Cas9 protein, such as DNA binding function.
[1035] In some embodiments, the Cas protein may include any CRISPR-associated protein, including but not limited to Cas12a, Cas12b1, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn 2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof, and preferably comprises a nickase mutation (e.g., a mutation corresponding to the D10A mutation of the wild-type Cas9 polypeptide of SEQ REF NO: 18). In various other embodiments, the napDNAbp can be any of the following proteins: Cas9, Cas12a (Cpf1), Cas12e (CasX), Cas12d (CasY), Cas12b1 (C2c1), Cas13a (C2c2), Cas12c (C2c3), GeoCas9, CjCas9, Cas12g, Cas12h, Cas12i, Cas13b, Cas13c, Cas13d, Cas14, Csn2, xCas9, SpCas9-NG, ring-arranged Cas9 or Argonaute (Ago) domain, or a functional variant or fragment thereof.
[1036] Table 8: Exemplary Cas proteins
[1037]
[1038]
[1039] In some embodiments, the lead editor as described herein may comprise a Cas12a (Cpf1) polypeptide or a functional variant thereof. In some embodiments, the Cas12a polypeptide comprises a mutation that reduces or eliminates the endonuclease domain of the Cas12a polypeptide. In some embodiments, the Cas12a polypeptide is a Cas12a nickase. In some embodiments, the Cas protein comprises an amino acid sequence having at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a naturally occurring Cas12a polypeptide.
[1040] In some embodiments, the lead editor comprises a Cas protein, which is a Cas12b (C2c1) or Cas12c (C2c3) polypeptide. In some embodiments, the Cas protein comprises an amino acid sequence having at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a naturally occurring Cas12b (C2c1) or Cas12c (C2c3) protein. In some embodiments, the Cas protein is a Cas12b nickase or a Cas12c nickase. In some embodiments, the Cas protein is a Cas12e, Cas12d, Cas13, Cas14a, Cas14b, Cas14c, Cas14d, Cas14e, Cas14f, Cas14g, Cas14h, Cas14u or CasΦ polypeptide. In some embodiments, the Cas protein comprises an amino acid sequence having at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a naturally occurring Cas12e, Cas12d, Cas13, Cas14a, Cas14b, Cas14c, Cas14d, Cas14e, Cas14f, Cas14g, Cas14h, Cas14u or CasΦ protein. In some embodiments, the Cas protein is a Cas12e, Cas12d, Cas13 or CasΦ nickase.
[1041] Flap endonuclease
[1042] In some embodiments, the lead editor further comprises an additional polypeptide component, for example, a flap endonuclease (FEN, for example, FEN1). In some embodiments, the flap endonuclease excises the 5' single-stranded DNA of the target gene editing strand and assists in incorporating the expected nucleotide editing into the target gene. In some embodiments, the FEN is connected or fused to another component. In some embodiments, the FEN is provided in trans, for example, as a separate polypeptide or polynucleotide encoding the FEN.
[1043] In some embodiments, the lead editor or the lead editing composition comprises a flap nuclease. In some embodiments, the flap nuclease is FEN1, or any FEN1 functional variant, functional mutant, or functional fragment thereof. In some embodiments, the flap nuclease is TREX2, EXO1, or any other flap nuclease known in the art, or any functional variant, functional mutant, or functional fragment thereof. In some embodiments, the flap nuclease has an amino acid sequence that is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any flap nuclease described herein or known in the art.
[1044] nuclear localization sequence
[1045] In some embodiments, the lead editor also includes one or more nuclear localization sequences (NLS). In some embodiments, NLS helps promote protein translocation into the nucleus. In some embodiments, the lead editor includes a fusion protein, such as a fusion protein comprising a DNA binding domain and a DNA polymerase comprising one or more NLS. In some embodiments, one or more polypeptides of the lead editor are fused or connected to one or more NLS. In some embodiments, the lead editor includes a DNA binding domain and a DNA polymerase domain provided in trans, wherein the DNA binding domain and / or the DNA polymerase domain are fused or connected to one or more NLS.
[1046] In certain embodiments, the lead editor or lead editor complex comprises at least one NLS. In some embodiments, the lead editor or lead editor complex comprises at least two NLSs. In embodiments having at least two NLSs, the NLSs can be the same NLS, or can be different NLSs.
[1047] In some cases, the lead editor may also include at least one nuclear localization sequence (NLS). In some cases, the lead editor may also include 1 NLS. In some cases, the lead editor may also include 2 NLS. In other cases, the lead editor may also include 3 NLS. In one case, the lead editor may also include more than 4, 5, 6, 7, 8, 9 or 10 NLS.
[1048] In addition, NLS can be expressed as part of the lead editor complex. In some embodiments, NLS can be located at almost any position in the protein amino acid sequence, and generally comprises a short sequence of three or more or four or more amino acids. The position of NLS fusion can be at the N-terminus, the C-terminus, or at any position within the sequence of the lead editor or its components (for example, inserted between the DNA binding domain and the DNA polymerase domain of the lead editor fusion protein, between the DNA binding domain and the linker sequence, between the DNA polymerase and the linker sequence, between the two linker sequences of the lead editor fusion protein or its components, in the order of N-terminus to C-terminus or C-terminus to N-terminus). In some embodiments, the lead editor is a fusion protein comprising NLS at the N-terminus. In some embodiments, the lead editor is a fusion protein comprising NLS at the C-terminus. In some embodiments, the lead editor is a fusion protein comprising at least one NLS at both the N-terminus and the C-terminus. In some embodiments, the lead editor is a fusion protein comprising two NLS at the N-terminus and / or the C-terminus.
[1049] Any NLS known in the art is also contemplated herein. NLS can be any naturally occurring NLS, or any non-naturally occurring NLS (e.g., an NLS having one or more mutations relative to a wild-type NLS). In some embodiments, one or more NLSs of a lead editor include a dichotomous NLS. In some embodiments, a nuclear localization signal (NLS) is primarily alkaline. In some embodiments, one or more NLSs of a lead editor are rich in lysine and arginine residues. In some embodiments, one or more NLSs of a lead editor include proline residues. In some embodiments, a nuclear localization signal (NLS) includes a sequence MDSLLMNRRKFLYQFKNVRWAKGRRETYLC, KRTADGSEF ESPKKKRKV, KRTADGSEFEPKKKRKV, NLSKRPAAIKKAGQAK KKK, RQRRNELKRSF, or NQSSNFGPMKGGNFGGRSSGPYGGGG QYFAKPRNQGGY.
[1050] In some embodiments, NLS is a single component NLS. For example, in some embodiments, NLS is SV40 large T antigen NLS PKKKRKV. In some embodiments, NLS is a two-part NLS. In some embodiments, the two-part NLS comprises two basic domains, and the two basic domains are separated by a spacer sequence comprising a variable number of amino acids. In some embodiments, NLS is a two-part NLS. In some embodiments, the two-part NLS consists of two basic domains, and the two basic domains are separated by a spacer sequence comprising a variable number of amino acids. In some embodiments, the spacer amino acid sequence comprises the African clawed frog nucleoplasmic protein sequence KRXXXXXXXXXXKKKL (SEQ REF NO: 4451), wherein X is any amino acid. In some embodiments, NLS is a non-canonical sequence, such as M9 of hnRNP Al protein, influenza virus nucleoprotein NLS and yeast Gal4 protein NLS.
[1051] Additional non-limiting examples of NLS sequences are provided in Table 9 below.
[1052] Table 9: Exemplary nuclear localization sequences
[1053]
[1054] Additional Prime Editor Components
[1055] The lead editors described herein may comprise additional functional domains, e.g., one or more domains that modify the folding, solubility, or charge of the lead editor. In some cases, the lead editor may comprise a solubility enhancing (SET) domain.
[1056] In some embodiments, the split intein comprises two halves of an intein protein, which may be referred to as the N-terminal half of the intein or intein-N, and the C-terminal half of the intein or intein-C, respectively. In some embodiments, intein-N and intein-C may each be fused to a protein domain (N-terminal and C-terminal exteins). Exteins may be any protein or polypeptide, such as any lead editor polypeptide component. In some embodiments, intein-N and intein-C of a split intein may non-covalently associate to form an active intein and catalyze a-trans-splicing reaction. In some embodiments, the trans-splicing reaction excises two intein sequences and connects two extein sequences with a peptide bond. Thus, intein-N and intein-C are spliced out, and the protein domain connected to intein-N is fused to the protein domain connected to intein-C in substantially the same manner as a continuous intein. In some embodiments, the split intein is derived from a eukaryotic intein, a bacterial intein, or an archaeal intein. Preferably, the split intein of this origin will have only the amino acid sequence necessary for catalyzing the trans-splicing reaction. In some embodiments, the intein-N or intein-C further comprises one or more amino acid substitutions compared to the wild-type intein-N or wild-type intein-C, such as amino acid substitutions that enhance the trans-splicing activity of the split intein. In some embodiments, the intein-C comprises 4 to 7 consecutive amino acid residues, at least 4 of which are from the last beta strand of the intein from which it is derived. In some embodiments, the split intein is derived from a Ssp DnaE intein, e.g., Synechocytis sp. PCC6803, or any intein or split intein known in the art, or any functional variant or fragment thereof.
[1057] In some embodiments, the lead editor includes one or more epitope tags. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, thioredoxin (Trx) tags, biotin carboxylase carrier protein (BCCP) tags, myc tags, calmodulin tags, polyhistidine tags (also referred to as histidine tags or His tags), maltose binding protein (MBP) tags, nus tags, glutathione-S-transferase (GST) tags, green fluorescent protein (GFP) tags, thioredoxin tags, S tags, Softag (e.g., Softag 1, Softag 3), strep tags, biotin ligase tags, FlAsH tags, V5 tags and SBP tags. For those skilled in the art, additional suitable sequences are apparent. In some embodiments, the fusion protein includes one or more His tags.
[1058] In some embodiments, the lead editor comprises one or more polypeptide domains encoded by one or more reporter genes. Examples of reporter genes include, but are not limited to, glutathione-5-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) and autofluorescent proteins, including blue fluorescent protein (BFP).
[1059] In some embodiments, the lead editor comprises one or more polypeptide domains that bind to a DNA molecule or bind to other cellular molecules. Examples of binding proteins or domains include, but are not limited to, maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusion, GAL4 DNA binding domain fusion, and herpes simplex virus (HSV) BP16 protein fusion.
[1060] In some embodiments, the lead editor comprises a protein domain that is capable of modifying the intracellular half-life of the lead editor.
[1061] In some embodiments, the lead editing complex comprises a fusion protein comprising a DNA binding domain (e.g., Cas9 (H840A)) and a reverse transcriptase (e.g., variant MMLV RT) having the following structure: [NLS]-[Cas9 (H840A)]-[Linker]-[MMLV_RT (D200N) (T330P) (L603W) (T306K) (W313F)], and the desired PEgRNA. In some embodiments, the lead editing complex comprises a lead editor fusion protein having an amino acid sequence of SEQ REF NO: 4440.
[1062] The polypeptides constituting the lead editor components may be fused by peptide linkers, or may be provided in trans in relation to each other. For example, a reverse transcriptase may be expressed, delivered, or otherwise provided as a separate component rather than as part of a fusion protein with a DNA binding domain. In such cases, the components of the lead editor may be associated by non-peptide linkages or co-localization functions. In some embodiments, the lead editor further comprises additional components that can interact, associate, or recruit other components of the lead editor or the lead editing system with the lead editor or the lead editing system. For example, the lead editor may comprise an RNA-protein recruitment polypeptide that can associate with an RNA-protein recruitment RNA aptamer. In some embodiments, the RNA-protein recruitment polypeptide may recruit a specific RNA sequence, or be recruited by a specific RNA sequence. Non-limiting examples of RNA-protein recruitment polypeptides and RNA aptamer pairs include MS2 coat protein and MS2 RNA hairpin, PCP polypeptide and PP7 RNA hairpin, Com polypeptide and Com RNA hairpin, Ku protein and telomerase Ku binding RNA motif, and Sm7 protein and telomerase Sm7 binding RNA motif. In some embodiments, the lead editor comprises a DNA binding domain fused or connected to an RNA-protein-recruited polypeptide. In some embodiments, the lead editor comprises a DNA polymerase domain fused or connected to an RNA-protein-recruited polypeptide. In some embodiments, the DNA binding domain and the DNA polymerase domain fused to the RNA-protein-recruited polypeptide, or the DNA binding domain and the DNA polymerase domain fused to the RNA-protein-recruited polypeptide are co-localized by the corresponding RNA-protein-recruited RNA aptamer of the RNA-protein-recruited polypeptide. In some embodiments, the corresponding RNA-protein-recruited RNA aptamer is fused or connected to a portion of a PEgRNA or ngRNA. For example, the MS2 coat protein is fused or connected to a DNA polymerase, and the MS2 hairpin is disposed on the PEgRNA for co-localizing the DNA binding domain (e.g., Cas9 nickase) guided by the DNA polymerase and the RNA.
[1063] In some embodiments, the lead editor comprises a polypeptide domain, an MS2 coat protein (MCP) that recognizes an MS2 hairpin. In some embodiments, the nucleotide sequence of the MS2 hairpin (or equivalently, an "MS2 aptamer") is: GCCAACATGAGGATCACCCAT GTCTGCAGGGCC. In some embodiments, the amino acid sequence of MCP is: GS ASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKV TCSVRQSSAQNRKYTIKVEVPKVATQTVGGEELPVAGWRSYLNM ELTIPIFATNSDCELIVKAMQGLLKDGNPIPSAIA ANSGIY.
[1064] In certain embodiments, the components of the lead editor are directly fused to each other. In certain embodiments, the components of the lead editor are associated with each other via a linker.
[1065] As used herein, a linker can be any chemical group or molecule that connects two molecules or parts (e.g., a DNA binding domain and a polymerase domain of a lead editor). In some embodiments, the linker is an organic molecule, group, polymer, or chemical part. In some embodiments, the linker comprises a non-peptide portion. The linker can be as simple as a covalent bond, or it can be a polymeric linker of multiple atoms, such as a polynucleotide sequence. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, a disulfide bond, a carbon-heteroatom bond, etc.).
[1066] In certain embodiments, two or more components of the lead editor are connected to each other by a peptide linker. In some embodiments, the length of the peptide linker is 5-100 amino acids, for example, a length of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150 or 150-200 amino acids. In some embodiments, the length of the peptide linker is 16 amino acids, 24 amino acids, 64 amino acids, or 96 amino acids.
[1067] In some embodiments, the linker comprises the amino acid sequence (GGGGS)n, (G)n(, (EAAAK)n, (GGS)n, (SGGS)n, (XP)n, or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises the amino acid sequence (GGS)n, wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGS SGGS. In some embodiments, the linker comprises the amino acid sequence SGGSGGSGGS. In some embodiments, the linker comprises the amino acid sequence SGGS. In other embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESAGSYPYDV PDYAGSAAPAAKKKKLDGSGSGGSSGGS.
[1068] In some embodiments, the linker comprises 1-100 amino acids. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGS. In some embodiments, the linker comprises the amino acid sequence SGGSGGSGGS. In some embodiments, the linker comprises the amino acid sequence SGGS. In some embodiments, the linker comprises the amino acid sequence GGSGGS(, GGSGGSGGS, SGGSSGGSSGSETPGTSESATPESAGSYPYDVPDYAGSAAPAAKKKKLDGSGSGGSSGGS or SGGSSGGSSGSETPGTSESATPESSGGSSGGSS.
[1069] In certain embodiments, two or more components of the lead editor are connected to each other by a non-peptide linker. In some embodiments, the linker is a carbon-nitrogen bond of an amide bond. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymerized (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises aminoalkanoic acid (e.g., glycine, acetic acid, alanine, β-alanine, 3-aminopropionic acid, 4-aminobutyric acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminocaproic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a benzene ring. The linker may comprise a functionalized portion to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.
[1070] The components of the lead editor can be connected to each other in any order. In some embodiments, the DNA binding domain and the DNA polymerase domain of the lead editor can be fused to form a fusion protein, or can be connected from the N-terminus to the C-terminus by a peptide or protein linker in any order. In some embodiments, the lead editor comprises a DNA binding domain fused or connected to the C-terminus of the DNA polymerase domain. In some embodiments, the lead editor comprises a DNA binding domain fused or connected to the N-terminus of the DNA polymerase domain. In some embodiments, the lead editor comprises a fusion protein comprising the structure NH2-[DNA binding domain]-[polymerase]-COOH; or NH2-[polymerase]-[DNA binding domain]-COOH, wherein each "]-[" indicates the presence of an optional connection sequence. In some embodiments, the lead editor comprises a fusion protein and a DNA polymerase domain provided in trans, wherein the fusion protein comprises the structure NH2-[DNA binding domain]-[RNA-protein recruitment polypeptide]-COOH. In some embodiments, the lead editor comprises a fusion protein and a DNA binding domain provided in trans, wherein the fusion protein comprises the structure NH2-[DNA polymerase domain]-[RNA-protein recruitment polypeptide]-COOH.
[1071] In some embodiments, the lead editor fusion protein, the polypeptide component of the lead editor, or the polynucleotide encoding the lead editor fusion protein or polypeptide component can be split into an N-terminal half and a C-terminal half or a polypeptide encoding an N-terminal half and a C-terminal half, and provided to the target DNA in the cell respectively. For example, in certain embodiments, the lead editor fusion protein can be split into two halves of the N-terminus and the C-terminus for separate delivery in an AAV vector, and then translated and co-localized in the target cell to reform a complete polypeptide or lead editor protein. In such cases, the two separate halves of the protein or fusion protein may each contain a split intein to promote the co-localization and reformation of the complete protein or fusion protein by the mechanism of trans-splicing promoted by the intein. In some embodiments, the lead editor comprises an N-terminal half fused to an intein-N and a C-terminal half fused to an intein-C, or a polynucleotide or vector (e.g., an AAV vector) encoding each thereof. When delivered and / or expressed in a target cell, intein-N and intein-C can be excised by protein trans-splicing, thereby producing a complete lead editor fusion protein in the target cell.
[1072] In some embodiments, the lead editor fusion protein comprises Cas9 (H840A) nickase and wild-type M-MLV RT. In some embodiments, the lead editor fusion protein comprises one or more separate components, or the lead editor fusion protein comprises Cas9 (H840A) nickase and wild-type M-MLV RT. In some embodiments, the lead editor fusion protein comprises Cas9 (H840A) nickase and M-MLV RT, which has amino acid substitutions D200N, T330P, T306K, W313F and L603W compared to wild-type M-MLV RT. The amino acid sequence of the exemplary lead editor fusion protein comprises Cas9 (H840A) nickase and M-MLV RT with amino acid substitutions D200N, T330P, T306K, W313F and L603W, and the separate components of the lead editor fusion protein are shown in Table 4. In some embodiments, the lead editor fusion protein comprises the complete amino acid sequence in Table 4. In some embodiments, the lead editor fusion protein comprises one or more individual components from Table 4.
[1073] In some embodiments, the lead editor fusion protein comprises an amino acid sequence that is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to a lead editor fusion protein sequence described herein or known in the art.
[1074]
[1075]
[1076]
[1077]
[1078] Lead Editing Composition
[1079] In some embodiments, compositions, systems, and methods of using lead editing compositions are disclosed herein. The term "lead editing composition" or "lead editing system" refers to a composition involved in a lead editing method as described herein. The lead editing composition may include a lead editor (e.g., a lead editor fusion protein) and a PEgRNA. The lead editing composition may also include other elements, such as a second strand nicking ngRNA. The components of the lead editing composition may be combined to form a complex for lead editing, or may be stored separately, for example, for administration purposes.
[1080] In some embodiments, the lead editing composition comprises a lead editor fusion protein complexed with a PEgRNA and optionally with an ngRNA. In some embodiments, the lead editing composition comprises a lead editor comprising a DNA binding domain and a DNA polymerase domain associated with each other by a PEgRNA. For example, the lead editing composition may comprise a lead editor comprising a DNA binding domain and a DNA polymerase domain interconnected by an RNA-protein recruitment aptamer RNA sequence, wherein the RNA-protein recruitment aptamer RNA sequence is connected to the PEgRNA. In some embodiments, the lead editing composition comprises a PEgRNA and a polynucleotide, a polynucleotide construct, or a vector encoding a lead editor fusion protein.
[1081] In some embodiments, the lead editing composition comprises PEgRNA, ngRNA and a polynucleotide, polynucleotide construct or vector encoding a lead editor fusion protein. In some embodiments, the lead editing composition comprises a plurality of polynucleotides, polynucleotide constructs or vectors, each of which encodes one or more lead editing composition components. In some embodiments, the PEgRNA of the lead editing composition is associated with the DNA binding domain of the lead editor (e.g., Cas9 nickase). In some embodiments, the PEgRNA of the lead editing composition is complexed with the DNA binding domain of the lead editor and guides the lead editor to the target DNA.
[1082] In some embodiments, the lead editing composition comprises one or more polynucleotides encoding lead editor components and / or PEgRNA or ngRNA. In some embodiments, the lead editing composition comprises a polynucleotide encoding a fusion protein, the fusion protein comprising a DNA binding domain and a DNA polymerase domain. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding a fusion protein, the fusion protein comprising a DNA binding domain and a DNA polymerase domain, and (ii) PEgRNA or a polynucleotide encoding PEgRNA. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding a fusion protein, the fusion protein comprising a DNA binding domain and a DNA polymerase domain, (ii) PEgRNA or a polynucleotide encoding PEgRNA, and (iii) ngRNA or a polynucleotide encoding ngRNA. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding a DNA binding domain (e.g., Cas9 nickase) of a lead editor, (ii) a polynucleotide encoding a DNA polymerase domain (e.g., reverse transcriptase) of a lead editor, and (iii) PEgRNA or a polynucleotide encoding PEgRNA. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding a DNA binding domain of a lead editor (e.g., a Cas9 nickase), (ii) a polynucleotide encoding a DNA polymerase domain of a lead editor (e.g., a reverse transcriptase), (iii) PEgRNA or a polynucleotide encoding PEgRNA, and (iv) ngRNA or a polynucleotide encoding ngRNA.
[1083] In some embodiments, the polynucleotide encoding the DNA binding domain or the polynucleotide encoding the DNA polymerase domain also encodes an additional polypeptide domain, such as an RNA-protein recruitment domain, such as an MS2 coat protein domain. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding the N-terminal half of the lead editor fusion protein and an intein-N and (ii) a polynucleotide encoding the C-terminal half of the lead editor fusion protein and an intein-C. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding the N-terminal half of the lead editor fusion protein and an intein-N, (ii) a polynucleotide encoding the C-terminal half of the lead editor fusion protein and an intein-C, (iii) PEgRNA or a polynucleotide encoding PEgRNA, and / or (iv) ngRNA or a polynucleotide encoding ngRNA. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding the N-terminal portion of the DNA binding domain and an intein-N, (ii) a polynucleotide encoding the C-terminal portion of the DNA binding domain, an intein-C, and a DNA polymerase domain. In some embodiments, the DNA binding domain is a Cas protein domain, such as a Cas9 nickase. In some embodiments, the lead editing composition comprises (i) a polynucleotide encoding the N-terminal portion of the DNA binding domain and an intein-N, (ii) a polynucleotide encoding the C-terminal portion of the DNA binding domain, an intein-C, and a DNA polymerase domain, (iii) a PEgRNA or a polynucleotide encoding a PEgRNA, and / or (iv) an ngRNA or a polynucleotide encoding an ngRNA.
[1084] In some embodiments, the lead editing system comprises one or more polynucleotides encoding one or more lead editor polypeptides, wherein the activity of the lead editing system can be temporarily regulated by controlling the time of vector delivery. For example, in some embodiments, the polynucleotide encoding the lead editor and the polynucleotide encoding the PEgRNA can be delivered simultaneously. For example, in some embodiments, the polynucleotide encoding the lead editor and the polynucleotide encoding the PEgRNA can be delivered sequentially.
[1085] In some embodiments, the polynucleotide encoding the lead editing system component may also include an element capable of modifying the intracellular half-life of the polynucleotide and / or regulating translation control. In some embodiments, the polynucleotide is RNA, such as mRNA. In some embodiments, the half-life of the polynucleotide (e.g., RNA) may increase. In some embodiments, the half-life of the polynucleotide (e.g., RNA) may be reduced. In some embodiments, the element may be capable of increasing the stability of the polynucleotide (e.g., RNA). In some embodiments, the element may be capable of reducing the stability of the polynucleotide (e.g., RNA). In some embodiments, the element may be within the 3'UTR of RNA. In some embodiments, the element may include a polyadenylation signal (PA). In some embodiments, the element may include a cap, such as an upstream mRNA or PEgRNA end. In some embodiments, RNA may not include PA, so that it undergoes faster degradation in the cell after transcription.
[1086] In some embodiments, the element may include at least one AU-rich element (ARE). ARE may be bound by ARE binding protein (ARE-BP) in a manner dependent on tissue type, cell type, time, cell localization and environment. In some embodiments, unstable elements may promote RNA decay, affect RNA stability, or activate translation. In some embodiments, the length of ARE may include 50 to 150 nucleotides. In some embodiments, ARE may include at least one copy of the sequence AUUUA. In some embodiments, at least one ARE may be added to the 3'UTR of RNA. In some embodiments, the element may be a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). In other embodiments, the element is a modified and / or truncated WPRE sequence that can enhance the expression of a transcript. In some embodiments, WPRE or an equivalent may be added to the 3'UTR of RNA. In some embodiments, the element may be selected from other RNA sequence motifs rich in fast or slow decay transcripts. In some embodiments, a polynucleotide (e.g., a vector) encoding PE or PEgRNA may self-destruct by cleaving a target sequence present on a polynucleotide (e.g., a vector). The cleavage can prevent continued transcription of PE or PEgRNA.
[1087] The polynucleotide encoding the lead editing composition component can be DNA, RNA, or any combination thereof. In some embodiments, the polynucleotide encoding the lead editing composition component is an expression construct. In some embodiments, the polynucleotide encoding the lead editing composition component is a vector. In some embodiments, the vector is a DNA vector. In some embodiments, the vector is a plasmid. In some embodiments, the vector is a viral vector, such as a retroviral vector, an adenoviral vector, a lentiviral vector, a herpes virus vector, or an adeno-associated virus vector (AAV).
[1088] In some embodiments, the polynucleotide encoding the polypeptide component of the lead editing composition is codon optimized by replacing at least one codon of the native sequence with a codon that is more frequently or most frequently used in the genes of the host cell (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons), while maintaining the native amino acid sequence. In some embodiments, the polynucleotide encoding the polypeptide component of the lead editing composition is operably linked to one or more expression control elements, such as a promoter, a 3'UTR, a 5'UTR, or any combination thereof. In some embodiments, the polynucleotide encoding the lead editing composition component is a messenger RNA (mRNA). In some embodiments, the mRNA comprises a cap at the 5' end and / or a poly A tail at the 3' end.
[1089] Pharmaceutical composition
[1090] Disclosed herein are pharmaceutical compositions comprising any of the lead editing composition components (e.g., the lead editors, fusion proteins, polynucleotides encoding the lead editor polypeptides, PEgRNAs, ngRNAs, and / or lead editing complexes described herein).
[1091] As used herein, the term "pharmaceutical composition" refers to a composition formulated for pharmaceutical use. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises additional agents (e.g., for specific delivery, increased half-life) or other therapeutic compounds.
[1092] In some embodiments, a pharmaceutically acceptable carrier includes any vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc, magnesium, calcium or zinc stearate or stearic acid), or solvent encapsulating material, which participates in the transport or transportation of a compound from one part of the body (e.g., a delivery site) to another part (e.g., an organ, tissue, or part of the body). A pharmaceutically acceptable carrier is "acceptable" in the sense that it is compatible with the other ingredients of the formulation and does not damage the tissues of the subject (e.g., physiological compatibility, sterility, physiological pH, etc.).
[1093] The preparation of the pharmaceutical composition described herein can be prepared by any method known in the field of pharmacology or developed in the future. In general, such preparation methods include the step of mixing the active ingredient with an excipient and / or one or more other auxiliary ingredients, and then, if necessary and / or required, the product is molded and / or the product is packaged into a desired single dose or multiple dose unit. The pharmaceutical preparation may additionally include a pharmaceutically acceptable excipient, which includes any and all solvents, dispersion media, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc. as used herein, such as suitable for the desired specific dosage form.
[1094] Editing Method
[1095] The methods and compositions disclosed herein can be used to edit a target gene of interest by prime editing.
[1096] In some embodiments, the lead editing method includes contacting the target gene with a PEgRNA and a lead editor (PE) polypeptide described herein. In some embodiments, the target gene is double-stranded and comprises two DNA chains that are complementary to each other. In some embodiments, contact with the PEgRNA and contact with the lead editor are performed sequentially. In some embodiments, contact with the lead editor is performed after contact with the PEgRNA. In some embodiments, contact with the PEgRNA is performed after contact with the lead editor. In some embodiments, contact with the PEgRNA and contact with the lead editor are performed simultaneously. In some embodiments, the PEgRNA and the lead editor are associated in a complex form before contacting the target gene.
[1097] In some embodiments, contacting the target gene with the lead editing composition results in the PEgRNA binding to the target strand of the target gene. In some embodiments, contacting the target gene with the lead editing composition results in the PEgRNA binding to the search target sequence on the target strand of the target gene after contact with the PEgRNA. In some embodiments, contacting the target gene with the lead editing composition results in the spacer sequence of the PEgRNA binding to the search target sequence having the search target sequence on the target strand of the target gene after said contact of the PEgRNA.
[1098] In some embodiments, contacting the target gene with the lead editing composition results in the lead editor binding to the target gene (e.g., the target gene) after the PE composition is contacted with the target gene. In some embodiments, the DNA binding domain of PE is associated with PEgRNA. In some embodiments, PE binds to the target gene, which is guided by PEgRNA. Therefore, in some embodiments, contact of the target gene results in the binding of the DNA binding domain of the lead editor of the target gene guided by PEgRNA.
[1099] In some embodiments, contacting the target gene with the lead editing composition causes the lead editor to produce a nick in the editing strand of the target gene after contacting the target gene, thereby generating a nick on the editing strand of the target gene. In some embodiments, contacting the target gene with the lead editing composition obtains a single-stranded DNA containing a free 3' end at the nick site of the editing strand of the target gene. In some embodiments, contacting the target gene with the lead editing composition causes the DNA binding domain of the lead editor to produce a nick in the editing strand of the target gene, thereby generating a single-stranded DNA containing a free 3' end at the nick site. In some embodiments, the DNA binding domain of the lead editor is a Cas domain. In some embodiments, the DNA binding domain of the lead editor is Cas9. In some embodiments, the DNA binding domain of the lead editor is a Cas9 nickase.
[1100] In some embodiments, contacting the target gene with the lead editing composition causes PEgRNA to hybridize with the 3' end of the nicked single-stranded DNA, thereby initiating DNA polymerization through the DNA polymerase domain of the lead editor. In some embodiments, the free 3' end of the single-stranded DNA generated at the nick site hybridizes with the primer binding site sequence (PBS) of the contacted PEgRNA, thereby initiating DNA polymerization. In some embodiments, DNA polymerization is reverse transcription catalyzed by the reverse transcriptase domain of the lead editor. In some embodiments, the method includes contacting the target gene with a DNA polymerase (e.g., a reverse transcriptase), which is part of a lead editor fusion protein or a lead editor complex (cis), or as a separate protein (trans).
[1101] In some embodiments, the target gene is contacted with the lead editing composition to generate edited single-stranded DNA, which is encoded by the 3' free end of the single-stranded DNA at the nick site by the editing template of the PEgRNA through DNA polymerase-mediated polymerization. In some embodiments, the editing template of the PEgRNA comprises one or more expected nucleotide edits compared to the endogenous sequence of the target gene. In some embodiments, the expected nucleotide edits are incorporated into the target gene by excision of the 5' single-stranded DNA of the target gene editing chain generated at the nick site and DNA repair. In some embodiments, the expected nucleotide edits are incorporated into the target gene by excision of the editing target sequence and DNA repair. In some embodiments, the 5' single-stranded DNA of the editing chain generated at the nick site is excised by a flap endonuclease. In some embodiments, the flap nuclease is FEN1. In some embodiments, the method further includes contacting the target gene with a flap endonuclease. In some embodiments, the flap endonuclease is provided as part of the lead editor fusion protein. In some embodiments, the flap endonuclease is provided in trans.
[1102] In some embodiments, contacting the target gene with the lead editing composition generates a mismatched heteroduplex comprising an edited strand of the target gene containing edited single-stranded DNA, and an unedited target strand of the target gene. Without being bound by theory, endogenous DNA repair and replication can resolve the mismatched edited DNA to incorporate nucleotide changes to form the desired edited target gene.
[1103] In some embodiments, the method further comprises contacting the target gene with a nick guide (ngRNA) disclosed herein. In some embodiments, the ngRNA comprises a spacer region that binds to a second search target sequence on the target gene editing chain. In some embodiments, the contacted ngRNA guides PE to introduce a gap in the target chain of the target gene. In some embodiments, the nick on the target chain (non-editing chain) leads to the use of the editing chain to repair the endogenous DNA repair mechanism of the non-editing chain, thereby incorporating the expected nucleotide editing into the two chains of the target gene and modifying the target gene. In some embodiments, the ngRNA comprises a spacer sequence, which is complementary to the second search target sequence on the editing chain and can hybridize with it only after the expected nucleotide editing is incorporated into the editing chain of the target gene.
[1104] In some embodiments, the target gene is contacted by ngRNA, PEgRNA and PE at the same time. In some embodiments, ngRNA, PEgRNA and PE form a complex when contacting the target gene. In some embodiments, the target gene is contacted with ngRNA, PEgRNA and the lead editor in sequence. In some embodiments, after contacting the target gene with PE, the target gene is contacted with ngRNA and / or PEgRNA. In some embodiments, before contacting the target gene with the lead editor, the target gene is contacted with ngRNA and / or PEgRNA.
[1105] In some embodiments, the target gene is in a cell. Thus, also provided herein are methods of modifying cells (such as human cells, human primary cells, and / or human iPSC-derived cells).
[1106] In some embodiments, the lead editing method includes introducing PEgRNA, a lead editor and / or ngRNA into a cell with a target gene. In some embodiments, the lead editing method includes introducing a lead editing composition comprising PEgRNA, a lead editor polypeptide and / or ngRNA into a cell with a target gene. In some embodiments, PEgRNA, a lead editor polypeptide and / or ngRNA form a complex before being introduced into a cell. In some embodiments, PEgRNA, a lead editor polypeptide and / or ngRNA form a complex after being introduced into a cell. Lead editors, PEgRNA and / or ngRNA and lead editing complexes can be introduced into cells by any delivery method described herein or any delivery method known in the art (including ribonucleoprotein (RNP), lipid nanoparticles (LNP), viral vectors, non-viral vectors, mRNA delivery and physical techniques (such as destroying cell membranes by microfluidic devices)). Lead editors, PEgRNA and / or ngRNA and lead editing complexes can be introduced into cells simultaneously or sequentially.
[1107] In some embodiments, the lead editing method includes introducing PEgRNA or a polynucleotide encoding PEgRNA, a lead editor polynucleotide encoding a lead editor polypeptide, and an optional ngRNA or a polynucleotide encoding ngRNA into a cell. In some embodiments, the method includes introducing PEgRNA or a polynucleotide encoding PEgRNA, a polynucleotide encoding a lead editor polypeptide, and / or ngRNA or a polynucleotide encoding ngRNA into the cell simultaneously. In some embodiments, the method includes introducing PEgRNA or a polynucleotide encoding PEgRNA, a polynucleotide encoding a lead editor polypeptide, and / or ngRNA or a polynucleotide encoding ngRNA into the cell in sequence. In some embodiments, the method includes introducing a polynucleotide encoding a lead editor polypeptide into the cell before introducing PEgRNA or a polynucleotide encoding PEgRNA and / or ngRNA or a polynucleotide encoding ngRNA. In some embodiments, before introducing PEgRNA or a polynucleotide encoding PEgRNA and / or ngRNA or a polynucleotide encoding ngRNA into the cell, a polynucleotide encoding a lead editor polypeptide is introduced into the cell and expressed in the cell. In some embodiments, after PEgRNA or polynucleotides encoding PEgRNA and / or ngRNA or polynucleotides encoding ngRNA are introduced into cells, polynucleotides encoding lead editor polypeptides are introduced into cells. Polynucleotides encoding lead editor polypeptides, PEgRNA or polynucleotides encoding PEgRNA and / or ngRNA or polynucleotides encoding ngRNA may be introduced into cells by any delivery method described herein or any delivery method known in the art (e.g., by RNP, LNP, viral vector, non-viral vector, mRNA...
Claims
1. A lead editing guide RNA (PEgRNA), comprising: (a) a spacer region comprising a region complementary to a search target sequence in the target strand of the double-stranded target DNA; (b) a guide RNA (gRNA) core that is capable of binding to the Cas protein; (c) an extension arm comprising: i. an editing template comprising a desired edit compared to the double-stranded target DNA, and ii. a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in the non-target strand of the double-stranded target DNA; and (d) a 3' nucleic acid motif selected from the group consisting of SEQ REF NOs 1-15.
2. A lead editing guide RNA (PEgRNA), comprising: (a) a spacer region comprising a region complementary to a search target sequence in the target strand of the double-stranded target DNA; (b) a guide RNA (gRNA) core that is capable of binding to the Cas protein; (c) an extension arm comprising: (i) an editing template comprising a desired edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in the non-target strand of the double-stranded target DNA; and (d) a 3' nucleic acid motif, wherein the 3' nucleic acid motif comprises a sequence selected from the group consisting of: (A) G-quadruplex or C-quadruplex derived from the VEGF gene promoter, (B) Pseudoknots from potato leafroll virus (PLRV), (C) MS2 protein binding sequence, (D) Moloney murine leukemia virus (MMLV) reverse transcriptase recruitment sequence, or (E) Moloney murine leukemia virus (MMLV) replication recognition sequence.
3. The PEgRNA of claim 2, wherein the selected 3' nucleic acid motif is a G-quadruplex or C-quadruplex derived from the VEGF gene promoter.
4. The PEgRNA of claim 3, wherein the G-quadruplex comprises SEQ REF NO:
10.
5. The PEgRNA of claim 3, wherein the C-quadruplex comprises SEQ REF NO:
11.
6. The PEgRNA of claim 2, wherein the selected 3' nucleic acid motif is the pseudoknot derived from potato leafroll virus (PLRV).
7. The PEgRNA of claim 6, wherein the pseudoknot comprises SEQ REFNO:
4.
8. The PEgRNA of claim 2, wherein the selected 3' nucleic acid motif comprises the MS2 protein binding sequence.
9. The PEgRNA of claim 8, wherein the MS2 protein binding sequence is SEQ REF NO:
9.
10. The PEgRNA of claim 2, wherein the selected 3' nucleic acid motif comprises the MMLV reverse transcriptase recruitment sequence.
11. The PEgRNA of claim 10, wherein the MMLV reverse transcriptase recruitment sequence comprises SEQ REF NO:
8.
12. The PEgRNA of claim 2, wherein the selected 3' nucleic acid motif comprises an MMLV replication recognition sequence.
13. The PEgRNA of claim 12, wherein the MMLV replication recognition sequence comprises a sequence selected from the group consisting of SEQ REF NO: 12-15.
14. The PEgRNA of claim 1, wherein the 3' nucleic acid motif comprises SEQ REF NO: 1, 2, 3, 5, 6 or 7.
15. The PEgRNA of any one of claims 1-14, wherein the PEgRNA comprises the spacer, the gRNA core, the editing template, the PBS, and the 3' nucleic acid motif in 5' to 3' order.
16. The PEgRNA of any one of claims 1 to 15, wherein the PEgRNA further comprises a linker immediately 5' of the 3' nucleic acid motif.
17. The PEgRNA of claim 16, wherein the linker is 2 to 12 nucleotides in length.
18. The PEgRNA of claim 17, wherein the linker is 8 nucleotides in length.
19. The PEgRNA of any one of claims 16 to 18, wherein the linker does not form a secondary structure.
20. The PEgRNA of any one of claims 16 to 19, wherein the linker does not have complete complementarity with the PBS sequence.
21. The PEgRNA of any one of claims 16 to 20, wherein the linker does not have complete complementarity with the editing template.
22. The PEgRNA of any one of claims 16 to 21, wherein the linker does not have complete complementarity with the scaffold.
23. The PEgRNA of any one of claims 16 to 22, wherein the linker does not have complete complementarity with the extension arm.
24. The PEgRNA of any one of claims 16-23, wherein the linker has no more than 90%, no more than 85%, no more than 80%, no more than 75%, no more than 70%, no more than 65%, no more than 60%, no more than 55%, no more than 50%, no more than 45%, no more than 40%, no more than 35%, no more than 30%, no more than 25%, no more than 20% or no more than 15% complementarity with the extension arm.
25. A lead editing guide RNA (PEgRNA), comprising: (a) a spacer region comprising a region complementary to a search target sequence in the target strand of the double-stranded target DNA; (b) an extension arm comprising: (i) an editing template comprising a desired edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in the non-target strand of the double-stranded target DNA; and (c) a guide RNA (gRNA) core having at least 80% identity to SEQ REF NO: 16 and containing one or more modifications relative to SEQ REF NO: 16, the one or more modifications comprising: i. a first insertion between nucleotides 12 and 13 and a second insertion between nucleotides 16 and 17, wherein the first insertion is the reverse complement of the second insertion; ii. a first insertion between nucleotides 52 and 53 and a second insertion between nucleotides 56 and 57, wherein the first insertion is the reverse complement of the second insertion; iii. complementary substitutions of nucleotides 2 and 29, 3 and 28, 4 and 27, 51 and 58, or a combination thereof; iv. replacing nucleotides 11-12 with replacement sequence 1 and replacing nucleotides 17-18 with replacement sequence 2, wherein the length of replacement sequence 1 is at least 3 nucleotides and wherein the replacement sequence 2 is the reverse complement of replacement sequence 1; v. a T to G substitution or a T to C substitution at nucleotide 5 and a complementary substitution at nucleotide 26; or vi. Any combination thereof.
26. The PEgRNA of claim 25, wherein the gRNA core comprises (i) a first insertion between nucleotides 12 and 13 and a second insertion between nucleotides 16 and 17.
27. The PEgRNA of claim 26, wherein the first insertion is 1 to 6 nucleotides in length.
28. The PEgRNA of claim 25, wherein the first insertion comprises the sequence UGCUG.
29. The PEgRNA of claim 26, wherein the second insertion comprises the sequence CAGCA.
30. The PEgRNA of claim 26, wherein the first insertion is 1 to 3 nucleotides in length.
31. The PEgRNA of claim 30, wherein the first insertion comprises a sequence selected from the group consisting of C, CC, CA, CG, A, AC, AA, AG, CCC, CCAC, CCAAC, and CCACAC.
32. The PEgRNA of claim 25, wherein the gRNA core comprises a first insertion between nucleotides 52 and 53 and a second insertion between nucleotides 56 and 57.
33. The PEgRNA of claim 32, wherein the first insertion is 1 to 8 nucleotides in length.
34. The PEgRNA of claim 25, wherein the gRNA core comprises complementary substitutions of nucleotides 2 and 29, 3 and 28, 4 and 27, 11 and 18, 12 and 17, 51 and 58, or a combination thereof.
35. The PEgRNA of claim 34, wherein the gRNA core comprises a U to A substitution at nucleotide 2.
36. The PEgRNA of claim 34, wherein the gRNA core comprises a U to A substitution at nucleotide 3.
37. The PEgRNA of claim 34, wherein the gRNA core comprises a U to A substitution at nucleotide 4.
38. The PEgRNA of claim 34, wherein the gRNA core comprises a U to G substitution at nucleotide 51 and optionally an A to C substitution at nucleotide 58.
39. The PEgRNA of claim 25, wherein the gRNA core comprises replacing nucleotides 11-12 with the replacement sequence 1 and replacing nucleotides 17-18 with the replacement sequence 2.
40. The PEgRNA of claim 39, wherein the length of the replacement sequence 1 is 3 to 5 nucleotides.
41. The PEgRNA of claim 40, wherein the replacement sequence 1 comprises a sequence selected from the group consisting of CAGC, CCGC, GGAC, UGC, UCC, GAGGC, AGC, GGC, CGCA, GCACA, GGUC, and GGG.
42. The PEgRNA of any one of claims 26-41, wherein the gRNA core further comprises a U to A substitution at nucleotide 5 and an A to U substitution at nucleotide 26.
43. The PEgRNA of any one of claims 25-42, wherein the gRNA core comprises complementary substitutions at nucleotides 52 and 57.
44. The PEgRNA of claim 43, wherein the gRNA core comprises a U to G substitution at nucleotide 52 and an A to C substitution at nucleotide 57.
45. The PEgRNA of claim 43, wherein the gRNA core comprises a U to C substitution at nucleotide 52 and an A to G substitution at nucleotide 57.
46. The PEgRNA of any one of claims 25-45, wherein the gRNA core comprises complementary substitutions at nucleotides 49 and 60.
47. The PEgRNA of claim 46, wherein the gRNA core comprises an A to G substitution at nucleotide 49 and a U to C substitution at nucleotide 60.
48. A lead editing guide RNA (PEgRNA), comprising: (a) a spacer region comprising a region complementary to a search target sequence in the target strand of the double-stranded target DNA; (b) an extension arm comprising: (i) an editing template comprising a desired edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in the non-target strand of the double-stranded target DNA; and (c) a guide RNA (gRNA) core having at least 80% identity to SEQ REF NO: 16 and containing one or more modifications relative to SEQ REF NO: 16, the one or more modifications comprising: i. a U to A substitution at nucleotide 5 and an A to U substitution at nucleotide 26, and ii. a modification selected from the group consisting of: a. a first insertion between nucleotides 12 and 13 having the sequence UGCUG and a second insertion between nucleotides 16 and 17 having the sequence CAGCA; b. a first insertion between nucleotides 12 and 13 having the sequence UGCUG and a second insertion between nucleotides 16 and 17 having the sequence CAGCA, an A to G substitution at nucleotide 49, a U to C substitution at nucleotide 60, a U to G substitution at nucleotide 51, and an A to C substitution at nucleotide 58; c. replacing nucleotides 11-12 with replacement sequence 1 and nucleotides 17-18 with replacement sequence 2, wherein the replacement sequence 1 comprises GGG and wherein the replacement sequence 2 comprises UCC; d. replacing nucleotides 11-12 with replacement sequence 1 and nucleotides 17-18 with replacement sequence 2, wherein the replacement sequence 1 comprises GGG and wherein the replacement sequence 2 comprises UCC; an A to G substitution at nucleotide 49, a U to C substitution at nucleotide 60, a U to G substitution at nucleotide 51, and an A to C substitution at nucleotide 58; or e. replacing nucleotides 11-12 with replacement sequence 1 and replacing nucleotides 17-18 with replacement sequence 2, wherein the replacement sequence 1 and replacement sequence 2 comprise the sequences CAGC and GCUG, CCGC and GCGG, GGAC and GUCC, GC and GC, CC and GG, GAGGC and GUCUC, AGC and GCU, GGC and GCC, CGCA and UGCG, GCACA and UUGGC, or GGUC and GGCC.
49. The PEgRNA of any one of claims 25-48, wherein the gRNA core comprises nucleotides 62-76 of SEQ REF NO:
16.
50. A lead editing guide RNA (PEgRNA), comprising: (a) a spacer region comprising a region complementary to a search target sequence in the target strand of the double-stranded target DNA; (b) an extension arm comprising: (i) an editing template comprising a desired edit compared to the double-stranded target DNA, and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in the non-target strand of the double-stranded target DNA; and (c) a guide RNA (gRNA) core comprising a sequence selected from the group consisting of SEQ REF NOs: 17-61, 3860-4253, 4255-4349, 4351-4359 and 4452.
51. The PEgRNA of claim 50, wherein the gRNA core comprises a sequence selected from the group consisting of SEQ REF NO: 4294, 4319, 4322, 4286, 4290, 4346, 4271, 4264, 4317, 4330, 4312, 4356, 4280, and 4452.
52. The PEgRNA of claim 50, wherein the gRNA core comprises SEQ REF NO: 4354.
53. The PEgRNA of any one of claims 25-52, further comprising: (d) a 3' nucleic acid motif selected from the group consisting of SEQ REF NO 1-15.
54. The PEgRNA of claim 53, wherein the 3' nucleic acid motif comprises SEQ REF NO: 1, 2, 3, 5, 6 or 7.
55. The PEgRNA of any one of claims 25-52, further comprising: (d) a 3' nucleic acid motif, wherein the 3' nucleic acid motif comprises a sequence selected from the group consisting of: (i) a G-quadruplex or C-quadruplex derived from the VEGF gene promoter, (ii) pseudoknots derived from potato leafroll virus (PLRV), (iii) MS2 protein binding sequence, (iv) Moloney murine leukemia virus (MMLV) reverse transcriptase recruitment sequence, or (v) Moloney murine leukemia virus (MMLV) replication recognition sequence.
56. The PEgRNA of claim 55, wherein the selected 3' nucleic acid motif is a G-quadruplex or C-quadruplex derived from the VEGF gene promoter.
57. The PEgRNA of claim 56, wherein the G-quadruplex comprises SEQ REF NO:
10.
58. The PEgRNA of claim 56, wherein the C-quadruplex comprises SEQ REF NO:
11.
59. The PEgRNA of claim 55, wherein the selected 3' nucleic acid motif is the pseudoknot derived from potato leaf roll virus (PLRV).
60. The PEgRNA of claim 59, wherein the pseudoknot comprises SEQ REFNO:
4.
61. The PEgRNA of claim 55, wherein the selected 3' nucleic acid motif comprises the MS2 protein binding sequence.
62. The PEgRNA of claim 61, wherein the MS2 protein binding sequence is SEQ REF NO:
9.
63. The PEgRNA of claim 55, wherein the selected 3' nucleic acid motif comprises the MMLV reverse transcriptase recruitment sequence.
64. The PEgRNA of claim 63, wherein the MMLV reverse transcriptase recruitment sequence comprises SEQ REF NO:
8.
65. The PEgRNA of claim 55, wherein the selected 3' nucleic acid motif comprises an MMLV replication recognition sequence.
66. The PEgRNA of claim 65, wherein the MMLV replication recognition sequence comprises a sequence selected from the group consisting of SEQ REF NOs: 12-15.
67. The PEgRNA of any one of claims 55-66, wherein the PEgRNA comprises the spacer, the gRNA core, the editing template, the PBS, and the 3' nucleic acid motif in 5' to 3' order.
68. The PEgRNA of any one of claims 53 to 67, wherein the PEgRNA further comprises a linker immediately 5' of the 3' nucleic acid motif.
69. The PEgRNA of claim 68, wherein the linker is 2 to 12 nucleotides in length.
70. The PEgRNA of claim 69, wherein the linker is 8 nucleotides in length.
71. The PEgRNA of any one of claims 68 to 70, wherein the linker does not form a secondary structure.
72. The PEgRNA of any one of claims 68 to 71, wherein the linker does not have complete complementarity with the PBS sequence.
73. The PEgRNA of any one of claims 68 to 72, wherein the linker does not have complete complementarity with the editing template.
74. The PEgRNA of any one of claims 68 to 73, wherein the linker does not have complete complementarity with the scaffold.
75. The PEgRNA of any one of claims 68 to 74, wherein the linker does not have complete complementarity with the extension arm.
76. The PEgRNA of any one of claims 68-75, wherein the linker has no more than 90%, no more than 85%, no more than 80%, no more than 75%, no more than 70%, no more than 65%, no more than 60%, no more than 55%, no more than 50%, no more than 45%, no more than 40%, no more than 35%, no more than 30%, no more than 25%, no more than 20% or no more than 15% complementarity with the extension arm.
77. A lead editing guide RNA (PEgRNA), comprising: (a) a spacer region comprising a region complementary to a search target sequence in the target strand of the double-stranded target DNA; (b) a guide RNA (gRNA) core that is capable of binding to the Cas protein; (c) an extension arm comprising: (i) an editing template comprising a desired edit compared to the double-stranded target DNA; and (ii) a primer binding site (PBS) comprising a region complementary to a region upstream of the nicking site in the non-target strand of the double-stranded target DNA, and (d) a tag sequence that is the reverse complement of the sequence within the editing template.
78. The PEgRNA of claim 77, wherein the tag sequence is 4 to 22 nucleotides in length.
79. The PEgRNA of claim 77, wherein the tag sequence is 4 to 10 nucleotides in length.
80. The PEgRNA of claim 77, wherein the tag sequence is 4 to 9 nucleotides in length.
81. The PEgRNA of claim 77, wherein the tag sequence is 6 to 8 nucleotides in length.
82. The PEgRNA of claim 77, wherein the tag sequence is 6 nucleotides in length.
83. The PEgRNA of claim 77, wherein the tag sequence is 8 nucleotides in length.
84. The PEgRNA of any one of claims 77-83, wherein the tag sequence is not fully complementary to the PBS.
85. The PEgRNA of any one of claims 77-84, wherein the tag sequence does not have complete complementarity with the gRNA core.
86. The PEgRNA of any one of claims 77-85, wherein the tag sequence does not have complete complementarity with the spacer region.
87. The PEgRNA of any one of claims 77-86, comprising the spacer, the gRNA core, the editing template, the PBS and the tag sequence in 5' to 3' order.
88. The PEgRNA of any one of claims 77-86, comprising the editing template, the PBS, the tag sequence, the spacer, and the gRNA core in 5' to 3' order.
89. The PEgRNA of claim 87 or 88, further comprising a linker between the PBS and the tag sequence.
90. The PEgRNA of claim 89, wherein the linker is 2 to 12 nucleotides in length.
91. The PEgRNA of claim 89, wherein the linker has a length of 4 to 8 nucleotides.
92. The PEgRNA of claim 89, wherein the linker is 4 to 6 nucleotides in length.
93. The PEgRNA of claim 89, wherein the linker is 8 nucleotides in length.
94. The PEgRNA of claim 89, wherein the linker is 6 nucleotides in length.
95. The PEgRNA of claim 89, wherein the linker is 4 nucleotides in length.
96. The PEgRNA of any one of claims 89-95, wherein the linker does not have complete complementarity with the PBS.
97. The PEgRNA of any one of claims 89-96, wherein the linker does not have complete complementarity with the gRNA core.
98. The PEgRNA of any one of claims 89-97, wherein the linker does not have complete complementarity with the spacer region.
99. The PEgRNA of any one of claims 89-98, wherein the linker does not form a secondary structure.
100. The PEgRNA of any one of claims 77-99, wherein the gRNA core comprises a sequence selected from the group consisting of SEQ REFNO: 16-60, 3860-4359 and 4452.
101. A lead editing system comprising: (a) a PEgRNA as described in any one of claims 1-100 or one or more polynucleotides encoding the PEgRNA; and (b) a lead editor comprising a Cas protein and a DNA polymerase or one or more polynucleotides encoding the lead editor.
102. The lead editing system of claim 101, wherein the Cas protein has nickase activity.
103. The lead editing system of claim 102, wherein the Cas protein is a Cas9 comprising a mutation in the HNH domain.
104. The lead editing system of claim 103, wherein the Cas9 is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ REF NO: [[4442]].
105. The lead editing system of claim 102, wherein the Cas protein is Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14a, Cas14b, Cas14c, Cas14d, Cas14e, Cas14f, Cas14g, Cas14h, Cas14u or 106. The lead editing system of claim 105, wherein the Cas protein is Cas 12a or Cas12b.
107. The prime editing system of any one of claims 101-106, wherein the DNA polymerase is a reverse transcriptase.
108. The prime editing system of claim 107, wherein the reverse transcriptase is a retroviral reverse transcriptase.
109. The lead editing system of claim 107, wherein the reverse transcriptase is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ REF NO:4444.
110. The lead editing system of any one of claims 101-109, wherein the Cas protein and the DNA polymerase are fused or linked in a fusion protein.
111. The lead editing system of claim 110, wherein the fusion protein comprises the sequence of SEQ REF NO:4440.
112. The lead editing system of any one of claims 101-111, wherein the one or more polynucleotides comprise (a) a first sequence encoding an N-terminal portion of the Cas protein and an intein-N and (b) a second sequence encoding an intein-C, a C-terminal portion of the Cas protein, and the DNA polymerase.
113. The lead editing system of any one of claims 101-112, comprising one or more vectors, wherein the one or more vectors comprise the one or more polynucleotides encoding the PEgRNA and the one or more polynucleotides encoding the lead editor.
114. The lead editing system of claim 113, wherein the one or more vectors are AAV vectors.
115. The lead editing system of any one of claims 101-112, wherein the one or more polynucleotides are mRNA.
116. A lipid nanoparticle (LNP) or ribonucleoprotein (RNP) comprising the lead editing system of any one of claims 101-111 or 115.
117. A method for editing double-stranded target DNA, the method comprising contacting the target DNA with (a) a PEgRNA as described in any one of claims 1-100 and a lead editor comprising a Cas9 nickase and a reverse transcriptase, (b) a lead editing system as described in any one of claims 101-115, or (c) an LNP or RNP as described in claim 116.
118. The method of claim 117, wherein the target DNA is in a cell.
119. A method as described in claim 117 or 118, wherein the editing efficiency is at least 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 2.1 times, 2.2 times, 2.3 times, 2.4 times or 2.5 times higher than the editing efficiency of a control PEgRNA having the same spacer and extension arm, wherein the control PEgRNA contains a gRNA core having a sequence of SEQ REFNO: 16 and does not contain a 3' nucleic acid motif or tag.
120. The PEgRNA of claim 50, wherein the gRNA core comprises a sequence selected from the group consisting of: SEQ REF NO: 4352, 3860, 3862, 3865, 3908, 3915, 3982, 3991, 4035, 4261, 4262, 4263, 4264, 4265, 4266, 4268, 4277, 4278, 4280, 4283, 4284, 4285, 4286, 4269, 4287, 4288, 4289, 4290, 4291, 4270, 4271, 4272, 4274, 4275, 4276, 4292, 4301, 4302, 4303, 4304, 4305, 4306, 4307, 4308, 4309, 4310, 4311, 4312, 4313, 4314, 4315 4302, 4304, 4305, 4306, 4309, 4293, 4311, 4312, 4313, 4315, 4316, 4317, 4319, 4320, 4294, 4321, 4322, 4323, 4295, 4296, 4297, 4299, 4324, 4333, 4334, 4338, 4339, 4341, 4342, 4343, 4345, 4346, 4348, 4349, 4328, 4329, 4330, and 4332.
